EP3092231B1 - Sgc-stimulatoren - Google Patents

Sgc-stimulatoren Download PDF

Info

Publication number
EP3092231B1
EP3092231B1 EP14824644.0A EP14824644A EP3092231B1 EP 3092231 B1 EP3092231 B1 EP 3092231B1 EP 14824644 A EP14824644 A EP 14824644A EP 3092231 B1 EP3092231 B1 EP 3092231B1
Authority
EP
European Patent Office
Prior art keywords
ring
alkyl
membered heterocyclic
membered heteroaryl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP14824644.0A
Other languages
English (en)
French (fr)
Other versions
EP3092231A1 (de
Inventor
Paul Allen RENHOWE
James Edward SHEPPECK
Takashi Nakai
Karthik Iyer
Nicholas Robert Perl
Glen Robert RENNIE
Mark G. Currie
Kimberly Kafadar LONG
George Todd MILNE
Rajesh R. Iyengar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ironwood Pharmaceuticals Inc
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of EP3092231A1 publication Critical patent/EP3092231A1/de
Application granted granted Critical
Publication of EP3092231B1 publication Critical patent/EP3092231B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating and/or preventing various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable.
  • sGC soluble guanylate cyclase
  • Soluble guanylate cyclase is the primary receptor for nitric oxide (NO) in vivo.
  • NO nitric oxide
  • sGC can be activated via both NO-dependent and NO-independent mechanisms.
  • sGC converts GTP into the secondary messenger cyclic GMP (cGMP).
  • cGMP secondary messenger cyclic GMP
  • the increased level of cGMP in turn, modulates the activity of downstream effectors including protein kinases, phosphodiesterases (PDEs) and ion channels.
  • NO is synthesized from arginine and oxygen by various nitric oxide synthase (NOS) enzymes and by sequential reduction of inorganic nitrate.
  • NOS nitric oxide synthase
  • Three distinct isoforms of NOS have been identified: inducible NOS (iNOS or NOS II) found in activated macrophage cells; constitutive neuronal NOS (nNOS or NOS I), involved in neurotransmission and long term potentiation; and constitutive endothelial NOS (eNOS or NOS III) which regulates smooth muscle relaxation and blood pressure.
  • sGC stimulators are also useful in the treatment of lipid related disorders such as e.g., dyslipidemia, hypercholesterolemia, hypertriglyceridemia, sitosterolemia, fatty liver disease, and hepatitis.
  • lipid related disorders such as e.g., dyslipidemia, hypercholesterolemia, hypertriglyceridemia, sitosterolemia, fatty liver disease, and hepatitis.
  • Pulmonary hypertension is a disease characterized by sustained elevation of blood pressure in the pulmonary vasculature (pulmonary artery, pulmonary vein and pulmonary capillaries), which results in right heart hypertrophy, eventually leading to right heart failure and death.
  • pulmonary vasculature pulmonary artery, pulmonary vein and pulmonary capillaries
  • the bioactivity of NO and other vasodilators such as prostacyclin is reduced, whereas the production of endogenous vasoconstrictors such as endothelin is increased, resulting in excessive pulmonary vasoconstriction.
  • sGC stimulators have been used to treat PH because they promote smooth muscle relaxation, which leads to vasodilation.
  • NO-independent sGC stimulators Treatment with NO-independent sGC stimulators also promoted smooth muscle relaxation in the corpus cavernosum of healthy rabbits, rats and humans, causing penile erection, indicating that sGC stimulators are useful for treating erectile dysfunction.
  • NO-independent, heme-dependent, sGC stimulators such as those disclosed herein, have several important differentiating characteristics, including crucial dependency on the presence of the reduced prosthetic heme moiety for their activity, strong synergistic enzyme activation when combined with NO and stimulation of the synthesis of cGMP by direct stimulation of sGC, independent of NO.
  • the benzylindazole compound YC-1 was the first sGC stimulator to be identified. Additional sGC stimulators with improved potency and specificity for sGC have since been developed. These compounds have been shown to produce anti-aggregatory, anti-proliferative and vasodilatory effects.
  • WO 2012/064559 discloses various compounds as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders.
  • WO 2014/202588 discloses heteroaryl substituted pyrazoles and their use as pharmaceuticals.
  • WO 2013/092512 discloses substituted benzylpyrazoles and their use as pharmaceuticals.
  • This invention is directed to a compound according to Formula I, or a pharmaceutically acceptable salt thereof; it is also directed to pharmaceutical compositions comprising said compounds.
  • the invention is also directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
  • the invention is also directed to a pharmaceutical formulation or dosage form comprising the pharmaceutical composition and at least one excipient or carrier.
  • compounds of Formula I may be optionally substituted with one or more substituents, such as illustrated generally below, or as exemplified by particular classes, subclasses and species of the invention.
  • substituents such as illustrated generally below, or as exemplified by particular classes, subclasses and species of the invention.
  • the phrase "optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted.”
  • substituted refers to the replacement of one or more hydrogen radicals in a given structure with the radical of a specified substituent.
  • an optionally substituted group may have a substituent at each substitutable position of the group. When more than one position in a given structure can be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at each position unless otherwise specified.
  • groups such as -H, halogen, -NO 2 , -CN, -OH, -NH 2 or -OCF 3 would not be substitutable groups.
  • up to refers to zero or any integer number that is equal or less than the number following the phrase.
  • up to 3 means any one of 0, 1, 2, or 3.
  • a specified number range of atoms includes any integer therein. For example, a group having from 1-4 atoms could have 1, 2, 3 or 4 atoms.
  • stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in some embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
  • a stable compound is one that is not substantially altered when kept at a temperature of 25°C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
  • a chemically feasible compound is a compound that can be prepared by a person skilled in the art based on the disclosures herein supplemented, if necessary, relevant knowledge of the art.
  • a compound such as the compounds of Formula I or other compounds herein disclosed, may be present in its free form (e.g.,an amorphous form, or a crystalline form or a polymorph). Under certain conditions, compounds may also form co-forms. As used herein, the term co-form is synonymous with the term multi-component crystalline form. When one of the components in the co-form has clearly transferred a proton to the other component, the resulting co-form is referred to as a "salt". The formation of a salt is determined by how large the difference is in the pKas between the partners that form the mixture. For purposes of this disclosure, compounds include pharmaceutically acceptable salts, even if the term "pharmaceutically acceptable salts" is not explicitly noted.
  • structures depicted herein are also meant to include all stereoisomeric (e.g., enantiomeric, diastereomeric, atropoisomeric and cis-trans isomeric) forms of the structure; for example, the R and S configurations for each asymmetric center, Ra and Sa configurations for each asymmetric axis, ( Z ) and ( E ) double bond configurations, and cis and trans conformational isomers. Therefore, single stereochemical isomers as well as racemates, and mixtures of enantiomers, diastereomers, and cis-trans isomers (double bond or conformational) of the present compounds are within the scope of the present disclosure. Unless otherwise stated, all tautomeric forms of the compounds of the present disclosure are also within the scope of the invention. As an example, a substituent drawn as below: wherein R may be hydrogen, would include both compounds shown below:
  • the present disclosure also embraces isotopically-labeled compounds which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. All isotopes of any particular atom or element as specified are contemplated within the scope of the compounds of the invention, and their uses.
  • Exemplary isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 32 P, 33 P, 35 S, 18 F, 36 Cl, 123 I, and 125 I, respectively.
  • Certain isotopically-labeled compounds of the present invention e.g., those labeled with 3 H and 14 C are useful in compound and/or substrate tissue distribution assays.
  • Tritiated (i.e., 3 H) and carbon-14 (i.e., 14 C) isotopes are useful for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
  • Positron emitting isotopes such as 15 O, 13 N, 11 C, and 18 F are useful for positron emission tomography (PET) studies to examine substrate receptor occupancy.
  • Isotopically labeled compounds of the present invention can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples herein below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
  • aliphatic or "aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation. Unless otherwise specified, aliphatic groups contain 1-20 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-10 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms.
  • aliphatic groups contain 1-4 aliphatic carbon atoms and in yet other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms.
  • Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, or alkynyl groups. Specific examples of aliphatic groups include, but are not limited to: methyl, ethyl, propyl, butyl, isopropyl, isobutyl, vinyl, sec-butyl, tert-butyl, butenyl, propargyl, acetylene and the like.
  • the term "aliphatic chain” may be used interchangeably with the term "aliphatic” or "aliphatic group”.
  • alkyl refers to a saturated linear or branched-chain monovalent hydrocarbon radical. Unless otherwise specified, an alkyl group contains 1-20 carbon atoms (e.g., 1-20 carbon atoms, 1-10 carbon atoms, 1-8 carbon atoms, 1-6 carbon atoms, 1-4 carbon atoms or 1-3 carbon atoms).
  • alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t-butyl, pentyl, hexyl, heptyl, octyl and the like.
  • alkenyl refers to a linear or branched-chain monovalent hydrocarbon radical with at least one site of unsaturation, i.e., a carbon-carbon, sp 2 double bond, wherein the alkenyl radical includes radicals having "cis” and “trans” orientations, or alternatively, "E” and “Z” orientations.
  • an alkenyl group contains 2-20 carbon atoms (e.g., 2-20 carbon atoms, 2-10 carbon atoms, 2-8 carbon atoms, 2-6 carbon atoms, 2-4 carbon atoms or 2-3 carbon atoms). Examples include, but are not limited to, vinyl, allyl and the like.
  • alkynyl refers to a linear or branched monovalent hydrocarbon radical with at least one site of unsaturation, i.e., a carbon-carbon sp triple bond.
  • an alkynyl group contains 2-20 carbon atoms (e.g., 2-20 carbon atoms, 2-10 carbon atoms, 2-8 carbon atoms, 2-6 carbon atoms, 2-4 carbon atoms or 2-3 carbon atoms). Examples include, but are not limited to, ethynyl, propynyl, and the like.
  • carbocyclic refers to a ring system formed only by carbon and hydrogen atoms. Unless otherwise specified, throughout this disclosure, carbocycle is used as a synonym of "non-aromatic carbocycle” or “cycloaliphatic”. In some instances the term can be used in the phrase “aromatic carbocycle”, and in this case it refers to an "aryl group” as defined below.
  • cycloaliphatic refers to a cyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation but which is not aromatic, and which has a single point of attachment to the rest of the molecule. Unless otherwise specified, a cycloaliphatic group may be monocyclic, bicyclic, tricyclic, fused, spiro or bridged. In one embodiment, the term “cycloaliphatic” refers to a monocyclic C 3 -C 12 hydrocarbon or a bicyclic C 7 -C 12 hydrocarbon.
  • any individual ring in a bicyclic or tricyclic ring system has 3-7 members.
  • Suitable cycloaliphatic groups include, but are not limited to, cycloalkyl, cycloalkenyl, and cycloalkynyl. Examples of aliphatic groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, norbornyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, and the like.
  • cycloaliphatic also includes polycyclic ring systems in which the non-aromatic carbocyclic ring can be "fused" to one or more aromatic or non-aromatic carbocyclic or heterocyclic rings or combinations thereof, as long as the radical or point of attachment is on the non-aromatic carbocyclic ring.
  • Cycloalkyl refers to a ring system in which is completely saturated and which has a single point of attachment to the rest of the molecule. Unless otherwise specified, a cycloalkyl group may be monocyclic, bicyclic, tricyclic, fused, spiro or bridged. In one embodiment, the term “cycloalkyl” refers to a monocyclic C 3 -C 12 saturated hydrocarbon or a bicyclic C 7 -C 12 saturated hydrocarbon. In some embodiments, any individual ring in a bicyclic or tricyclic ring system has 3-7 members.
  • Suitable cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cycloheptenyl, norbornyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, and the like.
  • Heterocycle refers to a ring system in which one or more ring members are an independently selected heteroatom, which is completely saturated or that contains one or more units of unsaturation but which is not aromatic, and which has a single point of attachment to the rest of the molecule.
  • heterocycle is used as a synonym of "non-aromatic heterocycle”.
  • the term can be used in the phrase “aromatic heterocycle”, and in this case it refers to a "heteroaryl group” as defined below.
  • the term heterocycle also includes fused, spiro or bridged heterocyclic ring systems.
  • a heterocycle may be monocyclic, bicyclic or tricyclic.
  • the heterocycle has 3-18 ring members in which one or more ring members is a heteroatom independently selected from oxygen, sulfur or nitrogen, and each ring in the system contains 3 to 7 ring members.
  • a heterocycle may be a monocycle having 3-7 ring members (2-6 carbon atoms and 1-4 heteroatoms) or a bicycle having 7-10 ring members (4-9 carbon atoms and 1-6 heteroatoms).
  • Examples of bicyclic heterocyclic ring systems include, but are not limited to: adamantanyl, 2-oxa-bicyclo[2.2.2]octyl, 1-aza-bicyclo[2.2.2]octyl.
  • heterocycle also includes polycyclic ring systems wherein the heterocyclic ring is fused with one or more aromatic or non-aromatic carbocyclic or heterocyclic rings, or with combinations thereof, as long as the radical or point of attachment is on the heterocyclic ring.
  • heterocyclic rings include, but are not limited to, the following monocycles: 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino, 2-thiomorpholino, 3-thiomorpholino, 4-thiomorpholino, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-tetrahydropiperazinyl, 2-tetrahydropiperazinyl, 3-tetrahydropiperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 5-pyrazolinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2-thiazolidinyl, 3-thiazolidinyl
  • aryl (as in “aryl ring” or “aryl group”), used alone or as part of a larger moiety, as in “aralkyl”, “aralkoxy”, “aryloxyalkyl”, refers to a carbocyclic ring system wherein at least one ring in the system is aromatic and has a single point of attachment to the rest of the molecule. Unless otherwise specified, an aryl group may be monocyclic, bicyclic or tricyclic and contain 6-18 ring members.
  • aryl rings include, but are not limited to, phenyl, naphthyl, indanyl, indenyl, tetralin, fluorenyl, and anthracenyl.
  • aralkyl refers to a radical having an aryl ring substituted with an alkylene group, wherein the open end of the alkylene group allows the aralkyl radical to bond to another part of the compound of Formula I.
  • the alkylene group is a bivalent, straight-chain or branched, saturated hydrocarbon group.
  • C 7-12 aralkyl means an aralkyl radical wherein the total number of carbon atoms in the aryl ring and the alkylene group combined is 7 to 12.
  • aralkyl examples include, but not limited to, a phenyl ring substituted by a C 1-6 alkylene group, e.g., benzyl and phenylethyl, and a naphthyl group substituted by a C 1-2 alkylene group.
  • heteroaryl (or “heteroaromatic” or “heteroaryl group” or “aromatic heterocycle”) used alone or as part of a larger moiety as in “heteroaralkyl” or “heteroarylalkoxy” refers to a ring system wherein at least one ring in the system is aromatic and contains one or more heteroatoms, wherein each ring in the system contains 3 to 7 ring members and which has a single point of attachment to the rest of the molecule.
  • a heteroaryl ring system may be monocyclic, bicyclic or tricyclic and have a total of five to fourteen ring members. In one embodiment, all rings in a heteroaryl system are aromatic.
  • heteroaryl radicals where the heteroaryl ring is fused with one or more aromatic or non-aromatic carbocyclic or heterocyclic rings, or combinations thereof, as long as the radical or point of attachment is in the heteroaryl ring.
  • Bicyclic 6, 5 heteroaromatic system as used herein, for example, is a six membered heteroaromatic ring fused to a second five membered ring wherein the radical or point of attachment is on the six-membered ring.
  • Heteroaryl rings include, but are not limited to the following monocycles: 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g., 5-tetrazolyl), triazolyl (e.g., 2-triazolyl and 5-triazolyl), 2-thienyl,
  • cyclo encompasses mono-, bi- and tri-cyclic ring systems including cycloaliphatic, heterocyclic, aryl or heteroaryl, each of which has been previously defined.
  • Bridged bicyclic ring systems comprise two rings which share three or four adjacent ring atoms.
  • bridge refers to an atom or a chain of atoms connecting two different parts of a molecule.
  • the two atoms that are connected through the bridge (usually but not always, two tertiary carbon atoms) are referred to as "bridgeheads".
  • bridgeheads In addition to the bridge, the two bridgeheads are connected by at least two individual atoms or chains of atoms.
  • bridged bicyclic ring systems include, but are not limited to, adamantanyl, norbornanyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, bicyclo[3.2.3]nonyl, 2-oxa-bicyclo[2.2.2]octyl, 1-aza-bicyclo[2.2.2]octyl, 3-aza-bicyclo[3.2.1]octyl, and 2,6-dioxa-tricyclo[3.3.1.03,7]nonyl.
  • "Spiro" bicyclic ring systems share only one ring atom (usually a quaternary carbon atom) between the two rings.
  • ring atom refers to an atom such as C, N, O or S that is part of the ring of an aromatic ring, a cycloaliphatic ring, a heterocyclic or a heteroaryl ring.
  • a “substitutable ring atom” is a ring carbon or nitrogen atom bonded to at least one hydrogen atom. The hydrogen can be optionally replaced with a suitable substituent group.
  • substituted ring atom does not include ring nitrogen or carbon atoms which are shared when two rings are fused.
  • substitutedutable ring atom does not include ring carbon or nitrogen atoms when the structure depicts that they are already attached to one or more moiety other than hydrogen and no hydrogens are available for substitution.
  • Heteroatom refers to one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon, including any oxidized form of nitrogen, sulfur, phosphorus, or silicon, the quaternized form of any basic nitrogen, or a substitutable nitrogen of a heterocyclic or heteroaryl ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl).
  • two independent occurrences of a variable may be taken together with the atom(s) to which each variable is bound to form a 5-8-membered, heterocyclyl, aryl, or heteroaryl ring or a 3-8-membered cycloaliphatic ring.
  • Exemplary rings that are formed when two independent occurrences of a substituent are taken together with the atom(s) to which each variable is bound include, but are not limited to the following: a) two independent occurrences of a substituent that are bound to the same atom and are taken together with that atom to form a ring, where both occurrences of the substituent are taken together with the atom to which they are bound to form a heterocyclyl, heteroaryl, cycloaliphatic or aryl ring, wherein the group is attached to the rest of the molecule by a single point of attachment; and b) two independent occurrences of a substituent that are bound to different atoms and are taken together with both of those atoms to form a heterocyclyl, heteroaryl, cycloaliphatic or aryl ring, wherein the ring that is formed has two points of attachment with the rest of the molecule.
  • a phenyl group is substituted with two occurrences of -OR° as in Formula D
  • the term "vicinal” refers to the placement of substituents on a group that includes two or more carbon atoms, wherein the substituents are attached to adjacent carbon atoms.
  • the term "geminal” refers to the placement of substituents on a group that includes two or more carbon atoms, wherein the substituents are attached to the same carbon atom.
  • terminal refers to the location of a group within a substituent.
  • a group is terminal when the group is present at the end of the substituent not further bonded to the rest of the chemical structure.
  • Carboxyalkyl i.e., R x O(O)C-alkyl is an example of a carboxy group used terminally.
  • a group is internal when the group is present in the middle of a substituent at the end of the substituent bound to the rest of the chemical structure.
  • Alkylcarboxy e.g., alkyl-C(O)O- or alkyl-O(CO)-
  • alkylcarboxyaryl e.g., alkyl-C(O)O-aryl- or alkyl-O(CO)-aryl-
  • a bond drawn from a substituent to the center of one ring within a multiple-ring system represents substitution of the substituent at any substitutable position in any of the rings within the multiple ring system.
  • formula D3 represents possible substitution in any of the positions shown in formula D4:
  • each substituent only represents substitution on the ring to which it is attached.
  • Y is an optional substituent for ring A only
  • X is an optional substituent for ring B only.
  • alkoxy or “alkylthio” refer to an alkyl group, as previously defined, attached to the molecule, or to another chain or ring, through an oxygen (“alkoxy” i.e., -O-alkyl) or a sulfur (“alkylthio” i.e., -S-alkyl) atom.
  • C n-m “alkoxyalkyl”, C n-m “alkoxyalkenyl”, C n-m “alkoxyaliphatic”, and C n-m “alkoxyalkoxy” mean alkyl, alkenyl, aliphatic or alkoxy, as the case may be, substituted with one or more alkoxy groups, wherein the combined total number of carbons of the alkyl and alkoxy groups, alkenyl and alkoxy groups, aliphatic and alkoxy groups or alkoxy and alkoxy groups, combined, as the case may be, is between the values of n and m.
  • a C 4-6 alkoxyalkyl has a total of 4-6 carbons divided between the alkyl and alkoxy portion; e.g., it can be -CH 2 OCH 2 CH 2 CH 3 , -CH 2 CH 2 OCH 2 CH 3 or -CH 2 CH 2 CH 2 OCH 3 .
  • an optionally substituted C 4 alkoxyalkyl could be, for instance, -CH 2 CH 2 OCH 2 (Me)CH 3 or -CH 2 (OH)O CH 2 CH 2 CH 3 ;
  • aryloxy, arylthio, benzyloxy or benzylthio refer to an aryl or benzyl group attached to the molecule, or to another chain or ring, through an oxygen (“aryloxy”, benzyloxy e.g., -O-Ph, -OCH 2 Ph) or sulfur (“arylthio” e.g., -S-Ph, -S-CH 2 Ph) atom.
  • aryloxyalkyl means alkyl, alkenyl or aliphatic, as the case may be, substituted with one or more aryloxy or benzyloxy groups, as the case may be.
  • the number of atoms for each aryl, aryloxy, alkyl, alkenyl or aliphatic will be indicated separately.
  • a 5-6-membered aryloxy(C 1-4 alkyl) is a 5-6 membered aryl ring, attached via an oxygen atom to a C 1-4 alkyl chain which, in turn, is attached to the rest of the molecule via the terminal carbon of the C 1-4 alkyl chain.
  • haloalkyl means alkyl, alkenyl, aliphatic or alkoxy, as the case may be, substituted with one or more halogen atoms.
  • a C 1-3 haloalkyl could be -CFHCH 2 CHF 2 and a C 1-2 haloalkoxy could be -OC(Br)HCHF 2 .
  • This term includes perfluorinated alkyl groups, such as -CF 3 and -CF 2 CF 3 .
  • cyano refers to -CN or -C ⁇ N.
  • cyanoalkyl mean alkyl, alkenyl, aliphatic or alkoxy, as the case may be, substituted with one or more cyano groups.
  • amino refers to -NH 2 .
  • aminoalkyl means alkyl, alkenyl, aliphatic or alkoxy, as the case may be, substituted with one or more amino groups.
  • a C 1-3 aminoalkyl could be -CH(NH 2 )CH 2 CH 2 NH 2 and a C 1-2 aminoalkoxy could be -OCH 2 CH 2 NH 2 .
  • hydroxyl or "hydroxy” refers to -OH.
  • hydroxyalkyl means alkyl, alkenyl, aliphatic or alkoxy, as the case may be, substituted with one or more -OH groups.
  • a C 1-3 hydroxyalkyl could be -CH 2 (CH 2 OH)CH 3 and a C 4 hydroxyalkoxy could be -OCH 2 C(CH 3 )(OH)CH 3 .
  • a "carbonyl”, used alone or in connection with another group refers to -C(O) - or -C(O)H.
  • An aliphatic chain can be optionally interrupted by a carbonyl group or can optionally be substituted by an oxo group, and both expressions refer to the same: e.g., -CH 2 -C(O)-CH 3 .
  • linker refers to a bifunctional chemical moiety attaching a compound to a solid support or soluble support.
  • a "linker”, as used herein, refers to a divalent group in which the two free valences are on different atoms (e.g., carbon or heteroatom) or are on the same atom but can be substituted by two different substituents.
  • a methylene group can be C 1 alkyl linker (-CH 2 -) which can be substituted by two different groups, one for each of the free valences (e.g., as in Ph-CH 2 -Ph, wherein methylene acts as a linker between two phenyl rings).
  • Ethylene can be C 2 alkyl linker (-CH 2 CH 2 -) wherein the two free valences are on different atoms.
  • the amide group can act as a linker when placed in an internal position of a chain (e.g., -CONH-).
  • a linker can be the result of interrupting an aliphatic chain by certain functional groups or of replacing methylene units on said chain by said functional groups, e.g., a linker can be a C 1-6 aliphatic chain in which up to two methylene units are substituted by -C(O)- or -NH- (as in -CH 2 -NH-CH 2 -C(O)-CH 2 - or - CH 2 -NH-C(O)-CH 2 -).
  • Cyclic groups can also form linkers: e.g., a 1,6-cyclohexanediyl can be a linker between two R groups, as in A linker can additionally be optionally substituted in any portion or position.
  • protecting group refers to an agent used to temporarily block one or more desired reactive sites in a multifunctional compound.
  • a protecting group has one or more, or preferably all, of the following characteristics: a) reacts selectively in good yield to give a protected substrate that is stable to the reactions occurring at one or more of the other reactive sites; and b) is selectively removable in good yield by reagents that do not attack the regenerated functional group.
  • Exemplary protecting groups are detailed in Greene, T. W. et al., "Protective Groups in Organic Synthesis", Third Edition, John Wiley & Sons, New York: 1999 .
  • nitrogen protecting group refers to an agents used to temporarily block one or more desired nitrogen reactive sites in a multifunctional compound.
  • Preferred nitrogen protecting groups also possess the characteristics exemplified above, and certain exemplary nitrogen protecting groups are detailed in Chapter 7 in Greene, T. W., Wuts, P. G in "Protective Groups in Organic Synthesis", Third Edition, John Wiley & Sons, New York: 1999 .
  • the term "displaceable moiety” or “leaving group” refers to a group that is associated with an aliphatic or aromatic group as defined herein and is subject to being displaced by nucleophilic attack by a nucleophile.
  • amide coupling agent or “amide coupling reagent” means a compound that reacts with the hydroxyl moiety of a carboxy moiety thereby rendering it susceptible to nucleophilic attack.
  • exemplary amide coupling agents include DIC (diisopropylcarbodiimide), EDCI (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide), DCC (dicyclohexylcarbodiimide), BOP (benzotriazol-1-yloxy-tris(dimethylamino)-phosphonium hexafluorophosphate), pyBOP ((benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate), etc.
  • the compounds of the invention are defined herein by their chemical structures and/or chemical names. Where a compound is referred to by both a chemical structure and a chemical name, and the chemical structure and chemical name conflict, the chemical structure is determinative of the compound's identity.
  • the invention is directed to compounds according to Formula I, or a pharmaceutically acceptable salt thereof,
  • W is absent.
  • the compound is a compound of Formula IIa: wherein Q represents a -CZ 2 - group; each Z is independently selected from hydrogen or fluorine; and p is an integer selected from 1, 2, 3, 4 and 5.
  • Q represents a -CZ 2 - group
  • each Z is independently selected from hydrogen or fluorine
  • p is an integer selected from 1, 2, 3, 4 and 5.
  • up to 5 instances of Z are fluorine and the remaining instances of Z are hydrogen.
  • the compound is a compound of Formula IIIa:
  • X is N, and the moiety -N(R 1 )(R 2 ) is absent. In some embodiments of the compounds of Formula IIIa, X is C, and the moiety -N(R 1 )(R 2 ) is present. In some of these embodiments:
  • R 1 or R 2 when one of R 1 or R 2 is the C 3-8 cycloalkyl ring, 4 to 8-membered heterocyclic ring or 5 or 6-membered heteroaryl substituted with up to 5 instances of R 5f , two of the instances of R 5f attached to the same or different ring atoms of said R 1 or R 2 , together with said atom or atoms, form a C 3-8 cycloalkyl ring, a 4 to 6-membered heterocyclic ring, a phenyl or a 5 or 6-membered heterocyclic ring, resulting in a bicyclic system wherein the two rings are in a spiro, fused or bridged relationship, wherein said 4 to 6-membered heterocycle or said 5 or 6-membered heterocyclic ring contains up to two ring heteroatoms independently selected from N, O or S; and wherein said C 3-8 cycloalkyl ring, 4 to 6-membered heterocyclic ring, phenyl
  • X is N. In other embodiments, X is C.
  • the compounds have Formula IVa: wherein J D is absent or is selected from halogen, methyl, hydroxyl, methoxy, trifluoromethyl, trifluoromethoxy or -NR a R b ; in some of these embodiments, R a and R b are each independently selected from hydrogen, C 1-6 alkyl or a 3-6 cycloalkyl ring; alternatively, R a and R b , together with the nitrogen atom to which they are both attached, may form a 4-8 membered heterocyclic ring, or a 5-membered heteroaryl ring optionally containing up to two additional heteroatoms selected from N, O and S; wherein each of said 4-8 membered heterocyclic ring and 5-membered heteroaryl ring is optionally and independently substituted by up to 5 instances of fluorine; J A is selected from hydrogen or fluorine; and R 1 and R 2 are as defined supra.
  • the compounds of the invention are compounds of Formula IIb, or pharmaceutically acceptable salts thereof:
  • ring B is a phenyl.
  • ring B is a 5 or 6-membered heteroaryl ring, containing 1 or 2 ring heteroatoms selected from N, O or S.
  • X is C. In some of these embodiments, X is optionally substituted by J D . In other embodiments of the compounds of Formula IIb, X is N.
  • each J D is independently selected from halogen, a C 1-6 aliphatic, C 1-6 haloaliphatic, -N(R D ) 2 , -N(R d )COR D , -N(R d )COOR D , -OR D , -N(R d )SO 2 R D oxo or an optionally substituted C 3-8 cycloaliphatic ring.
  • o is 2 and each J D is independently selected from a halogen atom or -N(R D ) 2 , -N(R d )COR D , -OH, -N(R d )COOR D , or -N(R d )SO 2 R D .
  • o is 2 and one instance of J D is fluoro or chloro and the other instance of J D is -OH.
  • o is 2 and one instance of J D is -NH 2 and the other one is independently selected from -N(R D ) 2 , wherein at least one instance of R D is not hydrogen; or is -NHCOR D , -N(R d )COOR D or -N(R d )SO 2 R D .
  • o is 2 and one instance of J D is independently selected from -N(R D ) 2 or -NHCOR D and the other instance of J D is selected from fluoro or chloro.
  • o is 1 and J D is amino.
  • the compounds are compounds of Formula IIIb:
  • X is N; in these embodiments, -NR 1 R 2 is absent. In other embodiments, X is C.
  • the compounds are represented by Formula Vb: wherein, J D is absent or is selected from halogen, methyl, hydroxyl, methoxy, trifluoromethyl, trifluoromethoxy or -NR a R b ; in some of these embodiments, R a and R b are each independently selected from hydrogen, C 1-6 alkyl or a 3-6 cycloalkyl ring; alternatively, R a and R b , together with the nitrogen atom to which they are both attached, may form a 4-8 membered heterocyclic ring, or a 5-membered heteroaryl ring optionally containing up to two additional heteroatoms selected from N, O and S; wherein each of said 4-8 membered heterocyclic ring and 5-membered heteroaryl ring is optionally and independently substituted by up to 5 instances of fluorine; and J A is selected from hydrogen or fluorine.
  • ring B is phenyl or a 6-membered heteroaryl ring.
  • n is an integer selected from 1, 2, or3 and each J B is independently selected from halogen, a C 1-6 aliphatic or -OR B .
  • each J B is independently selected from halogen.
  • each J B is independently selected from fluoro or chloro.
  • each J B is fluoro.
  • each J B is methyl or ethyl.
  • n is 1.
  • J B is selected from halogen.
  • J B is fluoro or chloro.
  • J B is fluoro.
  • At least one J B is ortho to the attachment of the methylene linker between ring B and ring A.
  • each J B is independently selected from halogen.
  • each J B is independently selected from fluoro or chloro.
  • each J B is fluoro.
  • n is 1, the J B ortho to the attachment of the methylene linker between ring B and ring A is fluoro.
  • ring B is a 6-membered heteroaryl ring.
  • B is a pyridyl ring.
  • ring B is a pyrimidinyl ring.
  • each J D is independently selected from halogen, a C 1-6 aliphatic, C 1-6 haloaliphatic, -N(R D ) 2 , -N(R d )C(O)R D , -N(R d )C(O)OR D , -N(R d )C(O)N(R D ) 2 , -SO 2 R D , -SO 2 N(R D ) 2 , -N(R d )SO 2 R D , -SR D , -OR D or an optionally substituted C 3-8 cycloaliphatic ring.
  • each J D is independently selected from methyl, trifluoromethyl, chloro, fluoro, -N(R D ) 2 , N(R d )C(O)R D , -N(R d )SO 2 R D , or -OR D .
  • R d is independently selected from hydrogen or C 1-4 alkyl.
  • o is 1 or 2 and at least one instance of J D is independently selected from fluoro, chloro, hydroxyl and amino. In further embodiments, o is an integer selected from 1 or 2.
  • compounds have Formulae VIb, VIIb, Va or VIa: wherein ring E is a 5 or 6-membered heterocyclic ring, containing up to 3 heteroatoms selected from N, O and S; and wherein each J E is independently selected from oxo or -(Y)-R 9 .
  • J D is absent or is selected from halogen, -NH 2 , or -OH.
  • ring E is a heterocyclic ring containing one nitrogen ring atom and at least one instance of J E is oxo.
  • one J E is oxo and two other instances of J E are independently selected from -(Y)-R 9 .
  • each -(Y)-R 9 is independently selected from a C 1-6 alkyl; a 5 or 6-membered heteroaryl ring containing between 1 and 3 heteroatoms independently selected from N, O or S and optionally substituted by one or more instances of C 1-6 alkyl or halogen; and -(CO)NH-R 10 .
  • R 10 is a C 3-6 cycloalkyl ring.
  • the compounds of the invention are represented by one of Formulae VIIa or VIIIb:
  • one instance of J E is oxo and two other instances of J E are independently selected from C 1-6 alkyl; a 5 or 6-membered heteroaryl ring, containing between 1 and 3 heteroatoms independently selected from N, O, or S and optionally substituted by one or more instances of C 1-6 alkyl or halogen; and -(CO)NH-R 10 .
  • R 10 is a C 3-6 cycloalkyl ring.
  • the compounds of the invention are represented by one of Formulae VIIIa or XIXb:
  • both -(Y)-R 9 substituents are attached to any ring carbon anywhere on the ring, provided that both -(Y)-R 9 substituents are attached to the same ring carbon.
  • each J D is independently selected from -NH 2 or is absent; and wherein each J A is alternatively: i) when R 1 and R 2 are not simultaneously hydrogen, each J A is independently selected from hydrogen or halogen; or ii) when R 1 and R 2 are both simultaneously hydrogen, each J A is independently selected from -C(O)R D , -C(O)OR D , -OC(O)R D , -C(O)N(R D ) 2 , -N(R D ) 2 , -N(R d )C(O)R D , -N(R d )C(O)OR D , -N(R d )C(O)N(R D ) 2 , -OC(O)N(R D ) 2 , -SO 2 R D
  • R C is C 1-6 aliphatic optionally substituted with up to 6 instances of fluoro. In some embodiments, R C is C 1-6 alkyl optionally substituted with up to 6 instances of fluoro. In other embodiments, R C is ethyl or methyl; the ethyl or methyl may be optionally substituted with up to 5 instances of fluoro. In still other embodiments, R C is a C 3-6 cycloaliphatic, optionally substituted with up to 4 instances of fluoro.
  • the compound is selected from those depicted in Table I below: Table I I-1 I-2 I-3 I-4 I-5 I-6 I-7 I-8 I-9 I-10 I-11 I-12 I-13 I-14 I-15 I-16 I-17 I-19 I-20 I-21 I-22 I-23 I-24 I-26 I-27 I-28 I-30 I-31 I-32 I-33 I-34 I-35 I-36 I-37 I-38 I-40 I-41 I-42 I-43 I-44 I-45 I-46 I-47 I-48 I-49 I-50 I-51 I-52 I-53 I-54 I-55 I-56 I-57 I-58 I-59 I-60 I-61 I-62 I-63 I-64 I-65 I-66 I-67 I-68 I-69 I-70 I-71 I-72;
  • the compounds of Formula I may be prepared according to the schemes and examples depicted and described below. Unless otherwise specified, the starting materials and various intermediates may be obtained from commercial sources, prepared from commercially available compounds or prepared using well-known synthetic methods. Another aspect of the present invention is a process for preparing the compounds of Formula I as disclosed herein.
  • Scheme 1 depicts the method of Argentine et al (Org. Process R&D 2009, 13, 131-143 ).
  • Substituted semicarbazides of the general structure 5 can be prepared by reacting commercially available tert -butylcarbazate 2 with bromide 3 to afford Boc-protected hydrazide 4.
  • Intermediate 4 can then be reacted directly with potassium cyanate in aqueous ethanol or alternatively with trimethylsilylisocyanate in THF followed by treatment with acid to deprotect the Boc protecting group and protodesilylate the trimethylsilyl protecting group to regioselectively afford semicarbazide 5.
  • Compound 3 when not commercially available, may be prepared from the corresponding alcohol by bromination with reagents such as PBr 3 in a solvent such as ether.
  • Alkyl hydrazines such as 6 can also be prepared by one skilled in the art by reacting alkyl halide 3 with hydrazine in polar solvent and subsequent reaction with potassium cyanate to directly afford semicarbazide 5.
  • Compounds comprising examples of Formula I may then be synthesized by activating carboxylic acid 7 with a variety of amide coupling reagents (such as HATU, BOP, TPI, or conversion of the acid to an acid chloride) in DMF and a base such as triethylamine and then reacting it with intermediate semicarbazide 5 to form acyl semicarbazide 8 which can be cyclized to the desired triazolone 1 by heating under acidic conditions such as camphorsulfonic acid (Argentine et al) or under basic conditions ( Deng et al Tetrahedron Lett. 2005, 7993-7996 ) such as NaOH in EtOH.
  • amide coupling reagents such as HATU, BOP, TPI, or conversion of the acid to an acid chloride
  • the 4-chloro substituent of intermediate 10 is generally more reactive than the 2-chloro substituent and can be chemoselectively displaced in a SNAr reaction with diverse nucleophiles (carbon-based, substituted amino, hydroxyl-containing, etc.) or with diverse nucleophiles using metal-assisted or organometallic reagent-mediated displacement (e.g., Suzuki reactions, Buchwald aminations, Sonogashira reactions, etc.) to give the mono-chloro intermediate 11.
  • diverse nucleophiles carbon-based, substituted amino, hydroxyl-containing, etc.
  • metal-assisted or organometallic reagent-mediated displacement e.g., Suzuki reactions, Buchwald aminations, Sonogashira reactions, etc.
  • the 2-chloro substituent of 11 can be transposed to ester 12a via a carbonylation reaction using a palladium catalyst and carbon monoxide in an alcoholic solvent under basic conditions ( WO2008/47201 , US2012/245124 , WO2008/9487 ).
  • the chloride of 11 can be displaced by cyanide under refluxing alcoholic/aqueous conditions or by using palladium-mediated cross-coupling with zinc cyanide in a polar solvent such as DMF or NMP to give nitrile 12b ( Wada et al Tetrahedron Lett. 2012, 53(14), 1720-1724 ).
  • Ester 12a can be hydrolyzed using NaOH or by dealkylative deprotection (e.g., potassium trimethylsilyloxide heated in a polar aprotic solvent) and nitrile 12b can be deprotected by hydrolysis in aqueous NaOH at 100 °C to give intermediate carboxylic acid 7.
  • dealkylative deprotection e.g., potassium trimethylsilyloxide heated in a polar aprotic solvent
  • nitrile 12b can be deprotected by hydrolysis in aqueous NaOH at 100 °C to give intermediate carboxylic acid 7.
  • Scheme 3 shows a complimentary method for making intermediate carboxylic acids 7 by condensation of an amidine such as commercially available methyl-2-amino-2-iminoacetate with a variety of 3-carbon electrophiles using reagents and conditions detailed in our earlier work ( WO2013101830 , WO2012003405 ) and others ( WO2011149921 , WO2013104703 , WO2013030288 , 2013004785 , 2012004259 ) to form substituted pyrimidine carboxylates.
  • an amidine such as commercially available methyl-2-amino-2-iminoacetate
  • WO2013104703 WO2013030288 , 2013004785 , 2012004259
  • Reaction (1) shows the condensation of methyl-2-amino-2-iminoacetate with the anion of ⁇ -hydroxy ethylacrylate in refluxing ethanol to give a 2-carboxy-4-hydroxypyrimidine 7a after ester deprotection using NaOH.
  • This intermediate can be further derivatized by treatment with phosphorus oxychloride in DCM followed by SNAr displacement by various carbon, oxygen, and in this case an amino nucleophile HNR D R D to give a functionalized pyrimidine carboxylate 7b.
  • Reactions (2) and (3) show an analogous example wherein the electrophile is a substituted malononitrile.
  • intermediate 7e can be further derivatized by treatment with phosphorus oxychloride in DCM followed by SNAr displacement by various carbon, oxygen, and in this case an amino nucleophile HNR D R D to give a functionalized 1,2,4-triazine carboxylate 7f.
  • Scheme 3 reaction (5) makes use of a diketone electrophile ( Beard et al WO2008030843 ) to provide diverse 1,2,4-triazine-3-carboxylates of the general structure 7g after ester hydrolysis.
  • Scheme 4 illustrates a method for making alkoxytriazoles of Formula I by simply replacing the semicarbazide 5 used in Scheme 1, with thiosemicarbazide 5' that can be prepared from 6 using potassium thiocyanate in alcoholic solvent. Coupling thiosemicarbazide 5' with carboxylic acid 7 using a coupling reagent such as HATU provides acylthiosemicarbazide 13 that can be cyclized to the triazolethione 14 under basic or acidic conditions. Following the method of Kane et al (J. Med. Chem.
  • triazolethione 14 reacts with methyl iodide under basic conditions such as K 2 CO 3 in acetone to give S-methylation and subsequent oxidation using reagents such as MCPBA or Oxone can provide the triazole sulfone 15. Displacement of this sulfone using an alcohol Rc-OH deprotonated with NaH in DMF and heating provides the desired alkoxytriazole 16 of Formula I.
  • pyrazole variants of Formula I compounds is detailed in Scheme 5.
  • the pyrazolone core structure can be synthesized by condensation of substituted hydrazine 6 with diethyl 2-oxosuccinate under acidic conditions to form hydroxypyrazole 17.
  • This intermediate may be O-alkylated with diverse electrophiles such as alkyl and aryl iodides and triflates under basic conditions to provide alkoxy pyrazole 18.
  • Treatment of 18 with ammonium chloride and trimethylaluminum gives the amidine 19 which can be condensed with 3-carbon electrophiles using the reagents, conditions, and references described above in Scheme 3, Reactions (1)-(3) to provide compounds of Formula I such as the substituted pyrimidines 20 .
  • Amidine 19 can be treated with hydrazine in refluxing alcohol to form the 2-aminohydrazone 21 that can be condensed with 2-carbon electrophiles using the reagents, conditions, and references described above in Scheme 3, Reactions (4)-(5) to provide compounds of Formula I such as the substituted triazines 22.
  • the invention in a second aspect, relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the compound of any one of the above embodiments, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
  • pharmaceutically acceptable salt refers to pharmaceutically acceptable organic or inorganic salts of a compound of Formula I.
  • the pharmaceutically acceptable salts of a compound of Formula I are used in medicine. Salts that are not pharmaceutically acceptable may, however, be useful in the preparation of a compound of Formula I or of their pharmaceutically acceptable salts.
  • a pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counter ion.
  • the counter ion may be any organic or inorganic moiety that stabilizes the charge on the parent compound.
  • a pharmaceutically acceptable salt may have more than one charged atom in its structure. Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counter ions. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counter ion.
  • salts of the compounds described herein include those derived from the compounds with inorganic acids, organic acids or bases.
  • the salts can be prepared in situ during the final isolation and purification of the compounds.
  • the salts can be prepared from the free form of the compound in a separate synthetic step.
  • suitable “pharmaceutically acceptable salts” refers to salts prepared form pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases.
  • Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc and the like. Particular embodiments include ammonium, calcium, magnesium, potassium and sodium salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N, N.sup.1-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine tripropylamine, tromethamine and the like.
  • basic ion exchange resins such as
  • salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like.
  • Particular embodiments include citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric and tartaric acids.
  • Other exemplary salts include, but are not limited, to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and palmoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-nap
  • the term “compound” also includes a pharmaceutically acceptable salt of the compound, whether or not the phrase “pharmaceutically acceptable salt” is actually used.
  • compositions and methods of administration are provided.
  • a typical formulation is prepared by mixing a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a carrier, diluent or excipient.
  • Suitable carriers, diluents and excipients are well known to those skilled in the art and include materials such as carbohydrates, waxes, water soluble and/or swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, and the like.
  • the particular carrier, diluent or excipient used will depend upon the means and purpose for which a compound of Formula I is being formulated.
  • Solvents are generally selected based on solvents recognized by persons skilled in the art as safe (GRAS-Generally Regarded as Safe) to be administered to a mammal.
  • safe solvents are non-toxic aqueous solvents such as water and other non-toxic solvents that are soluble or miscible in water.
  • Suitable aqueous solvents include water, ethanol, propylene glycol, polyethylene glycols (e.g., PEG400, PEG300), etc. and mixtures thereof.
  • the formulations may also include other types of excipients such as one or more buffers, stabilizing agents, antiadherents, surfactants, wetting agents, lubricating agents, emulsifiers, binders, suspending agents, disintegrants, fillers, sorbents, coatings (e.g., enteric or slow release) preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents and other known additives to provide an elegant presentation of the drug (i.e., a compound of Formula I or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).
  • excipients such as one or more buffers, stabilizing agents, antiadherents, surfactants, wetting agents, lubricating agents, emulsifiers, binders, suspending agents, disintegrants, fillers, sorbents, coatings (e.g., enteric or slow release
  • the formulations may be prepared using conventional dissolution and mixing procedures.
  • the bulk drug substance i.e., a compound of Formula I, a pharmaceutically acceptable salt thereof, or a stabilized form of the compound, such as a complex with a cyclodextrin derivative or other known complexation agent
  • a suitable solvent in the presence of one or more of the excipients described above.
  • a compound having the desired degree of purity is optionally mixed with pharmaceutically acceptable diluents, carriers, excipients or stabilizers, in the form of a lyophilized formulation, milled powder, or an aqueous solution.
  • Formulation may be conducted by mixing at ambient temperature at the appropriate pH, and at the desired degree of purity, with physiologically acceptable carriers.
  • the pH of the formulation depends mainly on the particular use and the concentration of compound, but may range from about 3 to about 8.
  • additives may be added directly to the spray-drying solution when forming the mixture such as the additive is dissolved or suspended in the solution as a slurry which can then be spray dried.
  • the additives may be added following spray-drying process to aid in the forming of the final formulated product.
  • the compound of Formula I or a pharmaceutically acceptable salt thereof is typically formulated into pharmaceutical dosage forms to provide an easily controllable dosage of the drug and to enable patient compliance with the prescribed regimen.
  • Pharmaceutical formulations of a compound of Formula I, or a pharmaceutically acceptable salt thereof may be prepared for various routes and types of administration. Various dosage forms may exist for the same compound, since different medical conditions may warrant different routes of administration.
  • a time-release formulation intended for oral administration to humans may contain approximately 1 to 1000 mg of active material compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95% of the total compositions (weight: weight).
  • the pharmaceutical composition can be prepared to provide easily measurable amounts for administration.
  • an aqueous solution intended for intravenous infusion may contain from about 3 to 500 ⁇ g of the active ingredient per milliliter of solution in order that infusion of a suitable volume at a rate of about 30 mL/hr can occur.
  • the initial pharmaceutically effective amount of the inhibitor administered will be in the range of about 0.01-100 mg/kg per dose, namely about 0.1 to 20 mg/kg of patient body weight per day, with the typical initial range of compound used being 0.3 to 15 mg/kg/day.
  • therapeutically effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
  • the therapeutically or pharmaceutically effective amount of the compound to be administered will be governed by such considerations, and is the minimum amount necessary to ameliorate, cure or treat the disease or disorder or one or more of its symptoms.
  • compositions of Formula I will be formulated, dosed, and administered in a fashion, i.e., amounts, concentrations, schedules, course, vehicles, and route of administration, consistent with good medical practice.
  • Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners, such as the age, weight, and response of the individual patient.
  • prophylactically effective amount refers to an amount effective in preventing or substantially lessening the chances of acquiring a disease or disorder or in reducing the severity of the disease or disorder before it is acquired or reducing the severity of one or more of its symptoms before the symptoms develop. Roughly, prophylactic measures are divided between primary prophylaxis (to prevent the development of a disease) and secondary prophylaxis (whereby the disease has already developed and the patient is protected against worsening of this process).
  • Acceptable diluents, carriers, excipients, and stabilizers are those that are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lys
  • the active pharmaceutical ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, e.g., hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively; in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions.
  • colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
  • Controlled drug delivery systems supply the drug to the body in a manner precisely controlled to suit the drug and the conditions being treated.
  • the primary aim is to achieve a therapeutic drug concentration at the site of action for the desired duration of time.
  • controlled release is often used to refer to a variety of methods that modify release of drug from a dosage form. This term includes preparations labeled as “extended release”, “delayed release”, “modified release” or “sustained release”.
  • sustained-release preparations are the most common applications of controlled release. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the compound, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides ( U.S. Pat. No.
  • “Immediate-release preparations” may also be prepared.
  • the objective of these formulations is to get the drug into the bloodstream and to the site of action as rapidly as possible. For instance, for rapid dissolution, most tablets are designed to undergo rapid disintegration to granules and subsequent deaggregation to fine particles. This provides a larger surface area exposed to the dissolution medium, resulting in a faster dissolution rate.
  • Agents described herein can be incorporated into an erodible or non-erodible polymeric matrix controlled release device.
  • an erodible matrix is meant aqueous-erodible or water-swellable or aqueous-soluble in the sense of being either erodible or swellable or dissolvable in pure water or requiring the presence of an acid or base to ionize the polymeric matrix sufficiently to cause erosion or dissolution.
  • the erodible polymeric matrix When contacted with the aqueous environment of use, the erodible polymeric matrix imbibes water and forms an aqueous-swollen gel or matrix that entraps the agent described herein.
  • the aqueous-swollen matrix gradually erodes, swells, disintegrates or dissolves in the environment of use, thereby controlling the release of a compound described herein to the environment of use.
  • One ingredient of this water-swollen matrix is the water-swellable, erodible, or soluble polymer, which may generally be described as an osmopolymer, hydrogel or water-swellable polymer.
  • Such polymers may be linear, branched, or cross linked.
  • the polymers may be homopolymers or copolymers. In certain embodiments, they may be synthetic polymers derived from vinyl, acrylate, methacrylate, urethane, ester and oxide monomers.
  • polysaccharides e.g., chitin, chitosan, dextran and pullulan; gum agar, gum arabic, gum karaya, locust bean gum, gum tragacanth, carrageenans, gum ghatti, guar gum, xanthan gum and scleroglucan), starches (e.g., dextrin and maltodextrin), hydrophilic colloids (e.g., pectin), phosphatides (e.g., lecithin), alginates (e.g., ammonium alginate, sodium, potassium or calcium alginate, propylene glycol alginate), gelatin, collagen, and cellulosics.
  • polysaccharides e.g., chitin, chitosan, dextran and pullulan
  • Cellulosics are cellulose polymer that has been modified by reaction of at least a portion of the hydroxyl groups on the saccharide repeat units with a compound to form an ester-linked or an ether-linked substituent.
  • the cellulosic ethyl cellulose has an ether linked ethyl substituent attached to the saccharide repeat unit, while the cellulosic cellulose acetate has an ester linked acetate substituent.
  • the cellulosics for the erodible matrix comprises aqueous-soluble and aqueous-erodible cellulosics can include, for example, ethyl cellulose (EC), methylethyl cellulose (MEC), carboxymethyl cellulose (CMC), CMEC, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), cellulose acetate (CA), cellulose propionate (CP), cellulose butyrate (CB), cellulose acetate butyrate (CAB), CAP, CAT, hydroxypropyl methyl cellulose (HPMC), HPMCP, HPMCAS, hydroxypropyl methyl cellulose acetate trimellitate (HPMCAT), and ethylhydroxy ethylcellulose (EHEC).
  • EC ethyl cellulose
  • MEC methylethyl cellulose
  • CMC carboxymethyl cellulose
  • CMEC hydroxyethyl cellulose
  • HPC hydroxyprop
  • the cellulosics comprises various grades of low viscosity (MW less than or equal to 50,000 Daltons, for example, the Dow MethocelTM series E5, E15LV, E50LV and K100LY) and high viscosity (MW greater than 50,000 Daltons, for example, E4MCR, E10MCR, K4M, K15M and K100M and the MethocelTM K series) HPMC.
  • low viscosity MW less than or equal to 50,000 Daltons
  • high viscosity MW greater than 50,000 Daltons
  • E4MCR, E10MCR, K4M, K15M and K100M and the MethocelTM K series HPMC.
  • Other commercially available types of HPMC include the Shin Etsu Metolose 90SH series.
  • erodible matrix material examples include, but are not limited to, pullulan, polyvinyl pyrrolidone, polyvinyl alcohol, polyvinyl acetate, glycerol fatty acid esters, polyacrylamide, polyacrylic acid, copolymers of ethacrylic acid or methacrylic acid (EUDRAGIT®, Rohm America, Inc., Piscataway, New Jersey) and other acrylic acid derivatives such as homopolymers and copolymers of butylmethacrylate, methylmethacrylate, ethylmethacrylate, ethylacrylate, (2-dimethylaminoethyl) methacrylate, and (trimethylaminoethyl) methacrylate chloride.
  • pullulan polyvinyl pyrrolidone
  • polyvinyl alcohol polyvinyl acetate
  • glycerol fatty acid esters polyacrylamide
  • polyacrylic acid copolymers of ethacrylic acid or me
  • the agents of the present invention may be administered by or incorporated into a non-erodible matrix device.
  • an agent described herein is distributed in an inert matrix.
  • the agent is released by diffusion through the inert matrix.
  • materials suitable for the inert matrix include insoluble plastics (e.g., methyl acrylate-methyl methacrylate copolymers, polyvinyl chloride, polyethylene), hydrophilic polymers (e.g., ethyl cellulose, cellulose acetate, cross linked polyvinylpyrrolidone (also known as crospovidone), and fatty compounds (e.g., carnauba wax, microcrystalline wax, and triglycerides).
  • insoluble plastics e.g., methyl acrylate-methyl methacrylate copolymers, polyvinyl chloride, polyethylene
  • hydrophilic polymers e.g., ethyl cellulose, cellulose acetate, cross linked polyvinylpyrrolidone (also known
  • the agents described herein may also be incorporated into an osmotic control device.
  • Such devices generally include a core containing one or more agents as described herein and a water permeable, non-dissolving and non-eroding coating surrounding the core which controls the influx of water into the core from an aqueous environment of use so as to cause drug release by extrusion of some or all of the core to the environment of use.
  • the coating is polymeric, aqueous-permeable, and has at least one delivery port.
  • the core of the osmotic device optionally includes an osmotic agent which acts to imbibe water from the surrounding environment via such a semi-permeable membrane.
  • the osmotic agent contained in the core of this device may be an aqueous-swellable hydrophilic polymer or it may be an osmogen, also known as an osmagent. Pressure is generated within the device which forces the agent(s) out of the device via an orifice (of a size designed to minimize solute diffusion while preventing the build-up of a hydrostatic pressure head).
  • osmotic control devices are disclosed in U. S. Patent Application Serial No. 09/495,061 .
  • the amount of water-swellable hydrophilic polymers present in the core may range from about 5 to about 80 wt% (including for example, 10 to 50 wt%).
  • core materials include hydrophilic vinyl and acrylic polymers, polysaccharides such as calcium alginate, polyethylene oxide (PEO), polyethylene glycol (PEG), polypropylene glycol (PPG), poly (2-hydroxyethyl methacrylate), poly (acrylic) acid, poly (methacrylic) acid, polyvinylpyrrolidone (PVP) and cross linked PVP, polyvinyl alcohol (PVA), PVA/PVP copolymers and PVA/PVP copolymers with hydrophobic monomers such as methyl methacrylate, vinyl acetate, and the like, hydrophilic polyurethanes containing large PEO blocks, sodium croscarmellose, carrageenan, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropyl methyl
  • hydrogels comprising interpenetrating networks of polymers that may be formed by addition or by condensation polymerization, the components of which may comprise hydrophilic and hydrophobic monomers such as those just mentioned.
  • Water-swellable hydrophilic polymers include but are not limited to PEO, PEG, PVP, sodium croscarmellose, HPMC, sodium starch glycolate, polyacrylic acid and cross linked versions or mixtures thereof.
  • the core may also include an osmogen (or osmagent).
  • the amount of osmogen present in the core may range from about 2 to about 70 wt% (including, for example, from 10 to 50 wt%).
  • suitable osmogens are water-soluble organic acids, salts and sugars that are capable of imbibing water to thereby effect an osmotic pressure gradient across the barrier of the surrounding coating.
  • Typical useful osmogens include but are not limited to magnesium sulfate, magnesium chloride, calcium chloride, sodium chloride, lithium chloride, potassium sulfate, sodium carbonate, sodium sulfite, lithium sulfate, potassium chloride, sodium sulfate, mannitol, xylitol, urea, sorbitol, inositol, raffinose, sucrose, glucose, fructose, lactose, citric acid, succinic acid, tartaric acid, and mixtures thereof.
  • the osmogen is glucose, lactose, sucrose, mannitol, xylitol, sodium chloride, including combinations thereof.
  • the rate of drug delivery is controlled by such factors as the permeability and thickness of the coating, the osmotic pressure of the drug-containing layer, the degree of hydrophilicity of the hydrogel layer, and the surface area of the device.
  • the thickness of the coating will reduce the release rate, while any of the following will increase the release rate: increasing the permeability of the coating; increasing the hydrophilicity of the hydrogel layer; increasing the osmotic pressure of the drug-containing layer; or increasing the device's surface area.
  • entrainment of particles of agents described herein in the extruding fluid during operation of such osmotic device is desirable.
  • the agent drug form is dispersed in the fluid before the particles have an opportunity to settle in the tablet core.
  • a disintegrant that serves to break up the compressed core into its particulate components.
  • standard disintegrants include materials such as sodium starch glycolate (e. g., ExplotabTM CLV), microcrystalline cellulose (e. g., AvicelTM), microcrystalline silicified cellulose (e. g., ProSoIvTM) and croscarmellose sodium (e.
  • non-gelling, non-swelling disintegrants are resins, for example, ion-exchange resins.
  • the resin is AmberliteTM IRP 88 (available from Rohm and Haas, Philadelphia, PA).
  • the disintegrant is present in amounts ranging from about 1-25% of the core agent.
  • an osmotic device is an osmotic capsule.
  • the capsule shell or portion of the capsule shell can be semipermeable.
  • the capsule can be filled either by a powder or liquid consisting of an agent described herein, excipients that imbibe water to provide osmotic potential, and/or a water-swellable polymer, or optionally solubilizing excipients.
  • the capsule core can also be made such that it has a bilayer or multilayer agent analogous to the bilayer, trilayer or concentric geometries described above.
  • Coated swellable tablets comprise a tablet core comprising an agent described herein and a swelling material, preferably a hydrophilic polymer, coated with a membrane, which contains holes, or pores through which, in the aqueous use environment, the hydrophilic polymer can extrude and carry out the agent.
  • the membrane may contain polymeric or low molecular weight water-soluble porosigens. Porosigens dissolve in the aqueous use environment, providing pores through which the hydrophilic polymer and agent may extrude.
  • porosigens are water-soluble polymers such as HPMC, PEG, and low molecular weight compounds such as glycerol, sucrose, glucose, and sodium chloride.
  • pores may be formed in the coating by drilling holes in the coating using a laser or other mechanical means.
  • the membrane material may comprise any film-forming polymer, including polymers which are water permeable or impermeable, providing that the membrane deposited on the tablet core is porous or contains water-soluble porosigens or possesses a macroscopic hole for water ingress and drug release.
  • Embodiments of this class of sustained release devices may also be multilayered, as described, for example, in EP378404 .
  • the osmotic controlled-release device may comprise a soft-gel or gelatin capsule formed with a composite wall and comprising the liquid formulation where the wall comprises a barrier layer formed over the external surface of the capsule, an expandable layer formed over the barrier layer, and a semipermeable layer formed over the expandable layer.
  • a delivery port connects the liquid formulation with the aqueous use environment.
  • the agents described herein may be provided in the form of microparticulates, generally ranging in size from about 10 ⁇ m to about 2mm (including, for example, from about 100 ⁇ m to 1mm in diameter).
  • Such multiparticulates may be packaged, for example, in a capsule such as a gelatin capsule or a capsule formed from an aqueous-soluble polymer such as HPMCAS, HPMC or starch; dosed as a suspension or slurry in a liquid ; or they may be formed into a tablet, caplet, or pill by compression or other processes known in the art.
  • Such multiparticulates may be made by any known process, such as wet- and dry-granulation processes, extrusion/spheronization, roller-compaction, melt-congealing, or by spray-coating seed cores.
  • wet-and dry-granulation processes the agent described herein and optional excipients may be granulated to form multiparticulates of the desired size.
  • microemulsions which generally are thermodynamically stable, isotropically clear dispersions of two immiscible liquids, such as oil and water, stabilized by an interfacial film of surfactant molecules ( Encyclopedia of Pharmaceutical Technology, New York: Marcel Dekker, 1992, volume 9 ).
  • surfactant emulsifier
  • co-surfactant co-emulsifier
  • an oil phase and a water phase are necessary.
  • Suitable surfactants include any surfactants that are useful in the preparation of emulsions, e.g., emulsifiers that are typically used in the preparation of creams.
  • the co-surfactant is generally selected from the group of polyglycerol derivatives, glycerol derivatives and fatty alcohols.
  • Preferred emulsifier/co-emulsifier combinations are generally although not necessarily selected from the group consisting of: glyceryl monostearate and polyoxyethylene stearate; polyethylene glycol and ethylene glycol palmitostearate; and caprilic and capric triglycerides and oleoyl macrogolglycerides.
  • the water phase includes not only water but also, typically, buffers, glucose, propylene glycol, polyethylene glycols, preferably lower molecular weight polyethylene glycols (e.g., PEG 300 and PEG 400), and/or glycerol, and the like, while the oil phase will generally comprise, for example, fatty acid esters, modified vegetable oils, silicone oils, mixtures of mono- di- and triglycerides, mono- and di-esters of PEG (e.g., oleoyl macrogol glycerides), etc.
  • buffers glucose, propylene glycol, polyethylene glycols, preferably lower molecular weight polyethylene glycols (e.g., PEG 300 and PEG 400), and/or glycerol, and the like
  • the oil phase will generally comprise, for example, fatty acid esters, modified vegetable oils, silicone oils, mixtures of mono- di- and triglycerides, mono- and di-esters of PEG (e.g., ole
  • Nanocapsules can generally entrap compounds in a stable and reproducible way.
  • ultrafine particles sized around 0.1 ⁇ m
  • polymers able to be degraded in vivo e.g., biodegradable polyalkyl-cyanoacrylate nanoparticles. Such particles are described in the prior art.
  • Implantable devices coated with a compound of this invention are another embodiment of the present invention.
  • the compounds may also be coated on implantable medical devices, such as beads, or co-formulated with a polymer or other molecule, to provide a "drug depot", thus permitting the drug to be released over a longer time period than administration of an aqueous solution of the drug.
  • Suitable coatings and the general preparation of coated implantable devices are described in U.S. Pat. Nos. 6,099,562 ; 5,886,026 ; and 5,304,121 .
  • the coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof.
  • the coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccharides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition.
  • the formulations include those suitable for the administration routes detailed herein.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations generally are found in Remington's. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
  • administer in reference to a compound, composition or formulation of the invention means introducing the compound into the system of the animal in need of treatment.
  • administration and its variants are each understood to include concurrent and/or sequential introduction of the compound and the other active agents.
  • compositions described herein may be administered systemically or locally, e.g.: orally (e.g., using capsules, powders, solutions, suspensions, tablets, sublingual tablets and the like), by inhalation (e.g., with an aerosol, gas, inhaler, nebulizer or the like), to the ear (e.g., using ear drops), topically (e.g., using creams, gels, liniments, lotions, ointments, pastes, transdermal patches, etc), ophthalmically (e.g., with eye drops, ophthalmic gels, ophthalmic ointments), rectally (e.g., using enemas or suppositories), nasally, buccally, vaginally (e.g., using douches, intrauterine devices, vaginal suppositories, vaginal rings or tablets, etc), via an implanted reservoir or the like, or parenterally depending on the severity and type of the disease being treated
  • parenteral includes, but is not limited to, subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • the compositions are administered orally, intraperitoneally or intravenously.
  • compositions described herein may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
  • Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar--agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and g
  • Tablets may be uncoated or may be coated by known techniques including microencapsulation to mask an unpleasant taste or to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
  • a water soluble taste masking material such as hydroxypropyl-methylcellulose or hydroxypropyl-cellulose may be employed.
  • Formulations of a compound of Formula I that are suitable for oral administration may be prepared as discrete units such as tablets, pills, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, e.g., gelatin capsules, syrups or elixirs.
  • Formulations of a compound intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water soluble carrier such as polyethyleneglycol or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water soluble carrier such as polyethyleneglycol or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • the active compounds can also be in microencapsulated form with one or more excipients as noted above.
  • aqueous suspensions When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents may be added. Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavoring and coloring agents and antioxidant.
  • sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, a preservative, flavoring and coloring agents and antioxidant.
  • Sterile injectable forms of the compositions described herein may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3 -butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or di-glycerides.
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of injectable formulations.
  • Oily suspensions may be formulated by suspending a compound of Formula I in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.
  • These compositions may be preserved by the addition of an anti-oxidant such as butylated hydroxyanisol or alpha-tocopherol.
  • Aqueous suspensions of a compound of Formula I contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients include a suspending agent, such as sodium carboxymethylcellulose, croscarmellose, povidone, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan mono
  • the aqueous suspension may also contain one or more preservatives such as ethyl or n-propyl p-hydroxy-benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose or saccharin.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • the rate of compound release can be controlled.
  • biodegradable polymers include poly(orthoesters) and poly(anhydrides).
  • Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
  • the injectable solutions or microemulsions may be introduced into a patient's bloodstream by local bolus injection.
  • a continuous intravenous delivery device may be utilized.
  • An example of such a device is the Deltec CADD-PLUSTM model 5400 intravenous pump.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds described herein with suitable non-irritating excipients or carriers such as cocoa butter, beeswax, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, beeswax, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, beeswax, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Other formulations suitable for vaginal administration may be presented as pess
  • compositions described herein may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the ear, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
  • Dosage forms for topical or transdermal administration of a compound described herein include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention.
  • the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body.
  • Such dosage forms can be made by dissolving or dispensing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin.
  • the rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation.
  • Topically-transdermal patches may also be used.
  • the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
  • the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2 octyldodecanol, benzyl alcohol and water.
  • the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride.
  • the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
  • the formulations may be applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w.
  • the active ingredients may be employed with either an oil-based, paraffinic or a water-miscible ointment base.
  • the active ingredients may be formulated in a cream with an oil-in-water cream base.
  • the aqueous phase of the cream base may include a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof.
  • the topical formulations may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulfoxide and related analogs.
  • the oily phase of emulsions prepared using a compound of Formula I may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. A hydrophilic emulsifier may be included together with a lipophilic emulsifier which acts as a stabilizer. In some embodiments, the emulsifier includes both an oil and a fat.
  • Emulgents and emulsion stabilizers suitable for use in the formulation of a compound of Formula I include TweenTM-60, SpanTM-80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.
  • compositions may also be administered by nasal aerosol or by inhalation.
  • Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
  • Formulations suitable for intrapulmonary or nasal administration have a particle size for example in the range of 0.1 to 500 micros (including particles in a range between 0.1 and 500 microns in increments microns such as 0.5, 1, 30, 35 microns, etc) which is administered by rapid inhalation through the nasal passage or by inhalation through the mouth so as to reach the alveolar sacs.
  • the pharmaceutical composition (or formulation) for use may be packaged in a variety of ways depending upon the method used for administering the drug.
  • an article for distribution includes a container having deposited therein the pharmaceutical formulation in an appropriate form.
  • Suitable containers are well-known to those skilled in the art and include materials such as bottles (plastic and glass), sachets, ampoules, plastic bags, metal cylinders, and the like.
  • the container may also include a tamper-proof assemblage to prevent indiscreet access to the contents of the package.
  • the container has deposited thereon a label that describes the contents of the container. The label may also include appropriate warnings.
  • the formulations may be packaged in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water, for injection immediately prior to use.
  • sterile liquid carrier for example water
  • Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described.
  • Preferred unit dosage formulations are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of the active ingredient.
  • a compound of Formula I or a pharmaceutically acceptable salt thereof may be formulated in a veterinary composition comprising a veterinary carrier.
  • Veterinary carriers are materials useful for the purpose of administering the composition and may be solid, liquid or gaseous materials which are otherwise inert or accepted in the veterinary art and are compatible with the active ingredient. These veterinary compositions may be administered parenterally, orally or by any other desired route.
  • the disclosure relates to the treatment of certain disorders by using sGC stimulators, either alone or in combination, or their pharmaceutically acceptable salts or pharmaceutical compositions comprising them, in a patient in need thereof.
  • the present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations thereof and their use, alone or in combination with one or more additional agents, for treating and/or preventing various diseases, wherein an increase in the concentration of NO or an increase in the concentration of cGMP might be desirable.
  • sGC soluble guanylate cyclase
  • Increased production of NO or increased concentration of cGMP in a tissue leads to vasodilation, inhibition of platelet aggregation and adhesion, anti-hypertensive effects, anti-remodeling effects, anti-fibrotic, anti-apoptotic effects, anti-inflammatory effects and neuronal signal transmission effects, among other effects.
  • the compounds here disclosed are sGC stimulators that may be useful in the prevention and/or treatment of diseases and disorders characterized by undesirable reduced bioavailability of and/or sensitivity to NO in a biological system (e.g., in the human body), such as those associated with conditions of oxidative stress or nitrosative stress.
  • cardiovascular disease refers to a disease based on the abnormal symptoms of circulatory organs such as the heart, blood vessels (arteries, capillaries, and veins) or both.
  • the term also includes any disease that affects the cardiovascular system in general, including cardiac disease, vascular diseases of the brain, vascular diseases of the kidney, liver and associated organs, or lung, and peripheral arterial disease, among others.
  • a "sGC-related cardiovascular disease” is one for which the NO/sGC/cGMP system is known or suspected to be involved and is a cardiovascular disease that can be treated or prevented by sGC activation/stimulation, by activation of a NO synthase, or by addition of NO or an NO-donor or an NO precursor such as L-Arginine or L-citruline, or by inhibition of a PDE (phosphodiesterase) enzyme responsible for the breakdown of cGMP, or a combination of the any of the above methods.
  • sGC activation/stimulation by activation of a NO synthase, or by addition of NO or an NO-donor or an NO precursor such as L-Arginine or L-citruline, or by inhibition of a PDE (phosphodiesterase) enzyme responsible for the breakdown of cGMP, or a combination of the any of the above methods.
  • PDE phosphodiesterase
  • vasodilation refers to the widening of blood vessels. It results from relaxation of smooth muscle cells within the vessel walls, in particular in the large veins, large arteries, and smaller arterioles. In essence, the process is the opposite of "vasoconstriction", which is the narrowing of blood vessels.
  • vasoconstriction which is the narrowing of blood vessels.
  • the response may be intrinsic (due to local processes in the surrounding tissue) or extrinsic (due to hormones or the nervous system).
  • the response may be localized to a specific organ (depending on the metabolic needs of a particular tissue, as during strenuous exercise), or it may be systemic (seen throughout the entire systemic circulation).
  • vasoconstriction refers to the narrowing of a blood vessel due to muscle contraction. Vasoconstriction is one mechanism by which the body regulates and maintains mean arterial pressure (MAP). Generalized vasoconstriction usually results in an increase in systemic blood pressure, but it may also occur in specific tissues, causing a localized reduction in blood flow.
  • MAP mean arterial pressure
  • bronchoconstriction is used to define the constriction of the airways in the lungs due to the tightening of surrounding smooth muscle, with consequent coughing, wheezing, and shortness of breath.
  • the condition has a number of causes, the most common being asthma. Exercise and allergies can bring on the symptoms in an otherwise asymptomatic individual. Other conditions such as chronic obstructive pulmonary disease (COPD) can also present with bronchoconstriction.
  • COPD chronic obstructive pulmonary disease
  • hypertension refers to an extremely common and highly preventable chronic condition in which blood pressure (BP) in the arteries is higher than normal or desired. If not properly controlled, it represents a significant risk factor for several serious cardiovascular and renal conditions.
  • Hypertension may be a primary disease, called “essential hypertension” or “idiopathic hypertension”, or it may be caused by or related to other diseases, in which case it is classified as “secondary hypertension”. Essential hypertension accounts for 90-95% of all cases.
  • resistant hypertension refers to hypertension that remains above goal blood pressure (usually less than 140/90 mmHg, although a lower goal of less than 130/80 mmHg is recommended for patients with comorbid diabetes or kidney disease), in spite of concurrent use of three antihypertensive agents belonging to different antihypertensive drug classes. People who require four or more drugs to control their blood pressure are also considered to have resistant hypertension.
  • Hypertension is an extremely common comorbid condition in diabetes, affecting ⁇ 20-60% of patients with diabetes, depending on obesity, ethnicity, and age. This type of hypertension is herein refered to as "diabetic hypertension".
  • type 2 diabetes hypertension is often present as part of the metabolic syndrome of insulin resistance also including central obesity and dyslipidemia.
  • hypertension may reflect the onset of diabetic nephropathy.
  • PH Pulmonary hypertension
  • pulmonary vasculature pulmonary artery, pulmonary vein and pulmonary capillaries
  • Common symptoms of PH include shortness of breath, dizziness and fainting, all of which are exacerbated by exertion. Without treatment, median life expectancy following diagnosis is 2.8 years.
  • PH exists in many different forms, which are categorized according to their etiology.
  • PAH pulmonary arterial hypertension
  • PH with left heart disease PH associated with lung diseases and /or hypoxaemia
  • PAH is rare in the general population, but the prevalence increases in association with certain common conditions such as HIV infection, scleroderma and sickle cell disease.
  • Other forms of PH are generally more common than PAH, and, for instance, the association of PH with chronic obstructive pulmonary disease (COPD) is of particular concern.
  • COPD chronic obstructive pulmonary disease
  • Current treatment for pulmonary hypertension depends on the stage and the mechanism of the disease.
  • coronary artery disease refers to a condition in which the blood supply to the heart muscle is partially or completely blocked (ischemia of the heart muscle or myocardium). This reduced blood supply to the myocardium may result in a number of “acute myocardial syndromes”: chest pain ("angina”, also called “angina pectoris”, stable or unstable) and different types of heart attacks ("myocardial infarction” or MI).
  • Angina also called “angina pectoris”, stable or unstable
  • MI myocardial infarction
  • Atherosclerosis refers to hardening of the arteries, due to fatty deposits in the artery walls which then may progress through formation of atherosclerotic plaques, to narrowing and eventually blockage of blood flow to the in the artery.
  • Atherosclerosis may affect other arteries as well, not just those of the heart.
  • a blood clot is the most common cause of the blockage of the artery, as usually the artery is already partially blocked due to atherosclerotic plaque (atheroma), the atheroma may rupture or tear, leading to the formation of a clot.
  • atherosclerotic plaque the atheroma
  • coronary artery disease is caused by spasm of a coronary artery, which can occur spontaneously or as a result of the use of certain drugs (e.g., cocaine, nicotine).
  • the cause of coronary artery disease is a birth defect, a viral infection (e.g., Kawasaki disease), systemic lupus erythematosus (lupus), inflammation of the arteries (arteritis), a blood clot that travelled from a heart chamber into one of the coronary arteries or physical damage (e.g., from injury or radiation therapy).
  • a viral infection e.g., Kawasaki disease
  • systemic lupus erythematosus e.g., systemic lupus erythematosus
  • inflammation of the arteries e.g., arthritis
  • a blood clot that travelled from a heart chamber into one of the coronary arteries or physical damage (e.g., from injury or radiation therapy).
  • Unstable angina refers to a change in the pattern of angina symptoms including prolonged or worsening angina and new onset of severe symptoms.
  • MI can be classified into two types: “Non-ST-segment elevation” MI and "ST-segment elevation” MI.
  • the complications of acute coronary syndromes depend on how much, how long, and where the coronary artery is blocked. If the blockage affects a large amount of heart muscle, the heart will not pump effectively. If the blockage shuts off blood flow to the electrical system of the heart, the heart rhythm may be affected. When a heart attack occurs, part of the myocardium dies. Dead tissue and the scar tissue that replaces it, does not contract. The scar tissue sometimes even expands or bulges when the rest of the heart tries to contract. Consequently there is less muscle to pump blood.
  • the heart's pumping ability may be so reduced that the heart cannot meet the body's demands for oxygen and blood. Heart failure, low blood pressure or both then develop. If more than half of the myocardium is damaged or dies, the heart generally cannot function and severe disability or death is likely.
  • Heart Failure is a progressive disorder of left ventricular (LV) myocardial remodeling that culminates in a complex clinical syndrome in which impaired cardiac function and circulatory congestion are the defining features, and results in insufficient delivery of blood and nutrients to body tissues.
  • the condition occurs when the heart is damaged or overworked and unable to pump out all the blood that returns to it from the systemic circulation. As less blood is pumped out, blood returning to the heart backs up and fluid builds up in other parts of the body. Heart failure also impairs the kidneys' ability to dispose of sodium and water, complicating fluid retention further.
  • Heart failure is characterized by autonomic dysfunction, neuro-hormonal activation and overproduction of cytokines, which contribute to progressive circulatory failure.
  • Symptoms of heart failure include: dyspnea (shortness of breath) while exercising or resting and waking at night due to sudden breathlessness, both indicative of pulmonary edema; general fatigue or weakness; edema of the feet, ankles and legs; rapid weight gain; or chronic cough, including that producing mucus or blood.
  • heart failure is classified as de novo, transient, acute, post-acute or chronic.
  • Acute heart failure i.e., the rapid or gradual onset of symptoms requiring urgent therapy, may develop de novo or as a result of chronic heart failure becoming decompensated.
  • the term "Heart failure” is often used to mean "chronic heart failure".
  • CHF congestive heart failure
  • CCF congestive cardiac failure
  • Common causes of heart failure include coronary artery disease including a previous myocardial infarction (heart attack), high blood pressure, atrial fibrillation, valvular heart disease, and cardiomyopathy. These cause heart failure by changing either the structure or the functioning of the heart.
  • heart failure due to reduced ejection fraction (HFREF)
  • HREF reduced ejection fraction
  • HPEF left ventricular systolic dysfunction
  • HNEF normal ejection fraction
  • Ejection fraction is the proportion of blood in the heart pumped out of the heart during a single contraction. It is a percentage with normal being between 50 and 75%.
  • Chronic heart failure is a long term situation, usually with stable treated symptomatology.
  • acute decompensated heart failure is worsening or decompensated heart failure, referring to episodes in which a person can be characterized as having a change in heart failure signs and symptoms resulting in a need for urgent therapy or hospitalization.
  • Heart failure may also occur in situations of high output (then it is termed “high output cardiac failure") where the ventricular systolic function is normal but the heart cannot deal with an important augmentation of blood volume.
  • Ejection Fraction is defined as the fraction of blood in the left and right ventricles that is pumped out with each heartbeat or cardiac cycle.
  • EF is applied to both the right ventricle, which ejects blood via the pulmonary valve into the pulmonary circulation, or the left ventricle, which ejects blood via the aortic valve into the cerebral and systemic circulation.
  • heart failure with preserved ejection fraction is commonly understood to refer to a manifestation of signs and symptoms of heart failure with an ejection fraction greater than 55%. It is characterized by a decrease in left ventricular compliance, leading to increased pressure in the left ventricle. Increased left atrial size is often seen with HFPEF as a result of the poor left ventricular function.
  • HFPEF heart failure with preserved ejection fraction
  • Risk factors are hypertension, hyperlipidemia, diabetes, smoking, and obstructive sleep apnea. In this type of heart failure, the heart muscle contracts well but the ventricle does not fill with blood well in the relaxation phase.
  • heart failure with reduced ejection fraction refers to heart failure in which the ejection fraction is less than 40%.
  • Diabetes is a common comorbidity in patients with heart failure and is associated with poorer outcomes as well as potentially compromising the efficacy of treatments.
  • Other important comorbidities include systemic hypertension, chronic airflow obstruction, sleep apnea, cognitive dysfunction, anemia, chronic kidney disease and arthritis.
  • Chronic left heart failure is frequently associated with the development of pulmonary hypertension.
  • the frequency of certain comorbidities varies by gender: among women, hypertension and thyroid disease are more common, while men more commonly suffer from chronic obstructive pulmonary disease (COPD), peripheral vascular disease, coronary artery disease and renal insufficiency.
  • COPD chronic obstructive pulmonary disease
  • Depression is a frequent comorbidity of heart failure and the two conditions can and often do complicate one another.
  • Cardiac cachexia has long been recognized as a serious and frequent complication of heart failure, affecting up to 15% of all heart failure patients and being associated with poor prognosis.
  • Cardiac cachexia is defined as the nonedematous, non-voluntary loss of at least 6% of body weight over a period of six months.
  • arrhythmias refers to abnormal heart rhythms that occur in more than 90 % of people who have had a heart attack. Sometimes the problem is with the part of the heart that triggers the heartbeat and the heart rate may be too slow, other times the problems may cause the heart to beat too rapidly or irregularly. Sometimes the signal to beat is not conducted from one part of the heart to the other and the heartbeat may slow or stop. In addition areas of the myocardium that have not died but have poor blood flow may be irritable. This causes heart rhythm problems such as ventricular tachycardia or ventricular fibrillation. This may lead to cardiac arrest if the heart stops pumping entirely.
  • the "pericardium” is the sack or membrane that surrounds the heart. "Pericarditis” or inflammation of this membrane may develop as a result of a heart attack and may result in fever, pericardial effusion, inflammation of the membranes covering the lungs (pleura), pleural effusion, and joint pain. Other complications after a heart attack may include malfunction of the mitral valve, rupture of the heart muscle, a bulge in the wall of the ventricle (ventricular aneurysm), blood clots, and low blood pressure.
  • cardiomyopathy refers to the progressive impairment of the structure and function of the muscular walls of the heart chambers.
  • the main types of cardiomyopathies are dilated, hypertrophic and restrictive. Cardiomyophaties often cause symptoms of heart failure, and they may also cause chest pain, fainting and sudden death.
  • mitral valve regurgitation refers to a situation in which the mitral valve of the heart doesn't close tightly, allowing blood to flow backward in the heart. As a result, blood can't move through the heart or to the rest of the body as efficiently, resulting in fatigue or shortness of breath.
  • sleep apnea refers to the most common of the sleep-disordered breathing disorders. It is a condition characterized by intermittent, cyclical reductions or total cessations of airflow, which may or may not involve obstruction of the upper airway. There are three types of sleep apnea: obstructive sleep apnea, the most common form, central sleep apnea and mixed sleep apnea.
  • CSA Central sleep apnea
  • metabolic syndrome refers to a group or clustering of metabolic conditions (abdominal obesity, elevated fasting glucose, "dyslipidemia” (i.e,. elevated lipid levels) and elevated blood pressure (HBP)) which occur together more often than by chance alone and that together promote the development of type 2 diabetes and cardiovascular disease.
  • Metabolic syndrome is characterized by a specific lipid profile of increased triglycerides, decreased high-density lipoprotein cholesterol (HDL-cholesterol) and in some cases moderately elevated low-density lipoprotein cholesterol (LDL-cholesterol) levels, as well as accelerated progression of "atherosclerotic disease” due to the pressure of the component risk factors.
  • hypercholesterolemia refers to elevated levels of cholesterol.
  • Familial hypercholesterolemia is a specific form of hypercholesterolemia due to a defect on chromosome 19 (19p13.1-13.3).
  • Hyperglyceridemia refers to elevated levels of glycerides (e.g., “hypertrigliceridemia” involves elevated levels of triglycerides).
  • Haperlipoproteinemia refers to elevated levels of lipoproteins (usually LDL unless otherwise specified).
  • steatosis refers to the abnormal retention of lipids within a cell. It usually reflects an impairment of the normal processes of synthesis and elimination of triglycerides. Excess fat accumulates in vesicles that displace the cytoplasm of the cell. In severe cases the cell may burst. Usually steatosis is observed in the liver as it is the organ mostly associated with fat metabolism. It can also be observed in the heart, kidneys and muscle tissue.
  • PVD peripheral vascular disease
  • PAD peripheral arterial disease
  • PAOD peripheral artery occlusive disease
  • PVD also includes a subset of diseases classified as microvascular diseases resulting from episodic narrowing of the arteries (e.g., "Raynaud's phenomenon"), or widening thereof (erythromelalgia), i.e., vascular spasms.
  • Peripheral arterial diseases include occlusive thrombotic vasculitis, peripheral arterial occlusive disease, Raynaud's disease, and Raynaud's syndrome. Common symptoms are cold leg or feet, intermittent claudication, lower limb pain and critical limb ischemia (lower limb ulcers and necrosis). Diagnosis and treatment guidelines for peripheral arterial disease can be found in Eur. J. Vasco Endovasc. Surg, 2007, 33(1), S1 .
  • stenosis refers to an abnormal narrowing in a blood vessel or other tubular organ or structure. It is also sometimes called a “stricture” (as in urethral stricture).
  • coarctation is a synonym, but is commonly used only in the context of aortic coarctation.
  • restenosis refers to the recurrence of stenosis after a procedure.
  • thrombosis refers to the formation of a blood clot ("thrombus") inside a blood vessel, obstructing the flow of blood through the circulatory system.
  • thrombus blood clot
  • the body uses platelets (thrombocytes) and fibrin to form a blood clot to prevent blood loss.
  • platelets thrombocytes
  • fibrin fibrin to form a blood clot to prevent blood loss.
  • blood clots may form in the body if the proper conditions present themselves. If the clotting is too severe and the clot breaks free, the traveling clot is now known as an "embolus”.
  • thromboembolism refers to the combination of thrombosis and its main complication, "embolism”.
  • a thrombus occupies more than 75% of surface area of the lumen of an artery, blood flow to the tissue supplied is reduced enough to cause symptoms because of decreased oxygen (hypoxia) and accumulation of metabolic products like lactic acid ("gout"). More than 90% obstruction can result in anoxia, the complete deprivation of oxygen and "infarction", a mode of cell death.
  • embolism is the event of lodging of an embolus (a detached intravascular mass capable of clogging arterial capillary beds at a site far from its origin) into a narrow capillary vessel of an arterial bed which causes a blockage (vascular occlusion) in a distant part of the body. This is not to be confused with a thrombus which blocks at the site of origin.
  • embolus a detached intravascular mass capable of clogging arterial capillary beds at a site far from its origin
  • blockage vascular occlusion
  • Ischemia is a restriction in blood supply to tissues, causing a shortage of oxygen and glucose needed for cellular metabolism (to keep tissue alive). Ischemia is generally caused by problems with blood vessels, with resultant damage to or dysfunction of tissue. It also means local anemia in a given part of a body sometimes resulting from congestion (such as vasoconstriction, thrombosis or embolism). If the "ischemia” takes place in the heart muscle (or “myocardium”) the ischemia is termed myocardial ischemia. Other types of ischemia are for instance cerebral ischemia, critical limb ischemia and the like.
  • Reperfusion occurs when blood supply returns to the tissue after a period of ischemia. Upon restoration of circulation to the tissue, inflammatory and oxidative stress processes may develop. One example of this chain of events is ischemia-reperfusion associated with organ transplants.
  • Reperfusion injury is the tissue damage caused when blood supply returns to the tissue after a period of ischemia and inflammation and oxidative damage ensue rather than restoration of normal function.
  • Reperfusion of ischemic issues is often associated with microvascular injury, particularly due to the increased permeability of capillaries and arterioles that lead to an increase in diffusion and fluid filtration across the tissues.
  • the activated endothelial cells produce more reactive oxygen species but less NO following reperfusion, and the imbalance results in an inflammatory response.
  • White blood cells carried to the area by the newly returned blood flow, release a host of inflammatory factors and free radicals in response to tissue damage.
  • the restored blood flow brings with it oxygen that damages cellular proteins, DNA and plasma membranes.
  • This process of ischemia-reperfusion is also thought to be responsible for formation and failure to heal of chronic wounds, (e.g., pressure sores or diabetic ulcers).
  • angiopathy as used herein is the generic term for a disease of the blood vessels (arteries, veins, and capillaries). The most common and most prevalent angiopathy is “diabetic angiopathy", a common complication of chronic diabetes. Another common type of angiopathy is “cerebral amyloid angiopathy” (CAA), also known as congophilic angiopathy, wherein amyloid deposits form in the walls of the blood vessels of the central nervous system.
  • CAA Cerebral amyloid angiopathy
  • congophilic is used because the presence of the abnormal aggregations of amyloid can be demonstrated by microscopic examination of brain tissue after application of a special stain called Congo red. The amyloid material is only found in the brain and as such the disease is not related to other forms of amyloidosis.
  • a "stroke”, or cerebrovascular accident (CVA) is the rapid loss of brain function(s) due to disturbance in the blood supply to the brain. This can be due to "ischemia” (lack of blood flow with resultant insufficient oxygen and glucose supply to the tissue) caused by blockage (thrombosis, arterial embolism, fat accumulation or a spasm), or a hemorrhage (leakage of blood). As a result, the affected area of the brain cannot function, which might result in an inability to move one or more limbs on one side of the body, inability to understand or formulate speech, or an inability to see one side of the visual field.
  • Risk factors for stroke include old age, hypertension, previous stroke or transient ischemic attack (TIA), diabetes, high cholesterol, cigarette smoking and atrial fibrillation. High blood pressure is the most important modifiable risk factor of stroke.
  • An "ischemic stroke” is occasionally treated in a hospital with thrombolysis (also known as a "clot buster”), and some hemorrhagic strokes benefit from neurosurgery.
  • thrombolysis also known as a "clot buster”
  • Prevention of recurrence may involve the administration of antiplatelet drugs such as aspirin and dipyridamole, control and reduction of hypertension, and the use of statins. Selected patients may benefit from carotid endarterectomy and the use of anticoagulants.
  • Vascular dementia is the 2nd most common cause of dementia among the elderly. It is more common among men and usually begins after age 70. It occurs more often in people who have vascular risk factors (e.g, hypertension, diabetes mellitus, hyperlipidemia, smoking) and in those who have had several strokes. Many people have both vascular dementia and Alzheimer disease. Vascular dementia typically occurs when multiple small cerebral infarcts (or sometimes hemorrhages) cause enough neuronal or axonal loss to impair brain function.
  • Vascular dementias include the following types: multiple lacunar infarction (wherein small blood vessels are affected and infarcts occur deep within hemispheric white and gray matter); multi-infarct dementia (wherein medium-sized blood vessels are affected); strategic single-infarct dementia (wherein a single infarct occurs in a crucial area of the brain such as the angular gyrus or the thalamus; Binswanger dementia or subcortical arteriosclerotic encephalopathy (wherein small-vessel dementia is associated with severe, poorly controlled hypertension and systemic vascular disease and which causes diffuse and irregular loss of axons and myelin with widespread gliosis, tissue death due to an infarction, or loss of blood supply to the white matter of the brain).
  • glioma refers to a type of tumor that starts in the brain or spine. It is called a glioma because it arises from glial cells. The most common site of gliomas is the brain. Gliomas make up about 30% of all brain and central nervous system tumors and 80% of all malignant brain tumors.
  • sexual dysfunction encompasses a series of conditions "characterized by disturbances in sexual desire and in the psychophysiological changes associated with the sexual response cycle"; while problems of this type are common, sexual dysfunction is only considered to exist when the problems cause distress for the patient.
  • sexual dysfunction can be either physical or psychological in origin. It can exist as a primary condition, generally hormonal in nature, although most often it is secondary to other medical conditions or to drug therapy for said conditions. All types of sexual dysfunction can be further classified as life-long, acquired, situational or generalized (or combinations thereof).
  • the DSM-IV-TR specifies five major categories of "female sexual dysfunction”: sexual desire/interest disorders; "sexual arousal disorders (including genital, subjective and combined)"; orgasmic disorder; dyspareunia and vaginismus; and persistent sexual arousal disorder.
  • FSAD Male sexual arousal disorder
  • FSAD encompasses both the lack of subjective feelings of excitement (i.e., subjective sexual arousal disorder) and the lack of somatic responses such as lubrication and swelling (i.e., genital/physical sexual arousal disorder).
  • FSAD may be strictly psychological in origin, although it generally is caused or complicated by medical or physiological factors.
  • Hypoestrogenism is the most common physiologic condition associated with FSAD, which leads to urogenital atrophy and a decrease in vaginal lubrication.
  • erectile dysfunction is a male sexual dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual performance.
  • a penile erection is the hydraulic effect of blood entering and being retained in sponge-like bodies within the penis. The process is often initiated as a result of sexual arousal, when signals are transmitted from the brain to nerves in the penis. Erectile dysfunction is indicated when an erection is difficult to produce.
  • cardiovascular disease and diabetes neurological problems (for example, trauma from prostatectomy surgery), hormonal insufficiencies (hypogonadism) and drug side effects.
  • compounds of Formula I that are stimulators of sGC, and their pharmaceutically acceptable salts thereof are therefore useful in the prevention and/or treatment of the following types of cardiac, pulmonary, peripheral, hepatic, kidney, or cerebral vascular/endothelial disorders, conditions and diseases related to circulation:
  • Inflammation refers to the complex biological response of vascular tissues to harmful stimuli, such as pathogens, damaged cells, or irritants.
  • harmful stimuli such as pathogens, damaged cells, or irritants.
  • the classical signs of acute inflammation are pain, heat, redness, swelling, and loss of function.
  • Inflammation is a protective attempt by the organism to remove the injurious stimuli and to initiate the healing process.
  • Inflammation is not a synonym for infection, even though the two are often correlated (the former often being a result of the latter). Inflammation can also occur in the absence of infection, although such types of inflammation are usually maladaptive (such as in atherosclerosis).
  • Inflammation is a stereotyped response, and therefore it is considered as a mechanism of innate immunity, as compared to adaptive immunity, which is specific for each pathogen.
  • inflammation is normally closely regulated by the body.
  • Inflammation can be classified as either acute or chronic.
  • acute inflammation is the initial response of the body to harmful stimuli and is achieved by the increased movement of plasma and leukocytes (especially granulocytes) from the blood into the injured tissues.
  • a cascade of biochemical events propagates and matures the inflammatory response, involving the local vascular system, the immune system, and various cells within the injured tissue.
  • Prolonged inflammation known as "chronic inflammation” leads to a progressive shift in the type of cells present at the site of inflammation and is characterized by simultaneous destruction and healing of the tissue from the inflammatory process.
  • compounds of Formula I that are stimulators of sGC, and their pharmaceutically acceptable salts thereof are therefore useful in the prevention and/or treatment of the following types of cardiac, pulmonary, peripheral, hepatic, kidney, digestive or Central Nervous System disorders, conditions and diseases which may involve inflammation or an inflammatory process:
  • wound healing refers to the intricate process where the skin (or another organ or tissue) repairs itself after injury.
  • the epidermis (outermost layer) and dermis (inner or deeper layer) exist in a steady-state equilibrium, forming a protective barrier against the external environment. Once the protective barrier is broken, the normal (physiologic) process of wound healing is immediately set in motion.
  • the classic model of wound healing is divided into three or four sequential, yet overlapping, phases: (1) hemostasis (not considered a phase by some authors), (2) inflammation, (3) proliferation and (4) remodeling.
  • a set of complex biochemical events takes place in a closely orchestrated cascade to repair the damage.
  • platelets adhere to the site of injury, become activated, and aggregate (join together), followed by activation of the coagulation cascade which forms a clot of aggregated platelets in a mesh of cross-linked fibrin protein. This clot stops active bleeding ("hemostasis").
  • bacteria and cell debris are phagocytosed and removed from the wound by white blood cells.
  • Platelet-derived growth factors (stored in the alpha granules of the platelets) are released into the wound that cause the migration and division of cells during the proliferative phase.
  • the proliferation phase is characterized by angiogenesis, collagen deposition, granulation tissue formation, epithelialization, and wound contraction.
  • vascular endothelial cells form new blood vessels.
  • fibroplasia and granulation tissue formation, fibroblasts grow and form a new, provisional extracellular matrix (ECM) by excreting collagen and fibronectin.
  • ECM extracellular matrix
  • re-epithelialization of the epidermis occurs, in which epithelial cells proliferate and 'crawl' atop the wound bed, providing cover for the new tissue.
  • myofibroblasts decrease the size of the wound by gripping the wound edges and contracting using a mechanism that resembles that in smooth muscle cells. When the cells' roles are close to complete, unneeded cells undergo apoptosis.
  • non-healing chronic wounds one example includes diabetic wounds or ulcers, and, in particular, diabetic foot ulcers.
  • Factors that contribute to non-healing chronic wounds are diabetes, venous or arterial disease, infection, and metabolic deficiencies of old age.
  • bone healing refers to a proliferative physiological process in which the body facilitates the repair of a bone fracture.
  • fracture healing several phases of recovery facilitate the proliferation and protection of the areas surrounding fractures and dislocations.
  • the length of the process depends on the extent of the injury, and usual margins of two to three weeks are given for the reparation of most upper bodily fractures; anywhere above four weeks given for lower bodily injury.
  • the healing process is mainly determined by the "periosteum” (the connective tissue membrane covering the bone).
  • the periosteum is one source of precursor cells which develop into “chondroblasts” and osteoblasts that are essential to the healing of bone.
  • the bone marrow when present), endosteum, small blood vessels, and fibroblasts are other sources of precursor cells.
  • compounds of Formula I that are stimulators of sGC and their pharmaceutically acceptable salts thereof, are therefore useful in the treatment of the following types of diseases, disorders or conditions in which stimulation of the processes of wound or bone healing would be desirable:
  • connective tissue refers to a kind of animal tissue that supports, connects, or separates different types of tissues and organs of the body. It is one of the four general classes of animal tissues, the others being epithelial, muscle, and nervous tissues. Connective tissue is found everywhere, including in the central nervous system. It is located in between other tissues. All CT has three main components--ground substances, fibers and cells--and all these components are immersed in the body fluids.
  • connective tissue disorder or condition refers to any condition that involves abnormalities in connective tissue in one or more parts of the body. Certain disorders are characterized by over-activity of the immune system with resulting inflammation and systemic damage to the tissues, usually with replacement of normal tissue (e.g., normal tissue of a certain organ) with connective tissue. Other disorders involve biochemical abnormalities or structural defects of the connective tissue itself. Some of these disorders are inherited, and some are of unknown etiology.
  • connective tissue diseases When connective tissue diseases are of autoimmune origin they are classified as “rheumatic disorders”, “autoimmune rheumatic disorders” or “autoimmune collagen-vascular disorders”.
  • autoimmune disorders In an "autoimmune disorder", antibodies or other cells produced by the body attack the body's own tissues. Many autoimmune disorders affect connective tissue in a variety of organs. In autoimmune disorders, inflammation and the immune response may result in connective tissue damage, around the joints and also in other tissues, including vital organs, such as the kidneys or organs of the gastrointestinal tract.
  • the sac that surrounds the heart (pericardium), the membrane that covers the lungs (pleura), the mediastinum (an undelineated group of structures in the thorax, surrounded by loose connective tissue, containing the heart, the great vessels of the heart, the esophagus, the trachea, the phrenic nerve, the cardiac nerve, the thoracic duct, the thymus, and the lymph nodes of the central chest) and even the brain may be affected.
  • fibrosis refers to the accumulation of connective tissue or fibrous tissue (scar tissue, collagen) in a certain organ or part of the body. If fibrosis arises from a single cell line it is called a "fibroma". Fibrosis occurs as the body attempts to repair and replace damaged cells, and thus can be a reactive, benign or a pathological state. Physiological fibrosis is similar to the process of scarring. A pathological state develops when the tissue in question is repeatedly and continuously damaged. A single episode of injury, even if severe, does not usually cause fibrosis. If injury is repeated or continuous (for instance as it occurs in chronic hepatitis) the body attempts to repair the damage, but the attempts result instead in excessive accumulation of scar tissue.
  • Scar tissue starts to replace regular tissue of the organ which performs certain functions that the scar tissue is not able to perform; it can also interfere with blood flow and limit blood supply to other cells. As a result, these other functional cells start to die and more scar tissue is formed.
  • blood pressure in the vein that carries blood from the intestine to the liver increases, giving rise to the condition known as "portal hypertension".
  • clerosis refers to the hardening or stiffening of tissue or a structure or organ that would normally be flexible, usually by replacement of normal organ specific tissue with connective tissue.
  • fibroses or fibrotic diseases including but not limited to pulmonary fibrosis (idiopathic pulmonary fibrosis, cystic fibrosis), fibrosis of the liver (or “cirrhosis”), endomyocardial fibrosis, old myocardial infarction, atrial fibrosis, mediastinal fibrosis, myelofibrosis (affecting the bone marrow), retroperitoneal fibrosis, progressive massive fibrosis (affects the lungs), nephrogenic fibrosis (affecting the skin), Crohn's disease, arthrofibrosis, Peyronie's disease (affecting the penis), Dupuytren's contracture (affecting the hands and fingers), some forms of adhesive capsulitis (affecting the shoulders).
  • pulmonary fibrosis idiopathic pulmonary fibrosis, cystic fibrosis
  • endomyocardial fibrosis old myocardial infarction
  • atrial fibrosis mediastinal fibro
  • scleroses or "sclerotic diseases” including but not limited to Amyotropic Lateral Sclerosis (ALS); atherosclerosis; focal segmental glomerulosclerosis and nephrotic syndrome; hippocampal sclerosis (affecting the brain); lichen sclerosus (a disease that hardens connective tissue of the vagina and penis); liver sclerosis (chirrhosis); multiple sclerosis or focal sclerosis (diseases that affects coordination); osteosclerosis (a disease in which bone densitiy is significantly reduced); otosclerosis (disease affecting the ears); tuberous sclerosis (rare genetic disease affecting multiple systems); primary sclerosing cholanginitis (hardening of the bile duct); primary lateral sclerosis (progressive muscle weakness in the voluntary muscles); and keloids.
  • ALS Amyotropic Lateral Sclerosis
  • atherosclerosis a disease that hardens connective tissue of the vagina and penis
  • liver sclerosis chirrhosis
  • systemic sclerosis or “progressive systemic scleroderma” refers to a condition which involves scarring of the joints, skin and internal organs as well as blood vessel abnormalities.
  • Systemic sclerosis can sometimes occur in limited forms, for examples sometimes affecting just the skin or mainly only certain parts of the skin or as CREST syndrome (wherein peripheral areas of the skin but not the trunk are involved).
  • the usual initial symptom of systemic sclerosis is swelling, then thickening and tightening of the skin at the end of the fingers.
  • “Raynaud's phenomenon” in which fingers suddenly and temporarily become very pale and tingle or become numb, painful or both, is common.
  • polymyositis refers to muscle inflammation.
  • skin inflammation refers to muscle inflammation that is accompanied by skin inflammation.
  • polychondritis refers to cartilage inflammation.
  • oesinophilic fasciitis refers to a rare disorder in which oesinophilic immune cells are released and results in inflammation and hardening of the "fasciae" which is the layer of tough fibrous tissue beneath the skin, on top and between the muscles.
  • the fasciae becomes painfully inflamed and swollen and gradually hardens in the arms and legs. As the skin of the arms and legs progressively hardens, they become difficult to move. Eventually the become stuck in unusual positions. Sometimes, if the arms are involved the person may develop carpal tunnel syndrome.
  • specific diseases of disorders which may be treated and/or prevented by administering an sGC stimulator of Formula I that are stimulators of sGC, and their pharmaceutically acceptable salts thereof, include but are not limited to the following type of diseases involving inflammation, autoimmunity or fibrosis (i.e., fibrotic diseases):
  • specific diseases of disorders which may be treated and/or prevented by administering an sGC stimulator of Formula I that are stimulators of sGC, and their pharmaceutically acceptable salts thereof, include but are not limited to: certain types of cancers; Sickle Cell Disease; Sickle Cell Anemia; cancer metastasis; osteoporosis; gastroparesis; functional dyspepsia; diabetic complications; alopecia or hair loss; diseases associated with endothelial dysfunction; and neurologic disorders associated with decreased nitric oxide production.
  • the disclosure relates to a method of treating a disease, health condition or disorder in a subject, comprising administering a therapeutically effective amount of a compound of Formula I , or a pharmaceutically acceptable salt thereof, to the subject in need of treatment, wherein the disease, health condition or disorder is selected from one of the diseases listed above.
  • compounds of the invention can be delivered in the form of implanted devices, such as stents.
  • a stent is a mesh 'tube' inserted into a natural passage/conduit in the body to prevent or counteract a disease-induced, localized flow constriction.
  • the term may also refer to a tube used to temporarily hold such a natural conduit open to allow access for surgery.
  • a drug-eluting stent is a peripheral or coronary stent (a scaffold) placed into narrowed, diseased peripheral or coronary arteries that slowly releases a drug to block cell proliferation, usually smooth muscle cell proliferation. This prevents fibrosis that, together with clots (thrombus), could otherwise block the stented artery, a process called restenosis.
  • the stent is usually placed within the peripheral or coronary artery by an Interventional Cardiologist or Interventional Radiologist during an angioplasty procedure.
  • Drugs commonly used in DES in order to block cell proliferation include paclitaxel or rapamycin analogues.
  • a sGC stimulator of the invention can be delivered by means of a drug-eluting stent coated with said sGC stimulator.
  • a drug-eluting stent coated with a sGC stimulator of the invention may be useful in the prevention of stent restenosis and thrombosis during percutaneous coronary interventions.
  • a drug-eluting stent coated with a sGC stimulator of the invention may be able to prevent smooth cell proliferation as well as to assist re-vascularization and re-generation of the endothelial tissue of the artery in which the stent is inserted.
  • CABG Coronary Artery Bypass Grafting
  • a sGC stimulator of the invention can be used for the prevention of saphenous graft failure during CABG.
  • Compounds of the invention may assist the process of endothelialization and help prevent thrombosis.
  • the sGC stimulator is delivered locally in the form of a gel.
  • the terms “subject” and “patient” are used interchangeably.
  • the terms “subject” and “patient” refer to an animal (e.g., a bird such as a chicken, quail or turkey, or a mammal), specifically a “mammal” including a non-primate (e.g., a cow, pig, horse, sheep, rabbit, guinea pig, rat, cat, dog, and mouse) and a primate (e.g., a monkey, chimpanzee and a human), and more specifically a human.
  • a non-primate e.g., a cow, pig, horse, sheep, rabbit, guinea pig, rat, cat, dog, and mouse
  • a primate e.g., a monkey, chimpanzee and a human
  • the subject is a non-human animal such as a farm animal (e.g., a horse, cow, pig or sheep), or a pet (e.g., a dog, cat, guinea pig or rabbit). In some embodiments, the subject is a human.
  • a farm animal e.g., a horse, cow, pig or sheep
  • a pet e.g., a dog, cat, guinea pig or rabbit.
  • the subject is a human.
  • the disclosure also provides a method for treating one of the above diseases, conditions and disorders in a subject, comprising administering a therapeutically effective amount of a compound of Table I, or a pharmaceutically acceptable salt thereof, to the subject in need of the treatment.
  • the invention provides the use of a compound of Table I, or a pharmaceutically acceptable salt thereof, in the treatment of one of these diseases, conditions and disorders in a subject in need of the treatment.
  • the invention further provides a method of making or manufacturing a medicament useful for treating one of these diseases, conditions and disorders comprising using a compound of Table I, or a pharmaceutically acceptable salt thereof.
  • biological sample refers to an in vitro or ex vivo sample, and includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; blood, saliva, urine, faeces, semen, tears, lymphatic fluid, ocular fluid, vitreous humour, or other body fluids or extracts thereof.
  • Treating refers to alleviating or abrogating the cause and/or the effects of the disorder or disease.
  • the terms “treat”, “treatment” and “treating” refer to the reduction or amelioration of the progression, severity and/or duration of an sGC, cGMP and/or NO mediated condition, or the amelioration of one or more symptoms (preferably, one or more discernable symptoms) of said condition (i.e., "managing” without “curing” the condition), resulting from the administration of one or more therapies (e.g., one or more therapeutic agents such as a compound or composition of the invention).
  • the terms “treat”; “treatment” and “treating” refer to the amelioration of at least one measurable physical parameter of an sGC, cGMP and/or NO mediated condition.
  • the terms “treat”, “treatment” and “treating” refer to the inhibition of the progression of an sGC, cGMP and/or NO mediated condition, either physically by, e.g., stabilization of a discernable symptom or physiologically by, e.g., stabilization of a physical parameter, or both.
  • preventing refers to administering a medicament beforehand to avert or forestall the appearance of one or more symptoms of a disease or disorder.
  • prevent is not an absolute term. In the medical art it is understood to refer to the prophylactic administration of a drug to substantially diminish the likelihood or seriousness of a condition, or symptom of the condition and this is the sense intended in this disclosure.
  • the Physician's Desk Reference a standard text in the field, uses the term “prevent” hundreds of times.
  • the terms "prevent”, “preventing” and “prevention” with regard to a disorder or disease refer to averting the cause, effects, symptoms or progression of a disease or disorder prior to the disease or disorder fully manifesting itself.
  • the methods of the disclosure are a preventative or "pre-emptive" measure to a patient, specifically a human, having a predisposition (e.g., a genetic predisposition) to developing an sGC, cGMP and/or NO related disease, disorder or symptom.
  • a predisposition e.g., a genetic predisposition
  • the methods of the disclosure are a preventative or "pre-emptive" measure to a patient, specifically a human, suffering from a disease, disorder or condition that makes him at risk of developing an sGC, cGMP or NO related disease, disorder or symptom.
  • the compounds and pharmaceutical compositions described herein can be used alone or in combination therapy for the treatment or prevention of a disease or disorder mediated, regulated or influenced by sGC, cGMP and/or NO.
  • Compounds and compositions here disclosed are also useful for veterinary treatment of companion animals, exotic animals and farm animals, including, without limitation, dogs, cats, mice, rats, hamsters, gerbils, guinea pigs, rabbits, horses, pigs and cattle.
  • the disclosure provides a method of stimulating sGC activity in a biological sample, comprising contacting said biological sample with a compound or composition of the invention.
  • a sGC stimulator in a biological sample is useful for a variety of purposes known to one of skill in the art. Examples of such purposes include, without limitation, biological assays and biological specimen storage.
  • the compounds and pharmaceutical compositions described herein can be used in combination therapy with one or more additional therapeutic agents.
  • the active agents may be administered separately or in conjunction.
  • the administration of one element may be prior to, concurrent to, or subsequent to the administration of the other agent.
  • an "effective amount" of the second agent will depend on the type of drug used. Suitable dosages are known for approved agents and can be adjusted by the skilled artisan according to the condition of the subject, the type of condition(s) being treated and the amount of a compound described herein being used. In cases where no amount is expressly noted, an effective amount should be assumed.
  • compounds described herein can be administered to a subject in a dosage range from between about 0.01 to about 10,000 mg/kg body weight/day, about 0.01 to about 5000 mg/kg body weight/day, about 0.01 to about 3000 mg/kg body weight/day, about 0.01 to about 1000 mg/kg body weight/day, about 0.01 to about 500 mg/kg body weight/day, about 0.01 to about 300 mg/kg body weight/day, about 0.01 to about 100 mg/kg body weight/day.
  • an effective amount can be achieved using a first amount of a compound of Table I or a pharmaceutically acceptable salt thereof and a second amount of an additional suitable therapeutic agent.
  • a compound of Table I and the additional therapeutic agent are each administered in an effective amount (i.e., each in an amount which would be therapeutically effective if administered alone).
  • the compound of Table I and the additional therapeutic agent are each administered in an amount which alone does not provide a therapeutic effect (a sub-therapeutic dose).
  • the compound of Table I can be administered in an effective amount, while the additional therapeutic agent is administered in a sub-therapeutic dose.
  • the compound of Table I can be administered in a sub-therapeutic dose, while the additional therapeutic agent, for example, a suitable cancer-therapeutic agent is administered in an effective amount.
  • the terms “in combination” or “co-administration” can be used interchangeably to refer to the use of more than one therapy (e.g., one or more prophylactic and/or therapeutic agents).
  • the use of the terms does not restrict the order in which therapies (e.g., prophylactic and/or therapeutic agents) are administered to a subject.
  • Co-administration encompasses administration of the first and second amounts of the compounds in an essentially simultaneous manner, such as in a single pharmaceutical composition, for example, capsule or tablet having a fixed ratio of first and second amounts, or in multiple, separate capsules or tablets for each.
  • co administration also encompasses use of each compound in a sequential manner in either order.
  • co-administration involves the separate administration of the first amount of a compound of Table I and a second amount of an additional therapeutic agent, the compounds are administered sufficiently close in time to have the desired therapeutic effect.
  • the period of time between each administration which can result in the desired therapeutic effect can range from minutes to hours and can be determined taking into account the properties of each compound such as potency, solubility, bioavailability, plasma half-life and kinetic profile.
  • a compound of Table I and the second therapeutic agent can be administered in any order within about 24 hours of each other, within about 16 hours of each other, within about 8 hours of each other, within about 4 hours of each other, within about 1 hour of each other or within about 30 minutes of each other.
  • a first therapy e.g., a prophylactic or therapeutic agent such as a compound described herein
  • a first therapy can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of a second therapy (e.g., a prophylactic or therapeutic agent such as an anti-cancer agent) to a subject.
  • a second therapy e.g., a prophylactic or therapeutic agent such as an anti-cancer agent
  • Examples of other therapeutic agents that may be combined with a compound of this disclosure, either administered separately or in the same pharmaceutical composition include, but are not limited to: (1) Endothelium-derived releasing factor (EDRF); (2) NO donors such as a nitrosothiol, a nitrite, a sydnonimine, a NONOate, a N-nitrosoamine, a N-hydroxyl nitrosamine, a nitrosimine, nitrotyrosine, a diazetine dioxide, an oxatriazole 5-imine, an oxime, a hydroxylamine, a N-hydroxyguanidine, a hydroxyurea or a furoxan.
  • EDRF Endothelium-derived releasing factor
  • NO donors such as a nitrosothiol, a nitrite, a sydnonimine, a NONOate, a N-nitrosoamine, a N-hydroxyl nitrosamine, a
  • glyceryl trinitrate also known as GTN, nitroglycerin, nitroglycerine, and trinitrogylcerin
  • GTN sodium nitroprusside
  • SNP sodium nitroprusside
  • SIN-1 3-morpholinosydnonimine
  • SNAP S-nitroso-N-acetylpenicillamine
  • DETA/NO diethylenetriamine/NO
  • NCX 4016 an m-nitroxymethyl phenyl ester of acetyl salicylic acid.
  • nitrovasodilators such as organic nitrate and nitrite esters, including nitroglycerin, amyl nitrite, isosorbide dinitrate, isosorbide 5-mononitrate, and nicorandil
  • Isosorbide (Dilatrate®-SR , Imdur®, Ismo®, Isordil®, Isordil®, Titradose®, Monoket®), FK 409 (NOR-3); FR 144420 (NOR-4); 3-morpholinosydnonimine; Linsidomine chlorohydrate (“SIN-1”); S-nitroso-N-acetylpenicillamine (“SNAP”); AZD3582 (CINOD lead compound), NCX 4016, NCX 701, NCX 1022, HCT 1026, NCX 1015, NCX 950, NCX 1000, NCX 1020, AZD 4717, NCX 1510/NCX 15
  • Nitric oxide donors are also as disclosed in U.S. Pat. Nos. 5,155,137 , 5,366,997 , 5,405,919 , 5,650,442 , 5,700,830 , 5,632,981 , 6,290,981 , 5,691,423 5,721,365 , 5,714,511 , 6,511,911 , and 5,814,666 , Chrysselis et al. (2002) J Med Chem.
  • Nitric Oxide Synthase substrates for example, n-hydroxyguanidine based analogs, such as N[G]-hydroxy-L-arginine (NOHA), 1-(3, 4-dimethoxy-2-chlorobenzylideneamino)-3-hydroxyguanidine, and PR5 (1-(3, 4-dimethoxy-2-chlorobenzylideneamino)-3-hydroxyguanidine); L-arginine derivatives (such as homo-Arg, homo-NOHA, N-tert-butyloxy- and N-(3-methyl-2-butenyl)oxy-
  • eNOS transcriptional enhancers including those described in US20050101599 (e.g., 2,2-difluorobenzo[1,3]dioxol-5-carboxylic acid indan-2-ylamide, and 4-fluoro-N-(indan-2-yl)-benzamide), and Sanofi-Aventis compounds AVE3085 and AVE9488 (CA Registry NO.
  • NO independent heme-independent sGC activators including, but not limited to: BAY 58-2667 (see patent publication DE19943635 ) HMR-1766 (ataciguat sodium, see patent publication WO2000002851 ) S 3448 (2-(4-chloro-phenylsulfonylamino)-4,5-dimethoxy-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzam ide (see patent publications DE19830430 and WO2000002851 ) and HMR-1069 (Sanofi-Aventis). (7) Heme-dependent sGC stimulators including, but not limited to:
  • the compounds and pharmaceutical formulations described herein may be contained in a kit.
  • the kit may include single or multiple doses of two or more agents, each packaged or formulated individually, or single or multiple doses of two or more agents packaged or formulated in combination.
  • one or more agents can be present in first container, and the kit can optionally include one or more agents in a second container.
  • the container or containers are placed within a package, and the package can optionally include administration or dosage instructions.
  • a kit can include additional components such as syringes or other means for administering the agents as well as diluents or other means for formulation.
  • kits can comprise: a) a pharmaceutical composition comprising a compound described herein and a pharmaceutically acceptable carrier, vehicle or diluent; and b) a container or packaging.
  • the kits may optionally comprise instructions describing a method of using the pharmaceutical compositions in one or more of the methods described herein (e.g., preventing or treating one or more of the diseases and disorders described herein).
  • the kit may optionally comprise a second pharmaceutical composition comprising one or more additional agents described herein for co therapy use, a pharmaceutically acceptable carrier, vehicle or diluent.
  • the pharmaceutical composition comprising the compound described herein and the second pharmaceutical composition contained in the kit may be optionally combined in the same pharmaceutical composition.
  • a kit includes a container or packaging for containing the pharmaceutical compositions and may also include divided containers such as a divided bottle or a divided foil packet.
  • the container can be, for example a paper or cardboard box, a glass or plastic bottle or jar, a re-sealable bag (for example, to hold a "refill" of tablets for placement into a different container), or a blister pack with individual doses for pressing out of the pack according to a therapeutic schedule. It is feasible that more than one container can be used together in a single package to market a single dosage form. For example, tablets may be contained in a bottle which is in turn contained within a box.
  • Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process, recesses are formed in the plastic foil. The recesses have the size and shape of individual tablets or capsules to be packed or may have the size and shape to accommodate multiple tablets and/or capsules to be packed. Next, the tablets or capsules are placed in the recesses accordingly and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed.
  • the tablets or capsules are individually sealed or collectively sealed, as desired, in the recesses between the plastic foil and the sheet.
  • the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.
  • a "daily dose” can be a single tablet or capsule or several tablets or capsules to be taken on a given day.
  • a daily dose of one or more compositions of the kit can consist of one tablet or capsule while a daily dose of another or more compositions of the kit can consist of several tablets or capsules.
  • a kit can take the form of a dispenser designed to dispense the daily doses one at a time in the order of their intended use. The dispenser can be equipped with a memory-aid, so as to further facilitate compliance with the regimen.
  • a memory-aid is a mechanical counter which indicates the number of daily doses that have been dispensed.
  • a battery-powered micro-chip memory coupled with a liquid crystal readout, or audible reminder signal which, for example, reads out the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken.
  • Scheme 1 depicts the method of Argentine et al (Org. Process R&D 2009, 13, 131-143 ).
  • Substituted semicarbazides of the general structure 5 can be prepared by reacting commercially available tert -butylcarbazate 2 with bromide 3 to afford Boc-protected hydrazide 4.
  • Intermediate 4 can then be reacted directly with potassium cyanate in aqueous ethanol or alternatively with trimethylsilylisocyanate in THF followed by treatment with acid to deprotect the Boc protecting group and protodesilylate the trimethylsilyl protecting group to regioselectively afford semicarbazide 5 .
  • Compound 3 when not commercially available, may be prepared from the corresponding alcohol by bromination with reagents such as PBr 3 in a solvent such as ether.
  • Alkyl hydrazines such as 6 can also be prepared by one skilled in the art by reacting alkyl halide 3 with hydrazine in polar solvent and subsequent reaction with potassium cyanate to directly afford semicarbazide 5 .
  • Compounds comprising examples of Formula I may then be synthesized by activating carboxylic acid 7 with a variety of amide coupling reagents (such as HATU, BOP, TPI, or conversion of the acid to an acid chloride) in DMF and a base such as triethylamine and then reacting it with intermediate semicarbazide 5 to form acyl semicarbazide 8 which can be cyclized to the desired triazolone 1 by heating under acidic conditions such as camphorsulfonic acid (Argentine et al) or under basic conditions ( Deng et al Tetrahedron Lett. 2005, 7993-7996 ) such as NaOH in EtOH.
  • amide coupling reagents such as HATU, BOP, TPI, or conversion of the acid to an acid chloride
  • the 4-chloro substituent of intermediate 10 is generally more reactive than the 2-chloro substituent and can be chemoselectively displaced in a SNAr reaction with diverse nucleophiles (carbon-based, substituted amino, hydroxyl-containing, etc.) or with diverse nucleophiles using metal-assisted or organometallic reagent-mediated displacement (e.g., Suzuki reactions, Buchwald aminations, Sonogashira reactions, etc.) to give the mono-chloro intermediate 11 .
  • diverse nucleophiles carbon-based, substituted amino, hydroxyl-containing, etc.
  • metal-assisted or organometallic reagent-mediated displacement e.g., Suzuki reactions, Buchwald aminations, Sonogashira reactions, etc.
  • the 2-chloro substituent of 11 can be transposed to ester 12a via a carbonylation reaction using a palladium catalyst and carbon monoxide in an alcoholic solvent under basic conditions ( WO2008/47201 , US2012/245124 , WO2008/9487 ).
  • the chloride of 11 can be displaced by cyanide under refluxing alcoholic/aqueous conditions or by using palladium-mediated cross-coupling with zinc cyanide in a polar solvent such as DMF or NMP to give nitrile 12b ( Wada et al Tetrahedron Lett. 2012, 53(14), 1720-1724 ).
  • Ester 12a can be hydrolyzed using NaOH or by dealkylative deprotection (e.g., potassium trimethylsilyloxide heated in a polar aprotic solvent) and nitrile 12b can be deprotected by hydrolysis in aqueous NaOH at 100 °C to give intermediate carboxylic acid 7.
  • dealkylative deprotection e.g., potassium trimethylsilyloxide heated in a polar aprotic solvent
  • nitrile 12b can be deprotected by hydrolysis in aqueous NaOH at 100 °C to give intermediate carboxylic acid 7.
  • Scheme 3 shows a complimentary method for making intermediate carboxylic acids 7 by condensation of an amidine such as commercially available methyl-2-amino-2-iminoacetate with a variety of 3-carbon electrophiles using reagents and conditions detailed in our earlier work ( WO2013101830 , WO2012003405 ) and others ( WO2011149921 , WO2013104703 , WO2013030288 , 2013004785 , 2012004259 ) to form substituted pyrimidine carboxylates.
  • an amidine such as commercially available methyl-2-amino-2-iminoacetate
  • WO2013104703 WO2013030288 , 2013004785 , 2012004259
  • Reaction (1) shows the condensation of methyl-2-amino-2-iminoacetate with the anion of ⁇ -hydroxy ethylacrylate in refluxing ethanol to give a 2-carboxy-4-hydroxypyrimidine 7a after ester deprotection using NaOH.
  • This intermediate can be further derivatized by treatment with phosphorus oxychloride in DCM followed by SNAr displacement by various carbon, oxygen, and in this case an amino nucleophile HNR D R D to give a functionalized pyrimidine carboxylate 7b .
  • Reactions (2) and (3) show an analogous example wherein the electrophile is a substituted malononitrile.
  • intermediate 7e can be further derivatized by treatment with phosphorus oxychloride in DCM followed by SNAr displacement by various carbon, oxygen, and in this case an amino nucleophile HNR D R D to give a functionalized 1,2,4-triazine carboxylate 7f .
  • Scheme 3 reaction (5) makes use of a diketone electrophile ( Beard et al WO2008030843 ) to provide diverse 1,2,4-triazine-3-carboxylates of the general structure 7g after ester hydrolysis.
  • Scheme 4 illustrates a method for making alkoxytriazoles of Formula I by simply replacing the semicarbazide 5 used in Scheme 1, with thiosemicarbazide 5' that can be prepared from 6 using potassium thiocyanate in alcoholic solvent. Coupling thiosemicarbazide 5' with carboxylic acid 7 using a coupling reagent such as HATU provides acylthiosemicarbazide 13 that can be cyclized to the triazolethione 14 under basic or acidic conditions. Following the method of Kane et al (J. Med. Chem.
  • triazolethione 14 reacts with methyl iodide under basic conditions such as K 2 CO 3 in acetone to give S-methylation and subsequent oxidation using reagents such as MCPBA or Oxone can provide the triazole sulfone 15 . Displacement of this sulfone using an alcohol Rc-OH deprotonated with NaH in DMF and heating provides the desired alkoxytriazole 16 of Formula I.
  • pyrazole variants of Formula I compounds is detailed in Scheme 5 .
  • the pyrazolone core structure can be synthesized by condensation of substituted hydrazine 6 with diethyl 2-oxosuccinate under acidic conditions to form hydroxypyrazole 17 .
  • This intermediate may be O-alkylated with diverse electrophiles such as alkyl and aryl iodides and triflates under basic conditions to provide alkoxy pyrazole 18 .
  • Amidine 19 can be treated with hydrazine in refluxing alcohol to form the 2-aminohydrazone 21 that can be condensed with 2-carbon electrophiles using the reagents, conditions, and references described above in Scheme 3, Reactions (4)-(5) to provide compounds of Formula I such as the substituted triazines 22 .
  • Step 1 Synthesis of ethyl 1-(2-fluorobenzyl)-5-hydroxy-1H-pyrazole-3-carboxylate.
  • Step 2 Synthesis of ethyl 1-(2-fluorobenzyl)-5-methoxy-1H-pyrazole-3-carboxylate.
  • Step 3 Synthesis of 1-(2-fluorobenzyl)-5-methoxy-1H-pyrazole-3-carboximidamide.
  • Step 1 Synthesis of ethyl 5-(difluoromethoxy)-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate.
  • Step 2 Synthesis of 5-(difluoromethoxy)-1-(2-fluorobenzyl)-1H-pyrazole-3-carboximidamide.
  • a mixture containing potassium hydrogencarbonate (1 equiv.), DBU (1 equiv.), 5-(difluoromethoxy)-1-(2-fluorobenzyl)-1H-pyrazole-3-carboximidamide (1 equiv.) and sodium ( E )-3-ethoxy-2-fluoro-3-oxoprop-1-en-1-olate (3 equiv.) in t -BuOH was heated at 85 °C for 24 h. The mixture was diluted in ethyl acetate and washed with water. The organic layer was dried, filtered and evaporated to give a crude oil.
  • Step 1 Synthesis of ethyl 5-hydroxy-1-(3,3,3-trifluoropropyl)-1H-pyrazole-3-carboxylate.
  • Step 2 Synthesis of ethyl 5-methoxy-1-(3,3,3-trifluoropropyl)-1H-pyrazole-3-carboxylate.
  • Step 3 Synthesis of 5-methoxy-1-(3,3,3-trifluoropropyl)-1H-pyrazole-3-carboximidamide.
  • Step 1 Synthesis of 1-(2-fluorobenzyl)-5-methoxy-1H-pyrazole-3-carboximidhydrazide.
  • Step 2 Synthesis of ethyl 2-(3-(1-(2-fluorobenzyl)-5-methoxy-1H-pyrazol-3-yl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl)-2-methyl propanoate.
  • the oil was purified via silica gel chromatography (40% ethyl acetate in hexanes) to deliver the desired intermediate, ethyl 2-(3-(1-(2-fluorobenzyl)-5-methoxy-1H-pyrazol-3-yl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl)-2-methyl propanoate (84 mg, 11% yield) as a white solid.
  • Step 1 Synthesis of ethyl 4-amino-2-(4-bromo-1-(2-fluorobenzyl)-5-methoxy-1H-pyrazol-3-yl)-5-methyl-6-oxo-6,7-dihydro-5 H-pyrrolo[2,3-d]pyrimidine-5-carboxylate.
  • the oil was purified by silica gel chromatography (0 to 100% ethyl acetate in hexanes) to deliver the desired intermediate, ethyl 4-amino-2-(4-bromo-1-(2-fluorobenzyl)-5-methoxy-1H-pyrazol-3-yl)-5-methyl-6-oxo-6,7-dihydro-5 H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (200 mg, quantitative yield) as an orange oil.
  • the oil was purified via silica gel chromatography (0 to 80% ethyl acetate in hexanes) to deliver a yellow oil containing the desired intermediate ethyl 4-amino-2-(4-cyano-1-(2-fluorobenzyl)-5-methoxy-1H-pyrazol-3-yl)-5-methyl-6-oxo-6,7-dihydro-5H -pyrrolo[2,3-d]pyrimidine-5-carboxylate.
  • Step 1 Synthesis of ethyl 1-(2-fluorobenzyl)-5-hydroxy-4-methyl-1H-pyrazole-3-carboxylate.
  • Step 2 Synthesis of ethyl 1-(2-fluorobenzyl)-5-methoxy-4-methyl-1H-pyrazole-3-carboxylate.
  • Step 1 Synthesis of ethyl 5-ethoxy-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate.
  • Step 2 Synthesis of 5-ethoxy-1-(2-fluorobenzyl)-1H-pyrazole-3-carboximidamide.
  • Step 1 Synthesis of ethyl 1-(2-fluorobenzyl)-5-isopropoxy-1H-pyrazole-3-carboxylate.
  • Step 2 Synthesis of 5-isopropoxy-1-(2-fluorobenzyl)-1H-pyrazole-3-carboximidamide.
  • the title compound was prepared following general procedure A in library format, except muscimol was the amine reactant, 3 equivalents of triethylamine was used, and contents were stirred at 70 °C for 2 d.
  • the resulting residue after workup was suspended in dichloromethane and a minimal amount of methanol. The precipitate was removed by filtration and the filtrate was concentrated under vacuum. The resulting residue was purified via silica gel chromatography (0 to 10% methanol in dichloromethane) to deliver the desired compound (87 mg, 96% yield) as a white solid.
  • 1 H NMR 500 MHz, DMSO- d 6 ) ⁇ ppm 8.34 (br.
  • the title compound was prepared following general procedure A in library format, except 2-aminoacetic acid (4 equiv.) was the amine reactant, 13.5 equivalents of triethylamine was used, and contents were stirred at 100 °C for 3 d as a solution in THF:water (2:1). The reaction was cooled to 23 °C, concentrated in vacuo, and the resulting crude material was purified via reverse phase HPLC to deliver the desired compound (2.7 mg, 12% yield) as a white solid.
  • the title compound was prepared following general procedure A in library format, except 2-aminoethanol (4 equiv.) was the amine reactant, 13.5 equivalents of triethylamine was used, and contents were stirred at 100 °C for 3 d as a solution in THF:water (2:1). The reaction was cooled to 23 °C, concentrated in vacuo, and the resulting crude material was purified via reverse phase HPLC to deliver the desired compound (7.5 mg, 35% yield) as a white solid.
  • the title compound was prepared following general procedure A in library format, except 5-aminopentanoic acid (4 equiv.) was the amine reactant, 13.5 equivalents of triethylamine was used, and contents were stirred at 100 °C for 3 d as a solution in THF: water (2:1). The reaction was cooled to 23 °C, concentrated in vacuo, and the resulting crude material was purified via reverse phase HPLC to deliver the desired compound (2.5 mg, 10% yield) as a white solid.
  • the title compound was prepared following general procedure A in library format, except 4-methylpyrrolidine-3-carboxylic acid (4 equiv.) was the amine reactant, 13.5 equivalents of triethylamine was used, and contents were stirred at 100 °C for 3 d as a solution in THF:water (2:1). The reaction was cooled to 23 °C, concentrated in vacuo, and the resulting crude material was purified via reverse phase HPLC to deliver the desired compound (6.3 mg, 25% yield) as a white solid.
  • the title compound was prepared following general procedure A in library format, except 2-aminoacetamide (8 equiv.) was the amine reactant, 20 equivalents of triethylamine was used, and contents were stirred at 100 °C for 18 h as a solution in THF:water (2:1). The reaction was concentrated under a stream of nitrogen, and the resulting crude material was purified by reverse phase HPLC to deliver the desired compound (1.8 mg, 8% yield) as a white solid.
  • the title compound was prepared following general procedure A in library format, except piperidine-4-sulfonamide (4 equiv.) was the amine reactant, 13.5 equivalents of triethylamine was used, and contents were stirred at 100 °C for 3 d as a solution in THF:water (2:1). The reaction was cooled to 23 °C, concentrated in vacuo, and the resulting crude material was purified via reverse phase HPLC to deliver the desired compound (1.1 mg, 4% yield) as a white solid.
  • the title compound was prepared following general procedure A in library format, except piperazine (1 equiv.) was the amine reactant, no triethylamine was used, and contents were stirred at 23 °C for 1 h, then 90 °C for 12 h as a solution in dioxane:water (3:1). The mixture was worked up according to procedure to deliver the desired compound (5 mg, 22% yield) as a white solid.
  • Step 1 Synthesis of ethyl 1-(2,3-difluorobenzyl)-5-hydroxy-1H-pyrazole-3-carboxylate.
  • Step 2 Synthesis of ethyl 1-(2,3-difluorobenzyl)-5-(difluoromethoxy)-1H-pyrazole-3-carboxylate.
  • Step 3 Synthesis of 1-(2,3-difluorobenzyl)-5-(difluoromethoxy)-1H-pyrazole-3-carboximidamide hydrochloride.
  • Step 1 Synthesis of ethyl 1-(2,4-difluorobenzyl)-5-hydroxy-1H-pyrazole-3-carboxylate.
  • Step 2 Synthesis of ethyl 1-(2,4-difluorobenzyl)-5-(difluoromethoxy)-1H-pyrazole-3-carboxylate
  • Step 3 Synthesis of 1-(2,4-difluorobenzyl)-5-(difluoromethoxy)-1H-pyrazole-3-carboximidamide hydrochloride.
  • Step 1 Synthesis of benzyl 2-(3,3,4,4,4-pentafluorobutyl)hydrazinecarboxylate.
  • Step 2 Synthesis of (3,3,4,4,4-pentafluorobutyl)hydrazine hydrochloride.
  • Step 3 Synthesis of ethyl 5-oxo-1-(3,3,4,4,4-pentafluorobutyl)-2,5-dihydro-1H-pyrazole-3-carboxylate.
  • Step 4 Synthesis of ethyl 5-oxo-1-(3,3,4,4,4-pentafluorobutyl)-2,5-dihydro-1H-pyrazole-3-carboxylate.
  • a mixture containing sodium 2-chloro-2,2-difluoroacetate (1,4 equiv.), potassium carbonate (1.1 equiv.), and ethyl 5-oxo-1-(3,3,4,4,4-pentafluorobutyl)-2,5-dihydro-1H-pyrazole-3-carboxylate (1 equiv.) in DMF was heated to 100 °C for 5 h.
  • the mixture was diluted in ethyl acetate and washed with water.
  • the organic layer was dried, filtered and evaporated to give an oil.
  • Step 5 Synthesis of 5-(difluoromethoxy)-1-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazole-3-carboximidamide hydrochloride.
  • Step 1 Synthesis of ethyl 2-(2-(2-fluorobenzyl)hydrazinyl)-2-iminoacetate
  • Step 2 Synthesis of ethyl 1-(2-fluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4--triazole-3-carboxylate
  • Step 3 Synthesis of 1-(2-fluorobenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazole-3-carboximidamide
  • Step 1 Synthesis of ethyl 1-(2-fluorobenzyl)-5-methoxy-1H-1,2,4-triazole-3-carboxylate
  • Step 2 Synthesis of 1-(2-fluorobenzyl)-5-methoxy-1H-1,2,4-triazole-3-carboximidamide
  • Step 1 ethyl 1-(2-fluorobenzyl)-4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazole-3-carboxylate
  • the title compound was prepared following general procedure A in library format, except (2R,3S)-3-methylpiperidine-2-carboxylic acid (10 equiv.) was the amine reactant, 20 equivalents of triethylamine was used, and contents were stirred as a solution in THF : water (2:1) at 100 °C for 18 h. The resulting residue after workup was purified via reverse phase HPLC to deliver the desired compound (2.5 mg, 10% yield) as a white solid.
  • the title compound was prepared following general procedure A in library format, except 4-methylpiperidine-4-carboxylic acid (2 equiv.) was the amine reactant, and contents were stirred as a solution in dioxane. Contents were concentrated under a stream of nitrogen, and the resulting residue was purified via reverse phase HPLC to deliver the desired compound (2.1 mg, 11% yield) as a white solid.
  • the title compound was prepared following general procedure A in library format, except 4-isopropylpiperidine-4-carboxylic acid (2 equiv.) was the amine reactant, and contents were stirred as a solution in dioxane. Contents were concentrated under a stream of nitrogen, and the resulting residue was purified via reverse phase HPLC to deliver the desired compound (6.3 mg, 30% yield) as a white solid.
  • the title compound was prepared following general procedure A in library format, except 1-((methylamino)methyl)cyclopentanecarboxylic acid (2 equiv.) was the amine reactant, and contents were stirred as a solution in dixoane. Contents were concentrated under a stream of nitrogen, and the resulting residue was purified via reverse phase HPLC to deliver the desired compound (4.2 mg, 21% yield) as a white solid.
  • the title compound was prepared following general procedure A in library format, except 2-methyl-1-(1H-tetrazol-5-yl)propan-1-amine was the amine reactant, and contents were stirred as a solution in dioxane. Contents were concentrated under a stream of nitrogen, and the resulting residue was purified via reverse phase HPLC to deliver the desired compound (6.5 mg, 33% yield) as a white solid.
  • the title compound was prepared following general procedure A in library format, except piperazin-2-one was the amine reactant, and contents were stirred as a solution in dioxane at 85 °C.
  • the title compound was prepared following general procedure A in library format, except 4-(hydroxymethyl)piperidin-4-ol was the amine reactant, and contents were stirred as a solution in dioxane at 85 °C. Contents were concentrated under a stream of nitrogen, and the resulting residue was purified via reverse phase HPLC to deliver the desired compound (8.6 mg, 45% yield) as a white solid.
  • Step 1 Synthesis of 2-(1-(2,3-difluorobenzyl)-5-(difluoromethoxy)-1H-pyrazol-3-yl)-5-fluoropyrimidine-4,6-diol
  • Step 2 Synthesis of 4,6-dichloro-2-(1-(2,3-difluorobenzyl)-5-(difluoromethoxy)-1H-pyrazol-3-yl)-5-fluoropyrimidine
  • a mixture containing triethylamine (1.1 equiv.), 10 wt% palladium on carbon (0.1 equiv.) and 4,6-dichloro-2-(1-(2,3-difluorobenzyl)-5-(difluoromethoxy)-1H-pyrazol-3-yl)-5-fluoropyrimidine (1 equiv.) in ethyl acetate was placed under hydrogen (80 psi) and 50 °C for 4 h. The mixture was cooled to 23 °C and passed through an acro disk filter to remove inorganic materials.
  • Example 2 Biological activity measurement by the sGC-HEK-cGMP assay, with LC/MS detection
  • HEK293 Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds. Compounds stimulating the sGC enzyme should cause an increase in the intracellular concentration of cGMP.
  • HEK 293 cells were seeded in Dulbecco's Modification of Eagle's Medium supplemented with fetal bovine serum (10 % final) and penicillin (100U/mL) / streptomycin (100 ⁇ g/mL) in a 50 ⁇ E volume at a density of 1.5x10 4 cells/well in a poly-D-lysine coated 384 well flat bottom plate. Cells were incubated overnight at 37°C in a humidified chamber with 5% CO 2 .
  • Test article and Diethylenetriamine NONOate (DETA-NONOate) solutions (x ⁇ M concentration for test article solution and 10 ⁇ M concentration for DETA-NONOate solution; wherein x is one of the following concentrations);
  • cGMP concentrations were determined from each sample using the LCMS conditions below ( Table 2 ) and calculated standard curve.
  • the standard curve was prepared in 10% acetic acid with 150ng/mL +3cGMP (isotopically labelled cGMP with a weight 3 units higher than wild type) with the following final concentrations of cGMP in ng/mL: 1, 5, 10, 50, 100, 250, 500, 1000, 2000.
  • Data were normalized to a high control using the following equation: 100*(Sample - Low Control)/(High Control - Low Control), where the low control is the average of 16 samples treated with 1% DMSO, and the high control is the average of 16 samples treated with 30 ⁇ M of Reference Compound Y depicted below.
  • the Absolute EC 50 was interpolated from the curve fit and is defined as the concentration at which a given compound elicits 50% of the high control response. Compounds failing to elicit a minimum response of 50% are reported as >30 ⁇ M.
  • Table 3 summarizes results obtained for selected compounds of the invention in this assay. Table 3.
  • Example 3A Biological activity measurement by the thoracic aortic rings assay
  • Thoracic aortic rings are dissected from anesthetized (isoflurane) male Sprague-Dawley rats weighing 275-299g. Tissues are immediately transferred to ice-cold Krebs-Henseleit solution, which has been aerated with 95% O 2 and 5% CO 2 for 30 minutes. Following removal of connective tissue, aortic sections are cut into 4 rings ( ⁇ 2 mm each) and suspended on 2 L-shaped hooks, with one hook fixed at the bottom of the tissue bath (Schuler Organ Bath, Harvard Apparatus) and the other connected to a force transducer (F30 Force Transducer, Harvard Apparatus).
  • Rings are then contracted with 100 ng/mL phenylephrine by adding 100 uL of a 10 ⁇ g/mL phenylephrine stock solution.
  • Tissues achieving a stable contraction are then treated in a cumulative, dose dependent manner with test compounds prepared in dimethylsulfoxide (DMSO).
  • DMSO dimethylsulfoxide
  • tissues are rinsed three times over a 5 minute period with Krebs-Heinseleit's solution (heated to 37°C and aerated with 95% O2 and 5% CO2), allowed to stabilize at baseline, and then used for characterization of other test articles or DMSO effects. All data are collected using the HSE-ACAD software provided by Harvard Apparatus.
  • Percent relaxation effects are calculated in Microsoft Excel using the recorded tension value of 100ng/mL phenylephrine treatment as 0% inhibition and treatment with 100 ⁇ M 3-isobutyl-1-methylxanthine as 100% inhibition.
  • EC50 values are calculated from concentration-response curves generated with GraphPad Prism Software.
  • Example 3B Biological activity measurement by the thoracic aortic rings assay
  • Example 3 As an alternative thoracic aortic rings assay, the procedure of Example 3 is used except that percent relaxation effects are calculated in Microsoft Excel using the recorded tension value of 100ng/mL phenylephrine treatment as 0 % inhibition and, after washing the tissue with buffer, the original resting tension of the tissue is used as 100% inhibition.
  • mice Male rats (250-350g body weight, supplied by Harlan Laboratories) were anesthetized with ketamine/xylazine and a heparinized saline fluid filled catheter implanted into the right femoral artery. The catheter was exteriorized between the scapula, capped, and the animal allowed to recover for at least 7 days post surgery prior to any compound testing. Prior to testing animals were maintained on normal diet, with free access to drinking water, under a 12 hour light-dark cycle.
  • Example 5 Purified human recombinant sGC ⁇ 1 ⁇ 1 enzyme assay performed in the presence of Diethylenetriamine NONOate (DETA-NONOate), a nitric oxide donor.
  • DETA-NONOate Diethylenetriamine NONOate
  • the assay reactions contained 0.1 M Tris (pH 8.0), 0.5 mg/mL BSA, 2 mM DTT, 4 mM MgCl 2 , 30uM DETA NONOate (Enzo Life Science P/N: ALX-430-014), and 12.5 ng/ml human soluble guanylate cyclase enzyme.
  • Test compounds in DMSO were then added (in a 3-fold titration of compound over a 10-point curve starting at 30uM final concentration, all samples had a 3% DMSO final concentration).
  • Guanosine 5'-triphosphate (Sigma-Aldrich P/N: G8877) was added to a final concentration of 300 ⁇ M and enzyme reactions were incubated (100 ⁇ L, 384-well plate format) at 37°C for 20 minutes.
  • the controls contained 3% DMSO (low control), or 30uM of Reference Compound Y (high control). After the 20 minute incubation, the reaction was stopped with the addition of 100 ⁇ L of ice cold 20% acetic acid.
  • cGMP concentrations in all samples were determined using the cGMP HTRF (Cisbio P/N: 62GM2PEC) assay per manufacturer's instructions.
  • a cGMP standard curve was fit using a 4-parameter fit (log(inhibitor) vs. response - variable slope) using GraphPad Prism Software v.6. Samples were diluted appropriately to ensure that values fell within the linear range of the standard curve.
  • the EC 50 was interpolated from the curve fit and is defined as the concentration at which the compound elicits 50% of the maximal response of the 30uM of Reference Compound Y, the high control compound. Table 5.
  • Enzyme data Compound Number sGC_Enz_HTRF_a1b1 EC 50 Abs (nM) I-1 A I-3 * I-4 C I-5 C I-6 C I-9 C I-10 * I-13 B I-17 C I-18 C I-19 B I-20 A I-21 C I-29 B I-30 B I-37 B I-38 A I-39 C I-48 C I-59 C I-64 B I-70 B
  • U-46619 In awake, spontaneously breathing lambs instrumented with vascular catheters and a tracheostomy tube, U-46619 is infused intravenously to increase mean pulmonary arterial pressure to 35 mm Hg.
  • Inhalation of microparticles composed of either BAY 41-2272, BAY 41-8543, or BAY 58-2667 and excipients (dipalmitoylphosphatidylcholine, albumin, lactose) produced dose dependent pulmonary vasodilation and increased transpulmonary cGMP release without significant effect on mean arterial pressure.
  • Inhalation of microparticles containing BAY 41-8543 or BAY 58-2667 increased systemic arterial oxygenation.
  • pulmonary vasodilation induced by iNO were augmented after inhaling BAY 41-8543 microparticles.
  • ODQ 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
  • pulmonary vasodilation and transpulmonary cGMP release induced by inhaling BAY 58-2667 microparticles were greatly enhanced after treatment with ODQ.
  • inhalation of microparticles containing agonists of sGC may provide an effective novel treatment for patients with pulmonary hypertension, particularly when responsiveness to iNO is impaired by oxidation of sGC.
  • BAY 41-2272, BAY 41-8543 are sGC stimulators whereas BAY 58-2667 is an sGC activator.
  • Guinea pig Guinea pig, Dunkin Hartley, male, Full barrier-bred and certified free of specific micro-organisms on receipt 525-609g on the experimental day, Harlan UK Ltd. Guinea pigs are housed in a group of 4 in solid-bottomed cages with Gold Flake bedding in a controlled environment (airflow, temperature and humidity). Food (FD1, Special Diet Services) and water are provided ad libitum.
  • a guinea pig is killed by exposure to a rising concentration of CO2 and the trachea removed.
  • the trachea is cleaned of extraneous tissue and cut open longitudinally in a line opposite the muscle, opened out and cut into strips 2 -3 cartilage rings wide.
  • a cotton loop is attached to one end of each tracheal strip and a length of cotton to the other end. Tracheal strips are then suspended between two platinum electrodes, using tissue holders, in a Myobath system (World Precision Instruments Stevenage, UK). The loop is attached over the hook at the bottom of the tissue holder and the other end attached to the arm of a FORT10 force transducer (World Precision Instruments Stevenage, UK) ensuring that the tissue is positioned between the two platinum electrodes.
  • the whole assembly is then lowered into a 10ml tissue bath containing modified Kreb's-Henseleit buffer, at 37 °C, bubbled with Carbogen.
  • a 1 g tension is applied to each piece of tissue and the tissue washed, followed by a 1 hour stabilization period.
  • the apparatus for electrical field stimulation is set to deliver a stimulation of frequency 80Hz pulse width 0.1 ms, with a gated, uni-polar pulse, every 2 minutes using a DS8000 8 channel digital stimulator (World Precision Instruments Stevenage, UK).
  • a voltage response curve is carried out on each tracheal strip at 2, 4, 6, 7, 8, 10, 12 V and a sub-maximal voltage then selected to apply to each tissue during the remainder of the experiment.
  • GTSM Guinea pig tracheal smooth muscle contraction is induced using sub-maximal Electrical Field Stimulation (EFS) (It is also possible to induce contraction by using a spasmogen substance, such as methacholine or histamine as described in Coleman et al.*).
  • EFS Electrical Field Stimulation
  • Compounds are dissolved in 100% DMSO at 3x10-2M and aliquots stored at -200 C. A separate aliquot is used for each experiment. Tissues are washed with Kreb's buffer and stimulated using the previously determined sub-maximal voltage for 1 hour to establish a stable baseline contraction prior to assessment of compound activity.
  • a cumulative dose response curve (DRC) to each test substance is then performed and changes in smooth muscle contraction measured.
  • the effect of each test substance in each experiment is expressed as a percentage inhibition of the baseline contraction, normalized to the relevant vehicle controls.
  • the experiment is performed three times, using tissue from three different animals.
  • the data from all three experiments are pooled, the DRC plotted, and the test substance potency and efficacy determined.
  • the potency of Ipratropium bromide is assessed alongside the test compounds and the IC50 determined to be 0.86nM (95% Cl, 0.78-0.94), in agreement with data previously produced in the system.
  • cystic fibrosis pancreatic disorders, gastrointestinal disorders, liver disorders, cystic fibrosis-related diabetes (CFRO), dry eye, dry mouth and Sjoegren's syndrome.
  • CFRO cystic fibrosis-related diabetes
  • transgenic mice expressing or not expressing the delta F508CFTR channel it is possible to measure differences on nasal potential difference and salivation in the presence of a test sGC stimulator by using the literature protocol described below (see WO2011095534 ).
  • mice were administered to mice via intraperitoneal injection (5 ml/kg BW) 60 min prior to the salivary secretion assay. After 60 min, mice were anaesthetized with a combination of 25 ketamine and diazepam. The solution was prepared to contain 1 ml of 5 mg/ml diazepam. and 1 ml of 100 mg/ml ketamine in 8 ml sterile saline. Anesthesia was induced by intraperitoneal injection of the solution (10 ml/kg BW). After anesthesia, mice were pretreated with a subcutaneous injection of 1 mM atropine (50 1-11) into the left cheek in order to avoid a cross-stimulation of cholinergic receptors.
  • 5 ml/kg BW 60 min prior to the salivary secretion assay. After 60 min, mice were anaesthetized with a combination of 25 ketamine and diazepam. The solution was prepared to contain 1 ml of 5 mg/ml diazep
  • nNOS neuronal Nitric Oxide Synthase
  • nNOS localization in animal models of nondystrophic myopathy following the literature protocols described below (" Loss of sarcolemmal nNOS is common in acquired and inherited neuromuscular disorders"; E.L. Finanger Hedderick et al., Neurology, 2011, 76(11), 960-967 ).
  • sGC stimulators for example an sGC stimulator of the invention
  • Skeletal muscle specimens from hibernating 13-lined ground squirrels have been used to evaluate the impact of immobility and catabolic stress on nNOS localization in the context of maintained muscle homeostasis and integrity. These animals are obligate hibernating mammals that are protected against skeletal muscle atrophy during hibernation. Despite hibernating for 5 months with almost complete immobility and no caloric intake, sarcolemmal expression of nNOS is preserved. These data together with patient and mouse data indicate that biochemical control of nNOS localization is complex and, importantly, that preserved sarcolemmal nNOS may be significant in maintaining muscle homeostasis.
  • Becker muscular dystrophy (BMD), characterized by progressive skeletal muscle wasting, is caused by mutations of the muscle protein dystrophin.
  • Martin et al. see “ Tadalafil Alleviates Muscle Ischemia in Patients with Becker Muscular Dystrophy”; Elizabeth A. Martin et al., Sci. Transl. Med. 4, 162ra155 (2012 ); " Vascular-targeted therapies for Duchenne muscular dystrophy”; Ennen et al., Skeletal Muscle, 2013, 3:9 ) assessed exercise-induced attenuation of reflex sympathetic vasoconstriction in the muscles of 10 patients with BMD and 7-age matched healthy male controls.
  • Reflex vasoconstriction was induced by simulated orthostatic stress and was measured as the forearm muscles were rested or lightly exercised in the form of rhythmic handgrip.
  • the investigators showed that exercise-induced attenuation of reflex vasoconstriction was defective in 9 out of 10 patients with BMD in whom the common dystrophin mutations disrupt targeting of neuronal NO synthase (nNOS) to the muscle sarcolemma.
  • nNOS neuronal NO synthase
  • DMD Duchenne muscular dystrophy
  • nNOS derived NO With exercise of healthy skeletal muscle, sarcolemmal nNOS derived NO attenuates local ⁇ -adrenergic vasoconstriction, thereby optimizing perfusion to meet the metabolic demands of the active muscle.
  • This protective mechanism (termed functional sympatholysis) is lost in mdx mice (a model of BMD and DMD), nNOS null mice, and boys with DMD causing functional muscle ischemia. Repeated bouts of functional ischemia could accelerate use-dependent injury of muscle fibers already weakened by dystrophin deficiency
  • dystrophic phenotype In the mdx mouse, many features of the dystrophic phenotype can be improved by multiple strategies that boost NO signaling, including transgenic expression of nNOS, transgenic expression of dystrophin minigenes that restore sarcolemmal nNOS (and thereby restore functional sympatholysis), administration of the NOS substrate L-arginine (24, 25), treatment with NO-donating drugs, and phosphodiesterase 5A (PDE5A) inhibition with the drug tadalafil or sildenafil.
  • NOS substrate L-arginine 24, 25
  • NO-donating drugs phosphodiesterase 5A (PDE5A) inhibition with the drug tadalafil or sildenafil.
  • PDE5A phosphodiesterase 5A
  • PDE5A inhibitors which prolong the half-life of guanosine 3',5'-monophosphate (cGMP)- the downstream target of NO in vascular smooth muscle- were shown in the mdx mouse to alleviate muscle ischemia, as well as injury and fatigue, after a brief bout of exercise. Also, these drugs were shown to improve cardiac dynamics in mdx mice and to rescue dystrophic skeletal muscle and prolong survival in dystrophin-deficient zebra fish.
  • cGMP guanosine 3',5'-monophosphate
  • Sickle-cell disease SCD
  • SCA sickle-cell anemia
  • drepanocytosis is a hereditary blood disorder, characterized by red blood cells that assume an abnormal, rigid, sickle shape. Sickling decreases the cells' flexibility and results in a risk of various complications. The sickling occurs because of a mutation in the hemoglobin gene. Individuals with one copy of the defunct gene display both normal and abnormal hemoglobin. This is an example of co-dominance. In 1994, in the US, the average life expectancy of persons with this condition was estimated to be 42 years in males and 48 years in females, but today, thanks to better management of the disease, patients can live into their 70s or beyond.
  • Sickle-cell anemia is a form of sickle-cell disease in which there is homozygosity for the mutation that causes HbS.
  • Sickle-cell anemia is also referred to as "HbSS”, “SS disease”, “hemoglobin S” or permutations of those names.
  • HbAS sickle cell trait
  • Other, rarer forms of sickle-cell disease are compound heterozygous states in which the person has only one copy of the mutation that causes HbS and one copy of another abnormal hemoglobin allele. They include sickle-hemoglobin C disease (HbSC), sickle beta-plus-thalassemia (HbS/ ⁇ + ) and sickle beta-zero-thalassemia (HbS/ ⁇ 0 ).
  • red blood cell (RBC) sickling and rheological abnormalities are central to the pathophysiology of sickle cell disease, vascular dysfunction resulting from complex interactions between sickled red blood cells (sRBC), endothelial cells, platelets and leukocytes play an equally important role.
  • sRBC sickled red blood cells
  • endothelial activation is associated with sickle cell-mediated hypoxia-reperfusion events (see for example " Advances in understanding of the pathogenesis of cerebrovascular vasculopathy in sickle cell anemia", P. Connes et al., Br. J. Haematol. 2013, 161, 484-98 ).
  • Red blood cell sickling and adhesion to endothelium initiate vaso-occlusion by impairing blood flow.
  • cytokines including C-reactive protein (CRP), tumor necrosis factor (TNF), interleukin-1 (IL-1) and interleukin-8 (IL-8).
  • CRP C-reactive protein
  • TNF tumor necrosis factor
  • IL-1 interleukin-1
  • IL-8 interleukin-8
  • sRBC promote endothelial up-regulation of TNF- ⁇ and IL-1- ⁇ (8-10).
  • Microarray studies of activated monocytes have shown differential expression of genes involved in inflammation, heme metabolism, cell cycle regulation, anti-oxidant responses, and angiogenesis.
  • L-arginine Dietary supplementation of the NO synthase substrate, L-arginine, has been studied extensively in sickle cell disease as a means of increase NO bioavailability. In sickle mice, oral L-arginine at high doses has been shown to decrease Gardos channel activity, dense cell formation and hemolysis, as well as functional improvements in vascular reactivity.
  • Sildenafil an agent aimed at amplifying the effect of endogenous NO by inhibiting PDE5, a downstream mediator of NO, is used widely in the general population to treat primary PHT.
  • Preliminary studies in sickle cell disease patients with severe PHT reported improvements in PAP and exercise capacity after treatment with sildenafil.
  • a multicenter trial (Treatment of Pulmonary Hypertension and Sickle Cell Disease with Sildenafil Therapy, Walk-PHaSST) testing the safety and efficacy of sildenafil in sickle cell disease patients with Doppler-defined PHT was stopped prematurely due to a higher frequency of serious side effects, including increased rates of VOE, headache, and visual disturbance in the treatment group.
  • Nitrite and niacin have also been investigated for their direct NO donor properties.
  • sodium nitrite infusions in adult sickle cell disease patients enhanced forearm blood flow, consistent with a NO donor mechanism of action.
  • a larger phase I/II trial is now investigating whether nitrite infusions administered as adjunctive therapy during acute VOE will improve microvascular blood flow and tissue oxygenation (clinicaltrials.gov NCT01033227).
  • the effect of niacin on improvement in endothelial-dependent vasodilation is also being assessed in a phase II randomized, controlled trial (clinicaltrials.gov NCT 00508989).
  • the sGC activator BAY 60-2770 ameliorates overactive bladder in obese mice (see “ The Soluble Guanylyl Cyclase Activator BAY 60-2770 ameliorates overactive bladder in obese mice”, Luiz O Leiria et al., The Journal of Urology, 2013, doi:10.1016/j.juro.2013.09.020 .).
  • the animal model described in this publication can analogously be used to assess the effect of an sGC stimulator (for example, an sGC stimulator of the invention) on overactive bladder.
  • a method or device that "comprises”, “has”, “includes” or “contains” one or more steps or elements possesses those one or more steps or elements, but is not limited to possessing only those one or more steps or elements.
  • a step of a method or an element of a device that "comprises”, “has”, “includes” or “contains” one or more features possesses those one or more features, but is not limited to possessing only those one or more features.
  • a device or structure that is configured in a certain way is configured in at least that way, but may also be configured in ways that are not listed.
  • each range is intended to be a shorthand format for presenting information, where the range is understood to encompass each discrete point within the range as if the same were fully set forth herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)

Claims (15)

  1. Verbindung nach Formel I, oder ein oder ein pharmazeutisch annehmbares Salz davon,
    Figure imgb0269
    wobei X ausgewählt ist aus N oder C;
    X1 ausgewählt ist aus N, CH, C(C1-4-Alkyl), C(C1-4-Fluoralkyl), C(Cl) und CF;
    W entweder wie folgt ist
    i) es fehlt, wobei JB direkt mit den zwei Kohlenstoffatom-tragenden J-Gruppen verbunden ist, jedes J unabhängig ausgewählt ist aus Wasserstoff, Methyl oder Fluor, n 1 ist und JB eine C1-6-Alkyl-Kette ist, optional substituiert durch bis zu 6 Vorkommen von Fluor; oder
    ii) ein Ring B ausgewählt aus Phenyl oder ein 5- oder 6-gliedriger Heteroaryl-Ring, der 1 oder 2 Ring-Heteroatome enthält, ausgewählt aus N, O oder S; wobei, wenn W Ring B ist:
    jedes J Wasserstoff ist;
    n 0 oder eine Ganzzahl ausgewählt aus 1 bis 3 ist;
    und jedes JB unabhängig ausgewählt ist aus Halogen, -CN, einer C1-6 aliphatischen, -ORB oder einer C3-8 cycloaliphatischen Gruppe; wobei jede der C1-6 aliphatischen und jede der C3-8 cycloaliphatischen Gruppe optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von R3;
    jedes RB unabhängig ausgewählt ist aus Wasserstoff, einem C1-6 aliphatischen oder einem C3-8 cycloaliphatischen; wobei jedes von dem RB, das ein C1-6 aliphatisches ist, und jedes von dem RB, das ein C3-8 cycloaliphatischer Ring ist, optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von R3a;
    jedes R3 unabhängig ausgewählt ist aus Halogen, -CN, C1-4-Alkyl, C1-4-Haloalkyl, -O(C1-4-Alkyl) oder -O(C1-4-Haloalkyl);
    jedes R3a unabhängig ausgewählt ist aus Halogen, -CN, C1-4-Alkyl, C1-4-Haloalkyl, -O(C1-4-Alkyl) oder -O(C1-4-Haloalkyl);
    o 0 oder eine Ganzzahl ausgewählt aus 1 bis 3 ist;
    jedes JD entweder fehlt oder unabhängig ausgewählt ist aus Wasserstoff, Halogen, -CN, -NO2, -ORD, -SRD, -C(O)RD, -C(O)ORD, -OC(O)RD, -C(O)N(RD)2, -N(RD)2, -N(Rd)C(O)RD, -N(Rd)C(O)ORD, -N(Rd)C(O)N(RD)2, -OC(O)N(RD)2, -SO2RD, -SO2N(RD)2, -N(Rd)SO2RD, einem C1-6 aliphatischen, -(C1-6 aliphatischen)-RD, einem C3-8 cycloaliphatischen Ring, einem 6- bis 10-gliedrigen Aryl-Ring, einem 4- bis 8-gliedrigen heterocyclischen Ring oder einem 5- bis 10-gliedrigen Heteroaryl-Ring; wobei jedes von dem 4- bis 8-gliedrigen heterocyclischen Ring und jedes von dem 5- bis 10-gliedrigen Heteroaryl-Ring zwischen 1 und 3 Heteroatome enthält, unabhängig ausgewählt aus O, N oder S; und wobei jedes von den C1-6 aliphatischen Ketten, jedes von dem C3-8 cycloaliphatischen Ring, jedes von dem 6- bis 10-gliedrigen Aryl-Ring, jedes von dem 4- bis 8-gliedrigen heterocyclischen Ring und jedes von dem 5- bis 10-gliedrigen Heteroaryl-Ring optional und unabhängig substituiert ist mit bis zu 5 Vorkommen von R5;
    jedes RD unabhängig ausgewählt ist aus Wasserstoff, einem C1-6 aliphatischen, -(C1-6 aliphatischen)-Rf, einem C3-8 cycloaliphatischen Ring, einem 4- bis 8-gliedrigen heterocyclischen Ring und Phenyl; wobei jedes von dem 4- bis 8-gliedrigen heterocyclischen Ring zwischen 1 und 3 Heteroatome enthält, unabhängig ausgewählt aus O, N und S; und wobei jede von den C1-6 aliphatischen Ketten, jedes von dem C3-8 cycloaliphatischen Ring, jedes von dem 4- bis 8-gliedrigen heterocyclischen Ring und jedes von dem Phenyl optional und unabhängig substituiert ist mit bis zu 5 Vorkommen von R5a; wobei, wenn ein RD eine von einer C1-6 aliphatischen oder einer -(C1-6 aliphatischen)-Rf Gruppe ist, eine oder zwei Einheiten -CH2-, die die C1-6 aliphatischen Ketten bilden, optional durch eine Gruppe ersetzt sein kann, unabhängig ausgewählt aus -C(O)-, -N(Rd) - oder -O-;
    jedes Rd unabhängig ausgewählt ist aus Wasserstoff, einem C1-6 aliphatischen, -(C1-6 aliphatischen)-Rf, einem C3-8 cycloaliphatischen Ring, einem 4- bis 8-gliedrigen heterocyclischen Ring, Phenyl oder einem 5 bis 6-gliedrigen Heteroaryl-Ring; wobei jedes von dem 4- bis 8-gliedrigen heterocyclischen Ring und jedes von dem 5- oder 6-gliedriger Heteroaryl-Ring zwischen 1 und 3 Heteroatome enthält, unabhängig ausgewählt aus O, N oder S; und wobei jede von den C1-6 aliphatischen Ketten, jedes von dem C3-8 cycloaliphatischen Ring, jedes von dem 4-bis 8-gliedrigen heterocyclischen Ring, jedes von dem Phenyl und jedes von dem 5 bis 6-gliedrigen Heteroaryl-Ring optional und unabhängig substituiert ist mit bis zu 5 Vorkommen von R5b;
    jedes Rf unabhängig ausgewählt ist aus einem C1-3-Alkyl, einem C3-8 cycloaliphatischen Ring, einem 4- bis 8-gliedrigen heterocyclischen Ring, Phenyl oder einem 5 bis 6-gliedrigen Heteroaryl-Ring; wobei jedes von dem 4- bis 8-gliedrigen heterocyclischen Ring und jedes von dem 5 bis 6-gliedrigen Heteroaryl-Ring zwischen 1 und 4 Heteroatome enthält, unabhängig ausgewählt aus O, N oder S; und wobei jedes von dem C3-8 cycloaliphatischen Ring, jedes von dem 4- bis 8-gliedrigen heterocyclischen Ring, jedes von dem Phenyl und jedes von dem 5 bis 6-gliedrigen Heteroaryl-Ring optional und unabhängig substituiert ist mit bis zu 5 Vorkommen von R5c;
    wenn JD -C(O)N(RD)2, -N(RD)2, -N(Rd)C(O)N(RD)2, -OC(O)N(RD)2 oder -SO2N(RD)2 ist, können die zwei RD-Gruppen zusammen mit dem Stickstoffatom, das an die zwei RD-Gruppen angelagert ist, einen 4- bis 8-gliedrigen heterocyclischen Ring oder einen 5-gliedrigen Heteroaryl-Ring bilden; wobei jedes von dem 4- bis 8-gliedrigen heterocyclischen Ring und jedes von dem 5-gliedriger Heteroaryl-Ring optional bis zu 3 zusätzliche Heteroatome enthält, unabhängig ausgewählt aus N, O oder S, zusätzlich zu dem Stickstoffatom, an das die zwei RD-Gruppen angelagert sind; und wobei jedes von dem 4- bis 8-gliedrigen heterocyclischen Ring und jedes von dem 5-gliedriger Heteroaryl-Ring optional und unabhängig substituiert ist mit bis zu 5 Vorkommen von R5d;
    wenn JD -N(Rd)C(O)RD ist, die RD-Gruppe zusammen mit dem Kohlenstoffatom, das an die RD-Gruppe angelagert ist, mit dem Stickstoffatom, das an die Rd-Gruppe angelagert ist, und mit der Rd-Gruppe einen 4- bis 8-gliedrigen heterocyclischen Ring oder einen 5-gliedrigen Heteroaryl-Ring bilden kann; wobei jedes von dem 4- bis 8-gliedrigen heterocyclischen Ring und jedes von dem 5-gliedriger Heteroaryl-Ring optional bis zu 2 zusätzliche Heteroatome enthält, unabhängig ausgewählt aus N, O oder S, zusätzlich zu dem Stickstoffatom, an das die Rd-Gruppe angelagert ist; und wobei jedes von dem 4- bis 8-gliedrigen heterocyclischen Ring und jedes von dem 5-gliedriger Heteroaryl-Ring optional und unabhängig substituiert ist mit bis zu 5 Vorkommen von R5d;
    wenn JD -N(Rd)C(O)ORD ist, die RD-Gruppe zusammen mit dem Sauerstoffatom, das an die RD-Gruppe angelagert ist, mit dem Kohlenstoffatom des Abschnitts -C(O)- der Gruppe -N(Rd)C(O)ORD Gruppe, wobei das Stickstoffatom an die Rd-Gruppe angelagert ist, mit der Rd-Gruppe einen 4- bis 8-gliedrigen heterocyclischen Ring bilden kann; wobei der 4- bis 8-gliedrige heterocyclischen Ring optional bis zu 2 zusätzliche Heteroatome enthält, unabhängig ausgewählt aus N, O oder S und optional und unabhängig substituiert ist mit bis zu 5 Vorkommen von R5d;
    wenn JD -N(Rd)C(O)N(RD)2 ist, eine der RD-Gruppen, die an das Stickstoffatom angelagert sind, zusammen mit dem Stickstoffatom und mit dem N-Atom, die an die Rd-Gruppe angelagert sind, und die Rd-Gruppe einen 4- bis 8-gliedrigen heterocyclischen Ring bilden kann; wobei der 4-bis 8-gliedrige heterocyclische Ring optional bis zu 2 zusätzliche Heteroatome enthält, unabhängig ausgewählt aus N, O oder S und optional und unabhängig substituiert ist mit bis zu 5 Vorkommen von R5d;
    wenn JD -N(Rd)SO2RD ist, die RD-Gruppe zusammen mit dem Schwefelatom, das an die RD-Gruppe angelagert ist, mit dem Stickstoffatom, das an die Rd-Gruppe angelagert ist und mit der Rd-Gruppe kombinieren kann, um einen 4- bis 8-gliedrigen heterocyclischen Ring zu bilden; wobei der 4- bis 8-gliedrige heterocyclische Ring optional bis zu 2 zusätzliche Heteroatome enthält, unabhängig ausgewählt aus N, O oder S und optional und unabhängig substituiert ist mit bis zu 5 Vorkommen von R5d;
    jedes R5 unabhängig ausgewählt ist aus Halogen, -CN, C1-6-Alkyl, -(C1-6-Alkyl)-R6, -OR6, -SR6, -COR6, -OC(O)R6, -C(O)OR6, -C(O)N(R6)2, -N(R6)C(O)R6, -N(R6)C(O)OR6, -N(R6)C(O)N(R6)2, -N(R6)2, -SO2R6, -SO2OH, -SO2NHOH, -SO2N(R6)2, -SO2N(R6)(CO)-R6, -N(R6)SO2R6, einem C7-12-Aralkyl-, einem C3-8-Cycloalkyl-Ring, einem 4- bis 7-gliedrigen heterocyclischen Ring, einem 5- oder 6-gliedrigen Heteroaryl-Ring, Phenyl oder einer Oxo-Gruppe; wobei jeder 5- oder 6-gliedrige Heteroaryl-Ring oder 4- bis 7-gliedrige heterocyclische Ring bis zu vier Ring-Heteroatome enthält, unabhängig ausgewählt aus N, O und S, wobei jede von den C1-6-Alkyl-Ketten, dem C7-12-Aralkyl-, demC3-8-Cycloalkyl-Ring, dem 4-bis 7-gliedrigen heterocyclischen Ring, dem 5- oder 6-gliedrigen Heteroaryl-Ring oder der Phenyl-Gruppe optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von Halogen, C1-4-Alkyl, C1-4 (Haloalkyl), -OH, -NH2, -NH(C1-4-Alkyl), -N(C1-4-Alkyl)2, -CN, -COOH, -CONH2, -COO(C1-4-Alkyl), -O(C1-4-Alkyl), -O(C1-4-Haloalkyl) oder Oxo;
    alternativ zwei Vorkommen von R5, die an das gleiche oder an verschiedene Atome von JD angelagert sind, zusammen mit dem Atom oder den Atomen von JD, an die sie angelagert sind, einen C3-8-Cycloalkyl-Ring, einen 4- bis 6-gliedrigen heterocyclischen Ring; einen Phenyl- oder einen 5- oder 6-gliedrigen Heteroaryl-Ring bilden können, was in einem bicylischen System resultiert, wobei die zwei Ringe des bicyclischen Systems in einem Spiro-, kondensierten oder überbrückten Verhältnis in Bezug aufeinander sind; wobei der 4- bis 6-gliedrige Heterocyclus oder der 5- oder 6-gliedriger Heteroaryl-Ring bis zu vier Ring-Heteroatome enthält, die unabhängig ausgewählt sind aus N, O oder S; und wobei der C3-8-Cycloalkyl-Ring, 4- bis 6-gliedrige heterocyclische Ring, Phenyl oder 5- oder 6-gliedrige Heteroaryl-Ring optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von C1-4-Alkyl, C1-4-Haloalkyl, C1-4-Alkoxy, C1-4-Haloalkoxy, Oxo, -C(O)O(C1-4-Alkyl), -C(O)OH, -NR(CO)O(C1-4-Alkyl), -CONH2, -OH oder Halogen; wobei R Wasserstoff oder ein C1-2-Alkyl ist;
    jedes R5a unabhängig ausgewählt ist aus Halogen, -CN, C1-6-Alkyl, -(C1-6-Alkyl)-R6a, -OR6a, -SR6a, -COR6a, -OC(O)R6a, -C(O)OR6a, -C(O)N(R6a)2, -N(R6a)C(O)R6a, -N(R6a)C(O)OR6a, -N(R6a)C(O)N(R6a)2, -N(R6a)2, -SO2R6a, -SO2OH, -SO2NHOH, -SO2N(R6a)2, -SO2N(R6a)(CO)-R6a, -N(R6a)SO2R6a, einem C7-12-Aralkyl, einem C3-8-Cycloalkyl-Ring, einem 4-bis 7-gliedrigen heterocyclischen Ring, einem 5- oder 6-gliedrigen Heteroaryl-Ring, einer Phenyl- oder einer Oxo-Gruppe; wobei jeder 5-oder 6-gliedrige Heteroaryl-Ring oder 4- bis 7-gliedrige heterocyclische Ring bis zu vier Ring-Heteroatome enthält, unabhängig ausgewählt aus N, O und S, wobei jede von den C1-6-Alkyl-Ketten, jedes von dem C7-12-Aralkyl, der C3-8-Cycloalkyl-Ring, der 4- bis 7-gliedrige heterocyclische Ring, der 5- oder 6-gliedrige Heteroaryl-Ring oder die Phenyl-Gruppe optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von Halogen, C1-4-Alkyl, C1-4 (Haloalkyl), -OH, -NH2, -NH(C1-4-Alkyl), -N(C1-4-Alkyl)2, -CN, -COOH, -COO(C1-4-Alkyl), -CONH2, -O(C1-4-Alkyl), -O(C1-4-Haloalkyl) oder Oxo;
    jedes R5b unabhängig ausgewählt ist aus Halogen, -CN, C1-6-Alkyl, -(C1-6-Alkyl)-R6a, -OR6a, -SR6a, -COR6a, -OC(O)R6a, -C(O)OR6a, -C(O)N(R6a)2, -N(R6a)C(O)R6a, -N(R6a)C(O)OR6a, -N(R6a)C(O)N(R6a)2, -N(R6a)2, -SO2R6a, -SO2OH, -SO2NHOH, -SO2N(R6a)2, -SO2N(R6a)(CO)-R6a, -N(R6a)SO2R6a, einem C7-12-Aralkyl, einem C3-8-Cycloalkyl-Ring, einem 4-bis 7-gliedrigen heterocyclischen Ring, einem 5- oder 6-gliedrigen Heteroaryl-Ring, einer Phenyl- oder einer Oxo-Gruppe; wobei jeder 5-oder 6-gliedrige Heteroaryl-Ring oder 4- bis 7-gliedrige heterocyclische Ring bis zu vier Ring-Heteroatome enthält, unabhängig ausgewählt aus N, O und S, wobei jede von den C1-6-Alkyl-Ketten, jedes von dem C7-12-Aralkyl, der C3-8-Cycloalkyl-Ring, der 4- bis 7-gliedrige heterocyclische Ring, der 5- oder 6-gliedrige Heteroaryl-Ring oder die Phenyl-Gruppe optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von Halogen, C1-4-Alkyl, C1-4 (Haloalkyl), -OH, -NH2, -NH(C1-4-Alkyl), -N(C1-4-Alkyl)2, -CN, -COOH, -COO(C1-4-Alkyl), -CONH2, -O(C1-4-Alkyl), -O(C1-4-Haloalkyl) oder Oxo;
    alternativ zwei Vorkommen von R5a oder zwei Vorkommen von R5b, die an das gleiche oder an verschiedene Atome von RD bzw. Rd angelagert sind, zusammen mit dem Atom oder den Atomen an die sie angelagert sind, einen C3-8-Cycloalkyl-Ring, einen 4- bis 6-gliedrigen heterocyclischen Ring; einen Phenyl- oder einen 5- oder 6-gliedrigen Heteroaryl-Ring bilden können, was in einem bicylischen System resultiert, wobei die zwei Ringe des bicyclischen Systems in einem Spiro-, kondensierten oder überbrückten Verhältnis in Bezug aufeinander sind; wobei der 4- bis 6-gliedrige Heterocyclus oder der 5- oder 6-gliedriger Heteroaryl-Ring bis zu vier Ring-Heteroatome enthält, die unabhängig ausgewählt sind aus N, O oder S; und wobei der C3-8-Cycloalkyl-Ring, 4- bis 6-gliedrige heterocyclische Ring, Phenyl oder 5- oder 6-gliedrige Heteroaryl-Ring optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von C1-4-Alkyl, C1-4-Haloalkyl, C1-4-Alkoxy, C1-4-Haloalkoxy, Oxo, -C(O)O(C1-4-Alkyl), -C(O)OH, -NR(CO)O(C1-4-Alkyl), -CONH2, -OH oder Halogen; wobei R Wasserstoff oder ein C1-2-Alkyl ist;
    jedes R5c unabhängig ausgewählt ist aus Halogen, -CN, C1-6-Alkyl, -(C1-6-Alkyl)-R6b, -OR6b, -SR6b, -COR6b, -OC(O)R6b, -C(O)OR6b, -C(O)N(R6b)2, -N(R6b)C(O)R6b, -N(R6b)C(O)OR6b, -N(R6b)C(O)N(R6b)2, -N(R6b)2, -SO2R6b, -SO2OH, -SO2NHOH, -SO2N(R6b)(CO)-R6b, -SO2N(R6b)2, -N(R6b)SO2R6b, einem C7-12-Aralkyl, einem C3-8-Cycloalkyl-Ring, einem 4- bis 7-gliedrigen heterocyclischen Ring, einem 5- oder 6-gliedrigen Heteroaryl-Ring, Phenyl oder einer Oxo-Gruppe; wobei jeder 5- oder 6-gliedrige Heteroaryl-Ring oder 4- bis 7-gliedrige heterocyclische- Ring bis zu vier Ring-Heteroatome enthält, unabhängig ausgewählt aus N, O und S, wobei jede von den C1-6-Alkyl-Ketten, das C7-12-Aralkyl, der C3-8-Cycloalkyl-Ring, der 4- bis 7-gliedrige heterocyclische Ring, der 5- oder 6-gliedrige Heteroaryl-Ring oder die Phenyl-Gruppen optional und unabhängig substituiert sind mit bis zu 3 Vorkommen von Halogen, C1-4-Alkyl, C1-4 (Haloalkyl), -OH, -NH2, -NH(C1-4-Alkyl), -N(C1-4-Alkyl)2, -CN, -COOH, -CONH2, -COO(C1-4-Alkyl), -O(C1-4-Alkyl), -O(C1-4-Haloalkyl) oder Oxo;
    alternativ zwei Vorkommen von R5c, die an das gleiche oder an verschiedene Atome von Rf angelagert sind, zusammen mit dem Atom oder den Atomen an die sie angelagert sind, einen C3-8-Cycloalkyl-Ring, einen 4- bis 6-gliedrigen heterocyclischen Ring; ein Phenyl oder einen 5- oder 6-gliedrigen Heteroaryl-Ring bilden können, was in einem bicylischen System resultiert, wobei die zwei Ringe des bicyclischen Systems in einem Spiro-, kondensierten oder überbrückten Verhältnis in Bezug aufeinander sind; wobei der 4- bis 6-gliedrige Heterocyclus oder der 5- oder 6-gliedriger Heteroaryl-Ring bis zu vier Ring-Heteroatome enthält, die unabhängig ausgewählt sind aus N, O oder S; und wobei der C3-8-Cycloalkyl-Ring, 4- bis 6-gliedrige heterocyclische Ring, Phenyl oder 5- oder 6-gliedrige Heteroaryl-Ring optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von C1-4-Alkyl, C1-4-Haloalkyl, C1-4-Alkoxy, C1-4-Haloalkoxy, Oxo, -C(O)O(C1-4-Alkyl), -C(O)OH, -CONH2, -NR(CO)O(C1-4-Alkyl), -OH oder Halogen; wobei R Wasserstoff oder ein C1-2-Alkyl ist;
    jedes R5d unabhängig ausgewählt ist aus Halogen, -CN, C1-6-Alkyl, -(C1-6-Alkyl)-R6, -OR6, -SR6, -COR6, -OC(O)R6, -C(O)OR6, -C(O)N(R6)2, -N(R6)C(O)R6, -N(R6)C(O)OR6, -N(R6)C(O)N(R6)2, -N(R6)2, -SO2OH, -SO2NHOH, -SO2N(R6)(CO)-R6, -SO2R6, -SO2N(R6)2, -N(R6)SO2R6, a C7-12-Aralkyl, einem C3-8-Cycloalkyl-Ring, einem 4- bis 7-gliedrigen heterocyclischen Ring, einem 5- oder 6-gliedrigen Heteroaryl-Ring, Phenyl oder einer Oxo-Gruppe; wobei jeder 5- oder 6-gliedrige Heteroaryl-Ring oder 4- bis 7-gliedrige heterocyclische Ring bis zu vier Ring-Heteroatome enthält, unabhängig ausgewählt aus N, O und S, wobei jede von den C1-6-Alkyl-Ketten, das C7-12-Aralkyl, der C3-8-Cycloalkyl-Ring, der 4- bis 7-gliedrige heterocyclische Ring, der 5- oder 6-gliedrige Heteroaryl-Ring oder die Phenyl-Gruppen optional und unabhängig substituiert sind mit bis zu 3 Vorkommen von Halogen, C1-4-Alkyl, C1-4 (Haloalkyl), -OH, -NH2, -NH(C1-4-Alkyl), -N(C1-4-Alkyl)2, -CN, -COOH, -CONH2, -COO(C1-4-Alkyl), -O(C1-4-Alkyl), -O(C1-4-Haloalkyl) oder Oxo;
    zwei Vorkommen von R5 oder zwei Vorkommen von R5d, die an das gleiche oder an verschiedene Atome von JD angelagert sind, zusammen mit dem Atom oder den Atomen an die sie angelagert sind, optional einen C3-8-Cycloalkyl-Ring, einen 4- bis 6-gliedrigen heterocyclischen Ring; ein Phenyl oder einen 5- oder 6-gliedrigen Heteroaryl-Ring bilden können, was in einem bicylischen System resultiert, wobei die zwei Ringe des bicyclischen Systems in einem Spiro-, kondensierten oder überbrückten Verhältnis in Bezug aufeinander sind; wobei der 4- bis 6-gliedrige Heterocyclus oder der 5- oder 6-gliedriger Heteroaryl-Ring bis zu vier Ring-Heteroatome enthält, die unabhängig ausgewählt sind aus N, O oder S; und wobei der C3-8-Cycloalkyl-Ring, 4- bis 6-gliedrige heterocyclische Ring, Phenyl oder 5- oder 6-gliedrige Heteroaryl-Ring optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von C1-4-Alkyl, C1-4-Haloalkyl, C1-4-Alkoxy, C1-4-Haloalkoxy, Oxo, -C(O)O(C1-4-Alkyl), -C(O)OH, -CONH2, -NR(CO)O(C1-4-Alkyl), -OH oder Halogen; wobei R Wasserstoff oder ein C1-2-Alkyl ist;
    jedes R6 unabhängig ausgewählt ist aus Wasserstoff, einem C1-6 aliphatischen, Phenyl, Benzyl, einem C3-8-Cycloalkyl-Ring, einem 4- bis 7-gliedrigen heterocyclischen Ring oder einem 5- oder 6-gliedrigen Heteroaryl-Ring, wobei jedes von dem C1-6 aliphatischen, jedes von dem Phenyl, jedes von dem Benzyl, jede von der C3-8-Cycloalkyl-Gruppe, jedes von dem 4- bis 7-gliedriger heterocyclischen Ring und jedes von dem 5- oder 6-gliedrigen Heteroaryl-Ring optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von Halogen, C1-4 -Alkyl, -OH, -NH2, -NH(C1-4-Alkyl), -N(C1-4-Alkyl)2, -CN, -COOH, -COO(C1-4-Alkyl), -O(C1-4-Alkyl), -O(C1-4-Haloalkyl) oder Oxo, wobei jedes von dem 5- oder 6-gliedrigen Heteroaryl-Ring oder 4-bis 7-gliedrigen heterocyclischen Ring bis zu 4 Ring-Heteroatome enthält, unabhängig ausgewählt aus N, O und S;
    jedes R6a unabhängig ausgewählt ist aus Wasserstoff, einem C1-6 aliphatischen, Phenyl, Benzyl, einem C3-8-Cycloalkyl-Ring, einem 4- bis 7-gliedrigen heterocyclischen Ring oder einem 5- oder 6-gliedrigen Heteroaryl-Ring, wobei jedes von dem C1-6 aliphatischen, jedes von dem Phenyl, jedes von dem Benzyl, jede von der C3-8-Cycloalkyl-Gruppe, jedes von dem 4- bis 7-gliedriger heterocyclischen Ring und jedes von dem 5- oder 6-gliedrigen Heteroaryl-Ring optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von Halogen, C1-4 -Alkyl, -OH, -NH2, -NH(C1-4-Alkyl), -N(C1-4-Alkyl)2, -CN, -COOH, -COO(C1-4-Alkyl), -O(C1-4-Alkyl), -O(C1-4-Haloalkyl) oder Oxo, wobei jedes von dem 5- oder 6-gliedrigen Heteroaryl-Ring oder 4-bis 7-gliedrigen heterocyclischen Ring bis zu 4 Ring-Heteroatome enthält, unabhängig ausgewählt aus N, O und S;
    jedes R6b unabhängig ausgewählt ist aus Wasserstoff, einem C1-6 aliphatischen, Phenyl, Benzyl, einem C3-8-Cycloalkyl-Ring, einem 4- bis 7-gliedrigen heterocyclischen Ring oder einem 5- oder 6-gliedrigen Heteroaryl-Ring, wobei jedes von dem C1-6 aliphatischen, jedes von dem Phenyl, jedes von dem Benzyl, jede von der C3-8-Cycloalkyl-Gruppe, jedes von dem 4- bis 7-gliedriger heterocyclischen Ring und jedes von dem 5- oder 6-gliedrigen Heteroaryl-Ring optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von Halogen, C1-4 -Alkyl, -OH, -NH2, -NH(C1-4-Alkyl), -N(C1-4-Alkyl)2, -CN, -COOH, -COO(C1-4-Alkyl), -O(C1-4-Alkyl), -O(C1-4-Haloalkyl) oder Oxo, wobei jedes von dem 5- oder 6-gliedrigen Heteroaryl-Ring oder 4-bis 7-gliedrigen heterocyclischen Ring bis zu 4 Ring-Heteroatome enthält, unabhängig ausgewählt aus N, O und S; wobei
    zwei Vorkommen von R6, die mit dem gleichen Stickstoffatom von R5- oder R5d verbunden sind, zusammen mit dem Stickstoffatom von R5 bzw. R5d, einen 5- bis 8-gliedrigen heterocyclischen Ring oder a 5-gliedriger Heteroaryl-Ring bilden können; wobei jeder von dem 5-bis 8-gliedrigen heterocyclischen Ring und jeder von dem 5-gliedrigen Heteroaryl-Ring optional bis zu 2 zusätzliche Heteroatome enthält, unabhängig ausgewählt aus N, O oder S;
    zwei Vorkommen von R6a, die mit einem Stickstoffatom von R5a oder R5b verbunden sind, zusammen mit dem Stickstoff einen 5- bis 8-gliedrigen heterocyclischen Ring oder einen 5-gliedriger Heteroaryl-Ring bilden können; wobei jeder von dem 5- bis 8-gliedrigen heterocyclischen Ring und jeder von dem 5-gliedrigen Heteroaryl-Ring optional bis zu 2 zusätzliche Heteroatome enthält, unabhängig ausgewählt aus N, O oder S;
    zwei Vorkommen von R6b, die mit einem Stickstoffatom von R5c verbunden sind, zusammen mit dem Stickstoff einen 5- bis 8-gliedrigen heterocyclischen Ring oder einen 5-gliedrigen Heteroaryl-Ring bilden können; wobei jeder von dem 5- bis 8-gliedrigen heterocyclischen Ring und jeder von dem 5-gliedrigen Heteroaryl-Ring optional bis zu 2 zusätzliche Heteroatome enthält, unabhängig ausgewählt aus N, O oder S;
    alternativ zwei JD-Gruppen, angelagert an zwei benachbarte Ring-D-Atome, zusammengenommen mit den zwei benachbarten Ring-D-Atomen, einen 5- bis 7-gliedrigen Heterocyclus oder einen 5-gliedrigen Heteroaryl-Ring, der zu Ring-D kondensiert ist, bilden können; wobei der 5- bis 7-gliedrige Heterocyclus oder das 5-gliedrige Ring-Heteroaryl von 1 bis 3 Heteroatome enthält, unabhängig ausgewählt aus N, O oder S; und wobei der 5- bis 7-gliedrige Heterocyclus oder der 5-gliedrige Heteroaryl-Ring optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von Oxo oder -(Y)-R9;
    wobei Y entweder fehlt oder eine C1-6-Alkyl-Kette ist, optional substituiert durch bis zu 6 Vorkommen von Fluor; und wobei, wenn Y die C1-6-Alkyl-Kette ist, bis zu 3 Methylen-Einheiten von dieser Alkyl-Kette durch eine Gruppe ersetzt sein kann, ausgewählt aus -O-, -C(O) - oder -N((Y1)-R99)-;
    Y1 entweder fehlt oder eine C1-6-Alkyl-Kette ist, optional substituiert durch bis zu 6 Vorkommen von Fluor;
    wenn Y1 fehlt, jedes R99 unabhängig ausgewählt ist aus Wasserstoff, C1-6-Alkyl optional substituiert mit bis zu 9 Fluoratomen, -COR10, -C(O)OR10, -C(O)N(R10)2, -C(O)N(R10)SO2R10, -SO2R10, -SO2N(R10)2, -SO2N(R10)COOR10, -SO2N(R10)C(O)R10, -SO2OH, -SO2NHOH, -SO2N(R10)(CO)R10, einem C3-6-Cycloalkyl-Ring, einem 4-8-gliedrigen heterocyclischen Ring, einem Phenyl-Ring oder einem 5-6-gliedrigen Heteroaryl-Ring; wobei jedes von dem 4- bis 8-gliedrigen heterocyclischen Ring oder 5- bis 6-gliedrigen Heteroaryl-Ring bis zu 4 Ring Heteroatome enthält, unabhängig ausgewählt aus N, O oder S; und wobei jedes von den C3-6-Cycloalkyl-Ringen, jeder von den 4- bis 8-gliedrigen heterocyclischen Ringen, jeder von den Phenyl- und jeder von den 5 bis 6-gliedrigen Heteroaryl-Ringen optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von R11a;
    wenn Y1 vorhanden ist, jedes R99 unabhängig ausgewählt ist aus Wasserstoff, Halogen, -CN, C1-6-Alkyl optional substituiert mit bis zu 9 Fluoratomen, -COR10, -OR10, -OC(O)R10, -C(O)OR10, -C(O)N(R10)2, -C(O)N(R10)SO2R10, -SO2R10, -SOR10, -SR10, -SO2N(R10)2, -SO2N(R10)COOR10, -SO2N(R10)C(O)R10, -SO2OH, -SO2NHOH, -SO2N(R10)(CO)R10, einem C3-6-Cycloalkyl-Ring, einem 4-8-gliedrigen heterocyclischen Ring, einem Phenyl-Ring oder einem 5-6-gliedrigen Heteroaryl-Ring; wobei jeder von dem 4- bis 8-gliedrigen heterocyclischen Ring oder 5- bis 6-gliedrigen Heteroaryl-Ring bis zu 4 Ring Heteroatome enthält, unabhängig ausgewählt aus N, O oder S; und wobei jeder von den C3-6-Cycloalkyl-Ringen, jeder von den 4- bis 8-gliedrigen heterocyclischen Ringen, jeder von den Phenyl- und jeder von den 5- bis 6-gliedrigen Heteroaryl-Ringen optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von R11a;
    jedes R9 unabhängig ausgewählt ist aus Wasserstoff, -CN, -OR10, -COR10, -OC(O)R10, -C(O)OR10, -C(O)N(R10)2, -C(O)N(R10)SO2R10, -N(R10)C(O)R10 -N(R10)C(O)OR10, -N(R10)C(O)N(R10)2, -N(R10)2, -SO2R10, -SO2N(R10)2, -SO2N(R10)COOR10, -SO2N(R10)C(O)R10, -N(R10)SO2R10, -SO2OH, -SO2NHOH, -SO2N(R10)(CO)-R10, einem C3-6-Cycloalkyl-Ring, einem 4-8-gliedrigen heterocyclischen Ring, einem Phenyl-Ring oder einem 5-6-gliedrigen Heteroaryl-Ring; wobei jeder von dem 4- bis 8-gliedrigen heterocyclischen Ring oder 5- bis 6-gliedrigen Heteroaryl-Ring bis zu 4 Ring Heteroatome enthält, unabhängig ausgewählt aus N, O oder S; und wobei jeder von den C3-6-Cycloalkyl-Ringen, jeder von den 4- bis 8-gliedrigen heterocyclischen Ringen, jeder von den Phenyl- und jeder von den 5 bis 6-gliedrigen Heteroaryl-Ringen optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von R11a;
    jedes R10 unabhängig ausgewählt ist aus Wasserstoff, einem C1-6-Alkyl, -(C1-6-Alkyl)-R13 Phenyl, Benzyl, einem C3-6-Cycloalkyl-Ring, einem 4- bis 7-gliedrigen heterocyclischen Ring oder einem 5- oder 6-gliedrigen Heteroaryl-Ring, wobei jeder 5- oder 6-gliedrige Heteroaryl-Ring oder 4- bis 7-gliedrige heterocyclische Ring bis zu 4 Ring Heteroatome enthält, unabhängig ausgewählt aus N, O und S; und wobei jedes von dem C1-6-Alkyl, jedes von dem Phenyl, jedes von dem Benzyl, jede von der C3-8-Cycloalkyl-Gruppe, jeder von dem 4- bis 7-gliedrigen heterocyclischen Ring und jeder 5- oder 6-gliedrige Heteroaryl-Ring optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von R11b;
    jedes R13 unabhängig ausgewählt ist aus einem Phenyl, einem Benzyl, einem C3-6-Cycloalkyl-Ring, einem 4- bis 7-gliedrigen heterocyclischen Ring oder einem 5- oder 6-gliedrigen Heteroaryl-Ring, wobei jeder 5- oder 6-gliedrige Heteroaryl-Ring oder 4- bis 7-gliedrige heterocyclische Ring bis zu 4 Ring Heteroatome enthält, unabhängig ausgewählt aus N, O und S; und wobei jedes von dem Phenyl, jedes von dem Benzyl, jede von der C3-8-Cycloalkyl-Gruppe, jeder von dem 4- bis 7-gliedrigen heterocyclischen Ring und jeder 5- oder 6-gliedrige Heteroaryl-Ring optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von R11c;
    jedes R11a unabhängig ausgewählt ist aus Halogen, C1-6-Alkyl, -CN, -OR12, -COR12, -C(O)OR12, -C(O)N(R12)2, -N(R12)C(O)R12, -N(R12)C(O)OR12, -N(R12)C(O)N(R12)2, -N(R12)2, -SO2R12, -SO2N(R12)2 oder -N(R12)SO2R12; wobei jedes von dem C1-6-Alkyl optional und unabhängig substituiert ist mit bis zu 6 Vorkommen von Fluor und/oder 3 Vorkommen von R121;
    jedes R11b unabhängig ausgewählt ist aus Halogen, C1-6-Alkyl, -CN, -OR12, -COR12, -C(O)OR12, -C(O)N(R12)2, -N(R12)C(O)R12, -N(R12)C(O)OR12, -N(R12)C(O)N(R12)2, -N(R12)2, -SO2R12, -SO2N(R12)2 oder -N(R12)SO2R12; wobei jedes von dem C1-6-Alkyl optional und unabhängig substituiert ist mit bis zu 6 Vorkommen von Fluor und/oder 3 Vorkommen von R121; und
    jedes R11c unabhängig ausgewählt ist aus Halogen, C1-6-Alkyl, -CN, -OR12, -COR12, -C(O)OR12, -C(O)N(R12)2, -N(R12)C(O)R12, -N(R12)C(O)OR12, -N(R12)C(O)N(R12)2, -N(R12)2, -SO2R12, -SO2N(R12)2 oder -N(R12)SO2R12; wobei jedes von dem C1-6-Alkyl optional und unabhängig substituiert ist mit bis zu 6 Vorkommen von Fluor und/oder 3 Vorkommen von R121;
    jedes R12 ausgewählt ist aus Wasserstoff, C1-4-Alkyl, C1-4 (Fluoroalkyl), -OH, -NH2, -NH(C1-4-Alkyl), -N(C1-4-Alkyl)2, -CN, -COOH, -COO(C1-4-Alkyl), -O(C1-4-Alkyl), -O(C1-4-Fluoralkyl) oder Oxo;
    jedes R121 ausgewählt ist aus C1-4-Alkyl, C1-4 (Fluoroalkyl), -OH, -NH2, -NH(C1-4-Alkyl), -N(C1-4-Alkyl)2, -CN, -COOH, -COO(C1-4-Alkyl), -O(C1-4-Alkyl), -O(C1-4-Fluoralkyl) oder Oxo;
    RC ausgewählt ist aus Wasserstoff, C1-6 aliphatischem, -(C1-6-Alkyl)-RN, einem 5- oder 6-gliedrigen Heteroaryl, Phenyl, einem 4- bis 7-gliedrigen heterocyclischen, einem C3-8 cycloaliphatischen, -C(O)R7, -C(O)OR7, -C(O)N(R7)2 und -C(O)N(R7)SO2R7; wobei jedes von dem 5- oder 6-gliedrigen Heteroaryl-Ring und 4- bis 7-gliedrigen heterocyclischen Ring bis zu 4 Ring-Heteroatome enthält, unabhängig ausgewählt aus N, O und S; wobei jedes von dem C1-6 aliphatischen und jeder C1-6-Alkyl-Abschnitt von dem -(C1-6-Alkyl)-RN optional und unabhängig substituiert ist mit bis zu 6 Vorkommen von Halogen und bis zu 2 Vorkommen von -CN, -COOR8, -OR8, Oxo, -N(R8)2, -C(O)N(R8)2, -N(R8)C(O)R8, -N(R8)C(O)OR8, -N(R8)C(O)N(R8)2, -SO2R8, -SO2N(R8)2, -NHOR8, -SO2N(R8)COOR8, -SO2N(R8)C(O)R8 und -N(R8)SO2R8;
    wobei jedes R7 unabhängig ausgewählt ist aus Wasserstoff, C1-6-Alkyl, C1-6-Fluoralkyl, einem C3-8-Cycloalkyl-Ring, Phenyl, einem 4- bis 7-gliedrigen heterocyclischen Ring oder einem 5- oder 6-gliedrigen Heteroaryl-Ring; wobei jeder von dem 5- oder 6-gliedrigen Heteroaryl-Ring oder 4- bis 7-gliedrigen heterocyclischen Ring bis zu 4 Ring-Heteroatome enthält, unabhängig ausgewählt aus N, O und S; und wobei jedes von dem C1-6-Alkyl, jedes von dem Phenyl, jede von de C3-8-Cycloalkyl-Gruppe, jeder von dem 4- bis 7-gliedrigen heterocyclischen Ring und jeder von dem 5- oder 6-gliedrigen Heteroaryl-Ring optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von Halogen, C1-4-Alkyl, -OH, -NH2, -NH(C1-4-Alkyl), -N(C1-4-Alkyl)2, -CN, -COOH, -COO(C1-4-Alkyl), -O(C1-4-Alkyl), -O(C1-4-Haloalkyl) oder Oxo;
    jedes R8 unabhängig ausgewählt ist aus Wasserstoff, C1-6-Alkyl, C1-6-Fluoralkyl, einem C3-8-Cycloalkyl-Ring, einem 4- bis 7-gliedrigen heterocyclischen Ring oder einem 5- oder 6-gliedrigen Heteroaryl-Ring; wobei jeder von dem 5- oder 6-gliedrigen Heteroaryl-Ring oder 4-bis 7-gliedrigen heterocyclischen Ring bis zu 4 Ring-Heteroatome enthält, unabhängig ausgewählt aus N, O und S; und wobei jedes von dem C1-6-Alkyl, jedes von dem Phenyl, jede von de C3-8-Cycloalkyl-Gruppe, jeder von dem 4- bis 7-gliedrigen heterocyclischen Ring und jeder von dem 5- oder 6-gliedrigen Heteroaryl-Ring optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von Halogen, C1-4-Alkyl, -OH, -NH2, -NH(C1-4-Alkyl), -N(C1-4-Alkyl)2, -CN, -COOH, -COO(C1-4-Alkyl), -O(C1-4-Alkyl), -O(C1-4-Haloalkyl) oder Oxo;
    jedes RN unabhängig ausgewählt ist aus einem Phenyl-Ring, einem monocyclischen 5- oder 6-gliedriger Heteroaryl-Ring, einem monocyclischen C3-6 cycloaliphatischen Ring, oder einem monocyclischen 4- bis 6-gliedrigen Heterocyclus; wobei der monocyclische 5- oder 6-gliedrige Heteroaryl-Ring oder der monocyclische 4- bis 6-gliedrige Heterocyclus zwischen 1 und 4 Heteroatome enthält, ausgewählt aus N, O oder S; wobei der monocyclische 5- oder 6-gliedrige Heteroaryl-Ring nicht ein 1,3,5-Triazinyl-Ring ist; und wobei das Phenyl, der monocyclische 5- bis 6-gliedrige Heteroaryl-Ring, der monocyclische C3-6 cycloaliphatische Ring, oder der monocyclische 4- bis 6-gliedrige Heterocyclus optional und unabhängig substituiert ist mit bis zu 6 Vorkommen von Fluor und/oder bis zu 3 Vorkommen von JM;
    jedes JM unabhängig ausgewählt ist aus -CN, einem C3-6 aliphatischen, -ORM, -SRM, -N(RM)2, einem C3-8 cycloaliphatischen Ring oder einem 4- bis 8-gliedrigen heterocyclischen Ring; wobei der 4- bis 8-gliedrige heterocyclische Ring 1 oder 2 Heteroatome enthält, unabhängig ausgewählt aus N, O oder S; wobei jedes von dem C1-6 aliphatischen, jeder von dem C3-8 cycloaliphatischen Ring und jeder von dem 4- bis 8-gliedrigen heterocyclischen Ring optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von R7c; und
    jedes RM unabhängig ausgewählt ist aus Wasserstoff, einem C1-6 aliphatischen, einem C3-8 cycloaliphatischen Ring oder einem 4- bis 8-gliedrigen heterocyclischen Ring; wobei jeder von dem 4- bis 8-gliedrigen heterocylischen Ring zwischen 1 und 3 Heteroatome enthält, unabhängig ausgewählt aus O, N oder S;
    jedes R7c unabhängig ausgewählt ist aus Halogen, -CN, -NO2, C1-4-Alkyl, C1-4-Haloalkyl, C3-8-Cycloalkyl-Ring, -OR8b, -SR8b, -N(R8b)2, -C(O)O(C1-4-Alkyl), -C(O)OH, -NR(CO)CO(C1-4-Alkyl) oder einer Oxo-Gruppe; wobei jede von der Cycloalkyl-Gruppe optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von Halogen;
    jedes R8b unabhängig ausgewählt ist aus Wasserstoff, C1-6-Alkyl, C1-6-Fluoralkyl, einem C3-8-Cycloalkyl-Ring, einem 4- bis 7-gliedrigen heterocyclischen Ring oder einem 5- oder 6-gliedrigen Heteroaryl-Ring; wobei jeder von dem 5- oder 6-gliedrigen Heteroaryl-Ring oder 4-bis 7-gliedrigen heterocyclischen Ring bis zu 4 Ring-Heteroatome enthält, unabhängig ausgewählt aus N, O und S; und wobei jedes von dem C1-6-Alkyl, jedes von dem Phenyl, jede von der C3-8-Cycloalkyl-Gruppe, jeder von dem 4- bis 7-gliedrigen heterocyclischen Ring und jeder von dem 5- oder 6-gliedrigen Heteroaryl-Ring optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von Halogen, C1-4-Alkyl, -OH, -NH2, -NH(C1-4-Alkyl), -N(C1-4-Alkyl)2, -CN, -COOH, -COO(C1-4-Alkyl), -O(C1-4-Alkyl), -O(C1-4-Haloalkyl) oder Oxo;
    wobei der oben beschriebene heterocyclische Ring vollständig gesättigt ist oder eine oder mehrere Unsättigungseinheiten enthält, aber nicht aromatisch ist;
    vorausgesetzt, dass die Verbindung keine Verbindung ist, die durch die folgende allgemeine Struktur dargestellt ist:
    Figure imgb0270
    wobei JA entweder Wasserstoff oder C1-4-Alkyl ist; und JB entweder Halogen oder C1-4-(Alkoxy) ist.
  2. Verbindung nach Anspruch 1, oder ein pharmazeutisch annehmbares Salz davon, wobei die Verbindung durch Formel IIa dargestellt ist:
    Figure imgb0271
     wobei Q eine Gruppe -CZ2- darstellt, jedes Z unabhängig ausgewählt ist aus Wasserstoff oder Fluor und p eine Ganzzahl ist, ausgewählt aus 1, 2, 3, 4 und 5.
  3. Verbindung nach den Ansprüchen 1 oder 2, oder ein pharmazeutisch annehmbares Salz davon, dargestellt durch Formel IIIa:
    Figure imgb0272
     wobei
    wenn X N ist, die Gruppierung -N(R1)(R2) fehlt;
    wenn X C ist, die Gruppierung -N(R1)(R2) vorhanden ist;
    R1 und R2, zusammen mit dem Stickstoffatom, an das sie angelagert sind, einen 4- bis 8-gliedrigen heterocyclischen Ring oder 5-gliedrigen Heteroaryl-Ring bilden; wobei der 4- bis 8-gliedrige heterocyclische Ring oder 5-gliedrige Heteroaryl-Ring optional zusätzlich zu dem Stickstoffatom, an das beide R1 und R2 angelagert sind, bis zu 3 Ring Heteroatome enthält, unabhängig ausgewählt aus N, O oder S und optional substituiert ist durch bis zu 5 Vorkommen von R5e;
    jedes R5e unabhängig ausgewählt ist aus Halogen, -CN, C1-6-Alkyl, -(C1-4-Alkyl)-R6, a C3-8-Cycloalkyl-Ring, C1-4 (Cyanoalkyl), -OR6, -SR6, -OCOR6, -COR6, -C(O)OR6, -C(O)N(R6)2, -N(R6)C(O)R6 -N(R6)2, -SO2R6, -SO2N(R6)2, -N(R6)SO2R6, -SO2OH, -SO2NHOH, -SO2N(R6)(CO)-R6, Benzyl, Phenyl oder einer Oxo-Gruppe; wobei jeder von dem Phenyl-Ring und jede von der Benzyl-Gruppe, optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von Halogen, -OH, -NH2, -NH(C1-4-Alkyl), -N(C1-4-Alkyl)2, -CN, C1-4-Alkyl, C1-4-Haloalkyl, -CONH2, -O(C1-4-Alkyl) oder -O(C1-4Haloalkyl); und wobei jede von den C1-6-Alkyl- oder C1-4-Alkyl-Ketten und jeder von dem C3-8-Cycloalkyl-Ring optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von Halogen; wobei
    jedes R6 unabhängig ausgewählt ist aus Wasserstoff, einem C1-6-Alkyl, einem C2-4-Alkenyl, Phenyl, Benzyl, oder einem C3-8-Cycloalkyl-Ring; wobei jedes von dem C1-6-Alkyl, jedes von dem C2-4-Alkenyl, jedes von dem Phenyl, jedes von dem Benzyl und jede von der C3-8-Cycloalkyl Gruppe optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von Halogen;
    alternativ zwei der Vorkommen von R5e, die an das gleiche oder an verschiedene Atome des gebildeten Rings durch R1, R2 angelagert sind, und der Stickstoff, an den R1 und R2 angelagert sind, zusammen mit dem Atom oder den Atomen, optional einen C3-8-Cycloalkyl-Ring, einen 4-bis 6-gliedrigen heterocyclischen Ring; ein Phenyl oder einen 5- oder 6-gliedrigen Heteroaryl-Ring bilden, was in einem bicylischen System resultiert, wobei die zwei Ringe des bicyclischen Systems in einem Spiro-, kondensierten oder überbrückten Verhältnis in Bezug aufeinander sind; wobei der 4- bis 6-gliedrige Heterocyclus oder der 5- oder 6-gliedrige Heteroaryl-Ring bis zu drei Ring-Heteroatome enthält, unabhängig ausgewählt aus N, O oder S; und wobei der C3-8-Cycloalkyl-Ring, 4- bis 6-gliedrige heterocyclische Ring, das Phenyl oder der 5- oder 6-gliedrige Heteroaryl-Ring optional und unabhängig substituiert sind mit bis zu 3 Vorkommen von C1-4-Alkyl, C1-4-Haloalkyl, C1--Alkoxy, C1-4-Haloalkoxy, Oxo, -C(O)O(C1-4-Alkyl), -CONH2, -C(O)OH, -NR(CO)O(C1-4-Alkyl), -OH oder Halogen; wobei R Wasserstoff oder ein C1-2-Alkyl ist;
    alternativ sind R1 und R2 jeweils unabhängig ausgewählt aus Wasserstoff, C1-6-Alkyl, einem C3-8-Cycloalkyl-Ring, einem 4- bis 8-gliedrigen heterocyclischen Ring, einem 5- oder 6-gliedrigen Heteroaryl-Ring, Phenyl oder einem C1-6-Alkyl-RY; wobei jeder von dem 4- bis 8-gliedrigen heterocyclischen Ring und jeder von dem 5- oder 6-gliedrigen Heteroaryl-Ring bis zu 3 Ring-Heteroatome enthält, unabhängig ausgewählt aus N, O und S; und wobei jedes von dem C1-6-Alkyl, C3-8-Cycloalkyl-Ring, 4- bis 8-gliedrigen heterocyclischen Ring, 5- oder 6-gliedrigen Heteroaryl-Ring, Phenyl und dem C1-6-Alkyl-Abschnitt der C1-6-Alkyl-RY-Gruppierung, die optional und unabhängig substituiert ist mit bis zu 5 Vorkommen von R5f;
    Ry ausgewählt ist aus einem C3-8-Cycloalkyl-Ring, einem 4- bis 8-gliedrigen heterocyclischen Ring, Phenyl, oder einem 5 bis 6-gliedrigen Heteroaryl-Ring; wobei jeder von dem 4- bis 8-gliedrigen heterocyclischen Ring oder 5- bis 6-gliedrigen heteroaromatischen Ring zwischen 1 und 4 Ring Heteroatome enthält, unabhängig ausgewählt aus N, O oder S; und wobei jeder von dem C3-8-Cycloalkyl-Ring, jeder von dem 4- bis 8-gliedrigen heterocyclischen Ring, jedes von dem Phenyl und jeder von dem 5 bis 6-gliedrigen Heteroaryl-Ring optional substituiert ist mit bis zu 5 Vorkommen von R5g;
    jedes R5f unabhängig ausgewählt ist aus Halogen, -CN, C1-6-Alkyl, -(C1-4-Alkyl)-R6a, einem C7-12-Aralkyl, C3-8-Cycloalkyl-Ring, C1-4(Cyanoalkyl), -OR6a, -SR6a, -OCOR6a, -COR6a, -C(O)OR6a, -C(O)N(R6a)2, -N(R6a)C(O)R6a, -N(R6a)2, -SO2OH, -SO2NHOH, -SO2N(R6a)(CO)-R6a, -SO2R6a, -SO2N(R6a)2, -N(R6a)SO2R6a, Phenyl oder einer Oxo-Gruppe; wobei jede von der Phenyl-Gruppe optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von Halogen, -OH, -NH2, -NH(C1-4-Alkyl), -N(C1-4-Alkyl)2, -CN, -CONH2, C1-4-Alkyl, C1-4-Haloalkyl, -O(C1-4-Alkyl) oder -O(C1-4-Haloalkyl); und wobei jedes von dem C7-12-Aralkyl, jedes von dem C1-6-Alkyl, jede von der C1-4-Alkyl-Kette und jeder von dem C3-8-Cycloalkyl-Ring optional und unabhängig substituiert ist mit bis zu drei Vorkommen von Halogen;
    jedes R6a unabhängig ausgewählt ist aus Wasserstoff, einem C1-6-Alkyl, einem C2-4-Alkenyl, Phenyl, Benzyl, oder einem C3-8-Cycloalkyl-Ring; wobei jedes von dem C1-6-Alkyl, jedes von dem C2-4 Alkenyl, jedes von dem Phenyl, jedes von dem Benzyl und jeder von dem C3-8-Cycloalkyl-Ring optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von Halogen;
    wenn eines von R1 oder R2 der C3-8-Cycloalkyl-Ring, 4- bis 8-gliedrige heterocyclische Ring oder das 5- oder 6-gliedriges Heteroaryl substituiert mit bis zu 5 Vorkommen von R5f ist, zwei der Vorkommen von R5f, die an den gleichen oder verschiedene Ringatome von dem R1 oder R2 angelagert sind, zusammen mit dem Atom oder den Atomen einen C3-8-Cycloalkyl-Ring, einen 4- bis 6-gliedrigen heterocyclischen Ring, ein Phenyl oder einen 5- oder 6-gliedrigen heterocyclischen Ring bilden, was in einem bicylischen System resultiert, wobei die zwei Ringe in einem Spiro-, kondensierten oder überbrückten Verhältnis sind, wobei der 4- bis 6-gliedrige Heterocyclus oder der 5- oder 6-gliedrige heterocyclische Ring bis zu zwei Ring-Heteroatome enthält, unabhängig ausgewählt aus N, O oder S; und wobei der C3-8-Cycloalkyl-Ring, 4- bis 6-gliedrige heterocyclische Ring, das Phenyl oder der 5- oder 6-gliedrige heterocyclische Ring optional substituiert ist durch bis zu 2 Vorkommen von C1-4-Alkyl, C1-4-Haloalkyl, Oxo, -(CO)O(C1-4-Alkyl), -NR'(CO)O(C1-4-Alkyl) oder Halogen; wobei R' Wasserstoff oder ein C1-2-Alkyl ist;
    jedes R5g unabhängig ausgewählt ist aus Halogen, -CN, C1-6-Alkyl, -(C1-4-Alkyl)-R6b, einem Benzyl, C3-8-Cycloalkyl-Ring, C1-4(Cyanoalkyl), -OR6b, -SR6b, -OCOR6b, -COR6b, -C(O)OR6b, -C(O)N(R6b)2, -N(R6b)C(O)R6b, -N(R6b)2, -SO2R6b, -SO2OH, -SO2NHOH, -SO2N(R6b)(CO)-R6b, -SO2N(R6b)2, -N(R6b)SO2R6b, Phenyl oder einer Oxo-Gruppe; wobei jedes von dem Phenyl und jede von der Benzyl-Gruppe optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von Halogen, -OH, -NH2, -NH(C1-4-Alkyl), -N(C1-4-Alkyl)2, -CN, -CONH2, C1-4-Alkyl, C1-4-Haloalkyl, -O(C1-4-Alkyl) oder -O(C1-4-Haloalkyl); und wobei jede von der C1-4-Alkyl-Kette und jede von der C3-8-Cycloalkyl-Gruppe optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von Halogen;
    jedes R6b unabhängig ausgewählt ist aus Wasserstoff, einem C1-6-Alkyl, einem C2-4-Alkenyl, Phenyl, Benzyl, oder einem C3-8-Cycloalkyl-Ring; wobei jedes von dem C1-6-Alkyl, jedes von dem C2-4-Alkenyl, jedes von dem Phenyl, jedes von dem Benzyl und jede von der C3-8-Cycloalkyl Gruppe optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von Halogen;
    alternativ zwei Vorkommen von R5g, die an das gleiche oder an verschiedene Atome von RY angelagert sind, zusammen mit dem Ringatom oder Ringatomen einen C3-8-Cycloalkyl-Ring, einen 4- bis 6-gliedrigen heterocyclischen Ring; ein Phenyl oder einen 5- oder 6-gliedrigen Heteroaryl-Ring bilden, was in einem bicylischen System resultiert, wobei die zwei Ringe in einem Spiro-, kondensierten oder überbrückten Verhältnis sind, wobei der 4- bis 6-gliedrige Heterocyclus oder der 5- oder 6-gliedrige Heteroaryl-Ring bis zu drei Heteroatome enthält, unabhängig ausgewählt aus N, O oder S; und wobei der C3-8-Cycloalkyl-Ring, 4- bis 6-gliedrige heterocyclische Ring, das Phenyl oder ein 5- oder 6-gliedriger Heteroaryl-Ring optional und unabhängig substituiert ist mit bis zu 3 Vorkommen von C1-4-Alkyl, C1-4-Haloalkyl, C1-4-Alkoxy, C1-4-Haloalkoxy, Oxo, -C(O)O(C1-4-Alkyl), -C(O)OH, -NR"(CO)O(C1-4-Alkyl), -OH oder Halogen; und
    R" Wasserstoff oder ein C1-2-Alkyl ist.
  4. Verbindung nach Anspruch 1, dargestellt durch Formel IIb, oder ein pharmazeutisch annehmbares Salz davon:
    Figure imgb0273
     wobei Ring B ein Phenyl oder ein 5- oder 6-gliedriger Heteroaryl-Ring ist, der 1 oder 2 Ring-Heteroatome enthält, ausgewählt aus N, O oder S.
  5. Verbindung nach Anspruch 4, oder ein pharmazeutisch annehmbares Salz davon, wobei jedes JD unabhängig ausgewählt ist aus Halogen, einem C1-6 aliphatischen, C1-6 haloaliphatischen, -N(RD)2, -N(Rd)CORD, -N(Rd)COORD, -ORD, -N(Rd)SO2RD oder einem optional substituierten C3-8 cycloaliphatischen Ring.
  6. Verbindung nach den Ansprüchen 4 oder 5, oder ein pharmazeutisch annehmbares Salz davon, wobei die Verbindung durch Formel IIIb dargestellt ist:
    Figure imgb0274
  7. Verbindung nach den Ansprüchen 4 oder 6, oder ein pharmazeutisch annehmbares Salz davon, dargestellt durch Formel IVb:
    Figure imgb0275
  8. Verbindung nach einem der Ansprüche 4 bis 6, oder ein pharmazeutisch annehmbares Salz davon, dargestellt durch Formel Vb:
    Figure imgb0276
     wobei JD fehlt oder ausgewählt ist aus Halogen, Methyl, Hydroxyl, Methoxy, Trifluormethyl, Trifluormethoxy oder -NRaRb; wobei Ra und Rb jedes unabhängig ausgewählt sind aus Wasserstoff, C1-6-Alkyl oder einem 3-6-Cycloalkyl-Ring; oder wobei Ra und Rb, zusammen mit dem Stickstoffatom, an das sie beide angelagert sind, einen 4-8-gliedrigen heterocyclischen Ring bilden, oder einen 5-gliedrigenr Heteroaryl-Ring, der optional bis zu zwei zusätzliche Heteroatome enthält, ausgewählt aus N, O und S; wobei jeder von dem 4-8-gliedrigen heterocyclischen Ring und 5-gliedrigen Heteroaryl-Ring optional und unabhängig substituiert ist mit bis zu 5 Vorkommen von Fluor; und JA ausgewählt ist aus Wasserstoff oder Fluor.
  9. Verbindung nach einem der Ansprüche 1, 2, 4 und 6, oder ein pharmazeutisch annehmbares Salz davon, wobei jedes JD unabhängig ausgewählt ist aus Halogen, einem C1-6 aliphatischen, einem C1-6 haloaliphatischen -N(RD)2, -N(Rd)C(O)RD, -N(Rd)C(O)ORD, -N(Rd)C(0O)N(RD)2, -SO2RD, -SO2N(RD)2, -N(Rd)SO2RD, -SRD, -ORDoder einem optional substituierten C3-8 cycloaliphatischen Ring, und wobei o eine Ganzzahl ist, ausgewählt zwischen 1 und 3.
  10. Verbindung nach Anspruch 9, oder ein pharmazeutisch annehmbares Salz davon, wobei jedes JD unabhängig ausgewählt ist aus Methyl, Trifluormethyl, Chlor, Fluor, -N(RD)2, N(Rd)C(O)RD, -N(Rd)SO2RD oder- ORD.
  11. Verbindung nach Anspruch 1, oder ein pharmazeutisch annehmbares Salz davon, dargestellt durch eine der Formeln VIIa oder VIIIb:
    Figure imgb0277
  12. Verbindung nach einem der Ansprüche 1, 4, oder 6, oder ein pharmazeutisch annehmbares Salz davon, dargestellt durch eine der Formeln Xb oder XIb:
    Figure imgb0278
    wobei jedes JD unabhängig ausgewählt ist aus -NH2 oder fehlt; und
    jedes JA alternativ wie folgt ist:
    i) wenn R1 und R2 nicht gleichzeitig Wasserstoff sind, ist jedes JA unabhängig ausgewählt aus Wasserstoff oder Halogen; oder
    ii) wenn R1 und R2 beide gleichzeitig Wasserstoff sind, jedes JA unabhängig ausgewählt ist aus -C(O)RD, -C(O)ORD, -OC(O)RD, -C(O)N(RD)2, -N(RD)2, -N(Rd)C(O)RD, -N(Rd)C(O)ORD, -N(Rd)C(O)N(RD)2, -OC(O)N(RD)2, -SO2RD, -SO2N(RD)2 oder -N(Rd)SO2RD.
  13. Verbindung nach einem der Ansprüche 1 oder 2, oder ein pharmazeutisch annehmbares Salz davon, dargestellt durch eine der Formeln XIXa oder Xa:
    Figure imgb0279
     wobei
    jedes JD unabhängig ausgewählt ist aus -NH2 oder fehlt; und jedes JA alternativ wie folgt ist:
    i) wenn R1 und R2 nicht gleichzeitig Wasserstoff sind, ist jedes JA unabhängig ausgewählt aus Wasserstoff oder Halogen; oder
    ii) wenn R1 und R2 beide gleichzeitig Wasserstoff sind, jedes JA unabhängig ausgewählt ist aus -C(O)RD, -C(O)ORD, -OC(O)RD, -C(O)N(RD)2, -N(RD)2, -N(Rd)C(O)RD, -N(Rd)C(O)ORD, -N(Rd)C(O)N(RD)2, -OC(O)N(RD)2, -SO2RD, -SO2N(RD)2 oder -N(Rd)SO2RD.
  14. Verbindung nach Anspruch 1, wobei die Verbindung ausgewählt ist aus einer der folgenden Verbindungen:
    Figure imgb0280
    Figure imgb0281
    Figure imgb0282
    Figure imgb0283
    Figure imgb0284
    Figure imgb0285
    Figure imgb0286
    Figure imgb0287
    Figure imgb0288
    Figure imgb0289
    Figure imgb0290
    Figure imgb0291
    Figure imgb0292
    Figure imgb0293
    Figure imgb0294
    Figure imgb0295
    Figure imgb0296
    Figure imgb0297
    Figure imgb0298
    Figure imgb0299
    Figure imgb0300
    Figure imgb0301
    Figure imgb0302
    Figure imgb0303
     oder einem pharmazeutisch annehmbaren Salz davon.
  15. Verbindung nach einem der Ansprüche 1 bis 14 zur Verwendung in der Behandlung von einer Krankheit, eines Gesundheitszustands oder einer Gesundheitsstörung, die aus Folgenden ausgewählt sind:
    • Störungen in Bezug auf hohen Blutdruck und verringerten koronaren Blutfluss; erhöhter akuter und chronischer koronarer Blutfluss; arterielle Hypertonie und vaskuläre Störung, die aus kardialen und renalen Komplikationen resultiert; arterielle Hypertonie und vaskuläre Störung, die aus Herzkrankheit, Schlaganfall, zerebraler Ischämie, Nierenversagen oder resistenter Hypertonie resultiert; diabetische Hypertonie; Essentielle Hypotonie; sekundäre Hypertonie;
    • Herzversagen; HFPEF; HFREF; akutes und chronisches Herzversagen und spezifischere Formen der Krankheit; akutes dekompensiertes Herzversagen, Rechtsherzversagen, Linksherzversagen, totales Herzversagen, ischämische Kardiomyopathie, dilatierte Kardiomyopathie, kongenitale Herzfehler, Herzversagen mit Herzklappenfehlern, Mitralklappenstenose, Mitralklappeninsuffizienz, Aortenklappenstenose, Aortenklappeninsuffizienz, Trikuspidstenose, trikuspidale Insuffizienz, Pulmonalklappenstenose, Pulmonalklappeninsuffizienz, kombinierte Herzklappenfehler; diabetische Herzfehler; alkoholische Kardiomyopathie, Speicherungs-Kardiomyopathien; diastolisches Herzversagen, systolisches Herzversagen, akute Phasen eines vorliegenden chronischen Herzversagens, degeneratives Herzversagen; diastolische oder systolische Dysfunktion; Koronarinsuffizienz; Arrhythmien; Verringerung von ventrikulärer Vorlast; Herzhypertrophie; Herzfehler/kardiorenales Syndrom; portale Hypertension; endotheliale Dysfunktion oder Verletzung; Störungen des atrialen und ventrikulären Rhythmus und Leitungsstörungen; Atrioventrikularblöcke vom Grad I-III (AVB I-III); supraventrikuläre Tachyarrhythmie, Vorhofflimmern, Vorhofflattern, Herzkammerflimmern, Herzkammerflattern, ventrikuläre Tachyarrhythmie, Torsade-de-Pointes-Tachykardie, atriale und ventrikuläre Extrasystolen, Extrasystolen der AV-Verbindung, Sick-Sinus-Syndrom, Synkopen, Reentry-Tachykardie des AV-Knotens; Wolff-Parkinson-White-Syndrom, akutes Koronarsyndrom; Boxer-Kardiomyopathie; ventrikuläre Extrasystole;
    • thromboembolische Störungen und Ischämien, Myokardischämie, Infarzierung, Herzanfall, Herzmuskelschwäche, endotheliale Dysfunktion, Schlaganfall, transitorische ischämische Attacken (transient ischemic attacks, TIAs); obstruktive Thrombangiitis; stabile oder instabile Angina pectoris; Koronarspasmen, Spasmen der Becken-Bein-Arterien; Variantangina, Prinzmetal-Angina; Schlaganfall; Herzhypertrophie; Präeklampsie; thrombogene Störungen; Ischämie-Reperfusions-Schaden; Ischämie-Reperfusion in Verbindung mit Organtransplantation; Ischämie-Reperfusion in Verbindung mit Lungentransplantation, Lungentransplantation oder Herztransplantation; Beibehaltung von Blutsubstituenten bei Traumapatienten;
    • periphere Arterienerkrankung; periphere arterielle Verschlusskrankheit; periphere vaskuläre Krankheit; Hypertonie; Raynaud-Syndrom oder Raynaud-Phänomen; primäres und sekundäres Raynaud-Phänomen; Raynaud-Krankheit, Ischämiesyndrom; periphere Embolie; Claudicatio intermitens; gefäßverengende Krise; Duchenne- und Becker-Muskeldystrophie; Mikrozirkulationsanomalien; Kontrolle von Gefäßundichtigkeit oder -permeabilität; lumbale Spinalkanalstenose; okklusive thrombotische Vasculitis; thrombotische Vasculitis; periphere Durchblutungsstörungen; arterielle und venöse Thrombosen; Microalbuminurie; periphere und autonome Neuropathien; diabetische Mikroangiopathien;
    • Ödem; Nierenödem wegen Herzversagen;
    • Alzheimer-Krankheit; Parkinson-Krankheit; vaskuläre Demenzen; vaskuläre kognitive Beeinträchtigung; zerebraler Vasospasmus; traumatische Hirnverletzung; Verbessern von Wahrnehmung, Konzentrationsfähigkeit, Lernfähigkeit oder Gedächtnisleistung nach kognitiven Störungen, wie sie z. B. jene, die bei einer leichten kognitiven Beeinträchtigung, altersbedingten Lern- und Gedächtnisstörungen, altersbedingtem Gedächtnisverlust, vaskulärer Demenz, Kopfverletzung, Schlaganfall, Demenz nach Schlaganfall, posttraumatischer Kopfverletzung, allgemeinen Konzentrationsstörungen und Konzentrationsstörungen bei Kindern mit Lern- und Gedächtnisproblemen vorkommen; Lewy-Körper-Demenz, Demenz mit Frontallappendegeneration einschließlich Pick-Syndrom; progressive nukleäre Blickparese; Demenz mit kortikobasaler Degeneration; amyotrophe Lateralsklerose (ALS); Huntington-Krankheit; Demyelinisierung, multiple Sklerose, thalamische Degeneration; Creutzfeldt-Jakob-Demenz, HIV-Demenz, Schizophrenie mit Demenz oder Korsakoff-Psychose; multiple Systematrophie und andere Formen von Parkinsonismus Plus; Bewegungsstörungen; Neuroprotektion; Angst, Anspannung und Depression, posttraumatische Belastungsstörung (PTSD); ZNS-bedingte sexuelle Dysfunktion und Schlafstörungen; pathologische Essstörungen und Verwendung von Genussmitteln und Suchtdrogen; Kontrolle von Hirndurchblutung, Kontrolle von Migränen; Prophylaxe und Kontrolle der Folgen von Hirninfarkt (Apoplexia cerebri), wie z. B. Schlaganfall, zerebrale Ischämie und Kopfverletzung;
    • Schock; kardiogener Schock; Sepsis oder septischer Schock oder anaphylaktischer Schock; Aneurysma; Kontrolle von Leukozytenaktivierung; Hemmung oder Modulation von Thrombozytenaggregation; Multiorganversagen (MOV);
    • pulmonale/respiratorische Bedingungen; pulmonale Hypertonie (PH), pulmonale arterielle Hypertonie (PAH) und assoziierte pulmonale vaskuläre Remodellierung; lokalisierte Thrombose und rechte Ventrikelhypertrophie; pulmonale Hypertonie; primäre pulmonale Hypertonie, sekundäre pulmonale Hypertonie, familiäre pulmonale Hypertonie, sporadische pulmonale Hypertonie, präkapilläre pulmonale Hypertonie, idiopathische pulmonale Hypertonie; thrombotische pulmonale Arteriopathie, plexogene pulmonale Arteriopathie; zystische Fibrose; Bronchialverengung oder pulmonale Bronchialverengung; akutes respiratorisches Distresssyndrom; Lungenfibrose, Lungentransplantation; asthmatische Krankheiten; andere Formen von PH; PH assoziiert mit linksventrikulärer Krankheit, HIV, SCD, Thrombembolie (CTEPH), Sarkoidose, COPD oder pulmonale Fibrose; akutes respiratorisches Distresssyndrom (ARDS), akute Lungenverletzung, Alpha-1-Antitrypsin-Mangel (A1AD), pulmonale Emphysem; durch Rauchen induziertes Emphysem und CF;
    • pulmonale Hypertonie assoziiert mit oder in Bezug auf: linksventrikuläre Dysfunktion, Hypoxämie, WHO-Gruppen I, II, III, IV und V Hypertensionen, Mitralklappenkrankheit, konstriktive Perikarditis, Aortastenose, Kardiomyopathie, Mediastinalfibrose, pulmonale Fibrose, anomaler pulmonaler venöser Abfluss, Lungenvenen-Verschlusskrankheitt, pulmonale Vaskulitis, kollagenvaskuläre Krankheit, kongenitale Herzkrankheit, Lungenvenenhypertonie, interstitielle Lungenkrankheit, schlafbezogene Atmungsstörung, Schlafapnoe, alveoläre Hypoventilationsstörungen, chronische Aussetzung an große Höhe, neonatale Lungenkrankheit, alveoläre kapillare Dysplasie, Sichelzellenkrankheit, andere Koagulationsstörungen, chronische Thrombembolie, Lungenembolie, Embolie wegen Tumor, Parasiten oder Fremdmaterial; pulmonale Hypertonie assoziiert mit oder in Bezug auf: Bindegewebekrankheit, Lupus, Schistosomiasis, Sarkoidose, chronische obstruktive pulmonale Krankheit, Asthma, Emphysem, chronische Bronchitis oder pulmonale kapillare Hämangiomatose; Histiozytose X, Lymphangiomatose und komprimierte Lungengefäße; komprimierte Gefäße durch Drüsenerkrankung, Tumor oder fibrosierende Mediastinitis;
    • arteriosklerotische Krankheiten oder Zustände; Arteriosklerose, Arteriosklerose assoziiert mit endothelialer Verletzung, Thrombozyt- und Monozytadhäsion und -aggregation, Proliferation und Migration von glattem Muskel; Restenose; Restenose, die sich nach Thrombolyse-Therapien entwickelt hat, perkutane transluminale Angioplastien (PTAs), transluminale Coronar-Angioplastien (PTCAs), Herztransplantations- und Bypass-Operationen; Entzündungsprozesse;
    • mikro- und makrovaskulärer Schaden; Vaskulitis; erhöhte Werte von Fibrinogen und DLD niedriger Dichte, erhöhte Konzentration von Plasminogenaktivator-Hemmer 1 (PA-1);
    • Krankheiten, die mit metabolischem Syndrom assoziiert sind: Adipositas, Dyslipidämie, Diabetes, hoher Blutdruck; lipid-bedingte Störungen: Dyslipidämie, Hypercholesterinämie, erhöhte Cholesterol-Werte des Lipoproteins hoher Dichte (HDL-Cholesterol) und in einigen Fällen moderat erhöhte Cholesterol-Werte des Lipoproteins niedriger Dichte (LDL-Cholesterol), Hypertriglyceridämien, Hyperglyceridemie, Hypolipoproteinanämien, Sitosterolämie, Fettleberkrankheit und Hepatitis; Präeklampsie; polyzystischer Nierenkrankheitfortschritt; subkutanes Fett; Adipositas; Lebersteatose oder anormale Lipid-Ansammlung in der Leber; Steatose des Herzens, der Nieren oder Muskeln; Abetalipoproteinämie; Sitosterolämie; Xanthomatose; Tangier-Krankheit; Obesitas; kombinierte Hyperlipidämien und metabolisches Syndrom; Hyperammonämie und verwandte Krankheiten und Störungen; hepatische Encephalopathien und andere toxische Encephalopathien und Reye-Syndrom;
    • sexuelle, gynäkologische und urologische Störungen oder Zustände; erektile Dysfunktion; Impotenz; vorzeitige Ejakulation; weibliche sexuelle Dysfunktion; weibliche sexuelle Erregungsdysfunktion, hypoaktive sexuelle Erregungsstörung, vaginale Atrophie, Dyspareunie, atrophische Vaginitis, gutartige Prostatahyperplasie (BPH) oder Hypertrophie oder Vergrößerung; Blasenauslassobstruktion; Blasenschmerzsyndrom (BPS); interstitielle Zystitis (IC); überaktive Blase; neurogene Blase und Inkontinenz; diabetische Nephropathie; primäre und sekundäre Dysmenorrhö; Syndrome des unteren Harntrakts (LUTS); Beckenschmerzen; gutartige und bösartige Krankheiten der Organe des männlichen und weiblichen urogenitalen Systems;
    • akute und chronische Niereninsuffizienz, akutes und chronisches Nierenversagen, sowie zugrundeliegende oder verwandte Nierenkrankheiten, wie z. B. Hypoperfusion, intradialytische Hypotension, obstruktive Uropathie, Glomerulopathien, Glomerulonephritis, akute Glomerulonephritis, Glomerulosklerose, tubulointerstitielle Krankheiten, nephropathische Krankheiten; primäre und kongenitale Nierenkrankheiten; Nephritis; Krankheiten, die durch abnormal reduzierte Kreatinin- und/oder Wasserausscheidung, abnormal erhöhte Blutkonzentration von Harnstoff, Stickstoff, Kalium und/oder Kreatinin, eine veränderte Aktivität von Nierenenzymen, veränderte Urinosmolarität oder verändertes Urinvolumen, erhöhte Microalbuminurie, Macroalbuminurie, Verletzungen von Glomeruli und Arteriolen, tubuläre Dilatation, Hyperphosphatemie und/oder Notwendigkeit einer Dialyse gekennzeichnet sind; Folgeschäden von Niereninsuffizienz; Lungenödem, Herzversagen, Uremie, Anemie, Elekrolytstörungen; Hyperkaliämie, Hyponatriämie; Störungen des Knochen- und Kohlenhydratmetabolismus;
    • Augenkrankheiten oder Augenstörungen; Glaukom, Retinopathie oder diabetische Retinopathie.
EP14824644.0A 2013-12-11 2014-12-10 Sgc-stimulatoren Active EP3092231B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361914908P 2013-12-11 2013-12-11
US201462051539P 2014-09-17 2014-09-17
PCT/US2014/069537 WO2015089182A1 (en) 2013-12-11 2014-12-10 Sgc stimulators

Publications (2)

Publication Number Publication Date
EP3092231A1 EP3092231A1 (de) 2016-11-16
EP3092231B1 true EP3092231B1 (de) 2018-06-27

Family

ID=52293206

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14824644.0A Active EP3092231B1 (de) 2013-12-11 2014-12-10 Sgc-stimulatoren

Country Status (8)

Country Link
US (2) US20160311826A1 (de)
EP (1) EP3092231B1 (de)
JP (1) JP2016540017A (de)
CN (1) CN106304835A (de)
CA (1) CA2933250A1 (de)
EA (1) EA032028B1 (de)
MX (1) MX2016007522A (de)
WO (1) WO2015089182A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2588465T3 (en) 2010-06-30 2017-05-01 Ironwood Pharmaceuticals Inc SGC stimulators
US9487508B2 (en) 2012-09-19 2016-11-08 Ironwood Pharmaceuticals, Inc. SGC stimulators
MX361208B (es) 2013-03-15 2018-11-30 Ironwood Pharmaceuticals Inc Estimuladores de guanilato ciclasa soluble (sgc).
WO2016044445A2 (en) * 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CA2961489A1 (en) * 2014-09-17 2016-03-24 Glen Robert RENNIE Sgc stimulators
CA2959757A1 (en) * 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
EA201891416A1 (ru) 2015-12-14 2018-12-28 Айронвуд Фармасьютикалз, Инк. ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА
SG11201900096QA (en) * 2016-07-07 2019-02-27 Ironwood Pharmaceuticals Inc Novel processes for preparation of soluble guanylate cyclase stimulators
CR20220309A (es) 2016-09-02 2022-09-16 Cyclerion Therapeutics Inc Estimuladores de sgc
US10918639B2 (en) 2016-10-11 2021-02-16 Bayer Pharma Aktiengesellschaft Combination containing SGC stimulators and mineralocorticoid receptor antagonists
JP7237823B2 (ja) 2016-10-11 2023-03-13 バイエル ファーマ アクチエンゲゼルシャフト Ｓｇｃアクチベーターとミネラルコルチコイド受容体アンタゴニストとを含む組合せ
US20190381039A1 (en) 2016-12-13 2019-12-19 Cyclerion Therapeutics, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS
CN108203396B (zh) * 2016-12-19 2020-12-08 江西东邦药业有限公司 一种脑啡肽酶抑制剂的合成
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (de) 2017-12-15 2019-06-19 Bayer AG Verwendung von sgc-stimulatoren und sgc-aktivatoren alleine oder in kombination mit pde5-inhibitoren zur behandlung von knochenerkrankungen einschliesslich osteogenesis imperfecta (oi)
JP7337067B2 (ja) * 2017-12-19 2023-09-01 サイクレリオン・セラピューティクス，インコーポレーテッド ｓＧＣ刺激薬
WO2019211081A1 (en) 2018-04-30 2019-11-07 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
BR112020022340A2 (pt) 2018-05-15 2021-02-02 Bayer Aktiengesellschaft benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
US20210177846A1 (en) 2018-07-11 2021-06-17 Cyclerion Therapeutics, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS
CA3126778A1 (en) 2019-01-17 2020-07-23 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
US20240115545A1 (en) * 2020-10-08 2024-04-11 Curome Biosciences Co., Ltd. Pharmaceutical composition containing b-lapachone as active ingredient for prevention or treatment of cholestatic liver disease

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
EP0192963B1 (de) 1985-02-27 1988-07-20 Werkzeugmaschinenfabrik Oerlikon-Bührle AG Schwingungsmesseinrichtung für ein Spiralkegelradgetriebe auf einer Zahnradprüfmaschine
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5721365A (en) 1989-09-15 1998-02-24 Us Health N-substituted piperazine NONOates
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5155137A (en) 1990-09-20 1992-10-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Complexes of nitric oxide with polyamines
AU668107B2 (en) 1991-09-24 1996-04-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs
US5814666A (en) 1992-04-13 1998-09-29 The United States As Represented By The Department Of Health And Human Services Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
US5691423A (en) 1992-08-24 1997-11-25 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-bound nitric oxide-nucleophile adducts
US5405919A (en) 1992-08-24 1995-04-11 The United States Of America As Represented By The Secretary Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders
US5910316A (en) 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US5632981A (en) 1992-08-24 1997-05-27 The United States Of America As Represented By The Department Of Health And Human Services Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
WO1995010267A1 (en) 1993-10-08 1995-04-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US5700830A (en) 1994-11-22 1997-12-23 The United States Of America As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents for reducing metastasis risk
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
CA2225250C (en) 1995-06-21 2005-03-22 Shionogi & Co., Ltd. Bicyclic amino derivatives and pgd2 antagonist containing the same
US5714511A (en) 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
WO1998025915A1 (fr) 1996-12-12 1998-06-18 Shionogi & Co., Ltd. Derives d'amide d'acide benzenecarboxylique condenses heterocycliques et antagonistes pgd2 renfermant ces derives
BR9714016A (pt) 1996-12-13 2000-02-29 Shionogi & Co Derivados de benzotiofenocarboxamida e antagonistas a pgd2, que compreendem os mesmos
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
HU228111B1 (en) 1998-07-08 2012-11-28 Sanofi Aventis Deutschland Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE69915346T2 (de) 1998-12-17 2004-07-22 Alza Corp., Mountain View Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE60115411D1 (de) 2000-04-12 2006-01-05 Merck Frosst Canada & Co Kirkl Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
US20010051624A1 (en) 2000-04-12 2001-12-13 Jones Thomas R. Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
FR2811989A1 (fr) 2000-07-18 2002-01-25 Sanofi Synthelabo Derives de polyfluoroalkytriazole, leur preparation et leur application en therapeutique
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
PE20020856A1 (es) 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
AR035431A1 (es) 2001-02-13 2004-05-26 Aventis Pharma Gmbh 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas, un metodo para su sintesis, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
TWI241190B (en) 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
US6511911B1 (en) 2001-04-03 2003-01-28 Advanced Micro Devices, Inc. Metal gate stack with etch stop layer
JP4292402B2 (ja) 2001-09-07 2009-07-08 小野薬品工業株式会社 インドール誘導体化合物、それらの製造方法およびそれらを有効成分として含有する薬剤
JPWO2003022814A1 (ja) 2001-09-07 2004-12-24 小野薬品工業株式会社 インドール誘導体化合物
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EP2423190A1 (de) 2002-05-16 2012-02-29 Shionogi&Co., Ltd. PGD-2-Rezetorantagonismus aufweisende Verbindungen
JPWO2003097042A1 (ja) 2002-05-16 2005-09-15 塩野義製薬株式会社 Ｐｇｄ２受容体拮抗剤
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
MXPA05003456A (es) 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
AU2003297398B2 (en) 2002-12-20 2009-09-24 Amgen Inc. Asthma and allergic inflammation modulators
US20050059660A1 (en) * 2003-08-01 2005-03-17 Pharmacia & Upjohn Company Novel combination
RU2006102981A (ru) 2003-08-04 2007-09-20 Пфайзер Продактс Инк. (Us) Лекарственные формы, обеспечивающие контролируемое высвобождение ингибиторов белка-переносчика эфиров холестерина и немедленное высвобождение ингибиторов hmg-соа-редуктазы
US8309608B2 (en) 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
KR20080056250A (ko) * 2005-09-29 2008-06-20 바이엘 헬스케어 아게 비뇨기 장애의 치료를 위한 ｐｄｅ 억제제 및 이들의 조합
GB0604937D0 (en) 2006-03-10 2006-04-19 Novartis Ag Organic compounds
CA2662852A1 (en) 2006-09-07 2008-03-13 Allergan, Inc. Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity
EP2101741B1 (de) 2006-10-17 2010-08-11 Bend Research, Inc. Feste dispersion mit schwer wasserlöslichem wirkstoff
MX2009011387A (es) * 2007-05-12 2009-11-09 Bayer Schering Pharma Ag Estimulantes de la gcs, activadores de la gcs y combinaciones para el tratamiento de trastornos urologicos.
BRPI0816382A2 (pt) 2007-09-06 2015-02-24 Merck Sharp & Dohme Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças
JP2011510082A (ja) 2008-01-24 2011-03-31 メルク・シャープ・エンド・ドーム・コーポレイション アンジオテンシンｉｉ受容体拮抗薬
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
AU2010218224B2 (en) 2009-02-26 2013-06-27 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
HUE028008T2 (en) 2010-02-05 2016-11-28 Adverio Pharma Gmbh sGC stimulators or sGC activators alone and in combination with PDE5 inhibitors for the treatment of cystic fibrosis
WO2011119518A1 (en) 2010-03-25 2011-09-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2575473B1 (de) 2010-05-27 2016-01-20 Merck Sharp & Dohme Corp. Lösliche guanylat-cyclase-aktivatoren
DK2588465T3 (en) 2010-06-30 2017-05-01 Ironwood Pharmaceuticals Inc SGC stimulators
JP5940062B2 (ja) 2010-07-09 2016-06-29 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 環縮合４−アミノピリミジンおよび可溶性グアニル酸シクラーゼの刺激剤としてのその使用
WO2012058132A1 (en) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US9061030B2 (en) * 2010-11-09 2015-06-23 Ironwood Pharmaceuticals, Inc. sGC stimulators
US9012651B2 (en) 2011-03-24 2015-04-21 Abbvie Inc. TRPV3 modulators
RU2014103960A (ru) 2011-07-06 2015-08-20 Байер Интеллектуэль Проперти Гмбх Гетероарилзамещенные пиразолопиридины и их применение в качестве стимуляторов растворимой гуанилатциклазы
AP2014007541A0 (en) 2011-09-02 2014-03-31 Bayer Ip Gmbh Substituted annellated pyrimidine and the use thereof
EP2794596B1 (de) * 2011-12-21 2017-05-31 Bayer Intellectual Property GmbH Substituierte benzylpyrazole
EP3112363A1 (de) 2011-12-27 2017-01-04 Ironwood Pharmaceuticals, Inc. 2-[1-[(2-fluorophenyl)methyl]-5-(3-isoxazolyl)-1h-pyrazol-3-yl]-pyrimidinderivate und verwandte verbindungen als stimulatoren der löslichen guanylatcyclase (lgc) zur behandlung von pulmonarer hypertonie
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
MX361208B (es) * 2013-03-15 2018-11-30 Ironwood Pharmaceuticals Inc Estimuladores de guanilato ciclasa soluble (sgc).
EP3010911A1 (de) * 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Heteroarylsubstituierte pyrazole

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
WO2015089182A1 (en) 2015-06-18
EA032028B1 (ru) 2019-03-29
MX2016007522A (es) 2017-12-15
US20210214364A1 (en) 2021-07-15
EP3092231A1 (de) 2016-11-16
CN106304835A (zh) 2017-01-04
CA2933250A1 (en) 2015-06-18
EA201691194A1 (ru) 2016-12-30
JP2016540017A (ja) 2016-12-22
US20160311826A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
EP3092231B1 (de) Sgc-stimulatoren
US10844064B2 (en) sGC stimulators
EP2897953B1 (de) Sgc-stimulatoren
US9309235B2 (en) SGC stimulators
EP3194382B1 (de) Pyrazolderivate als sgc-stimulatoren
CA2907111C (en) Sgc stimulators
EP2637659B1 (de) Sgc-stimulatoren
EP3194395B1 (de) Sgc-stimulatoren
US20170298055A1 (en) sGC STIMULATORS
US11180493B2 (en) SGC stimulators

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160708

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

17Q First examination report despatched

Effective date: 20170425

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1225030

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20180104

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1012214

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014027649

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180927

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180927

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180627

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180928

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1012214

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180627

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181027

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014027649

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

26N No opposition filed

Effective date: 20190328

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20190509 AND 20190515

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181210

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602014027649

Country of ref document: DE

Representative=s name: HERNANDEZ, YORCK, DIPL.-ING., DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602014027649

Country of ref document: DE

Owner name: CYCLERION THERAPEUTICS, INC., CAMBRIDGE, US

Free format text: FORMER OWNER: IRONWOOD PHARMACEUTICALS, INC., CAMBRIDGE, MASS., US

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20181231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181210

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181231

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181210

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180627

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180627

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20141210

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20221227

Year of fee payment: 9

Ref country code: FR

Payment date: 20221227

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20221228

Year of fee payment: 9

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230517